

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Svolos, V;Gordon, H;Lomer, MCE;Aloi, M;Bancil, A;Day, AS;Day, AS;Fitzpatrick, JA;Gerasimidis, K;Gkikas, K;Godny, L;Hedin, CRH;Katsanos, K;Narula, N;Russell, RK;Sarbagili-Shabat, C;Segal, JP;Sigall-Boneh, R;Sokol, H;Wall, CL;Whelan, K;Wine, E;Yanai, H;Hansen, R;Halmos, EP

Title:

European Crohn's and Colitis Organisation consensus on dietary management of inflammatory bowel disease

Date:

2025-09

Citation:

Svolos, V., Gordon, H., Lomer, M. C. E., Aloi, M., Bancil, A., Day, A. S., Day, A. S., Fitzpatrick, J. A., Gerasimidis, K., Gkikas, K., Godny, L., Hedin, C. R. H., Katsanos, K., Narula, N., Russell, R. K., Sarbagili-Shabat, C., Segal, J. P., Sigall-Boneh, R., Sokol, H. ,... Halmos, E. P. (2025). European Crohn's and Colitis Organisation consensus on dietary management of inflammatory bowel disease. Journal of Crohn's and Colitis Supplements, 19 (9), <https://doi.org/10.1093/ecco-jcc/jjaf122>.

Persistent Link:

<https://hdl.handle.net/11343/361764>

License:

CC BY

European Crohn's and Colitis Organisation consensus on dietary management of inflammatory bowel disease

Vaios Svolos^{#,1,2,1b}, Hannah Gordon^{#,3}, Miranda C.E. Lomer^{#,4,5,1b}, Marina Aloï^{6,7,1b}, Aaron Bancil^{5,1b}, Alice S. Day^{8,1b}, Andrew S. Day⁹, Jessica A. Fitzpatrick¹⁰, Konstantinos Gerasimidis^{1,1b}, Konstantinos Gkikas^{1,1b}, Lihi Godny^{11,1b}, Charlotte R.H. Hedin^{12,13,1b}, Konstantinos Katsanos¹⁴, Neeraj Narula^{15,1b}, Richard K. Russell^{16,1b}, Chen Sarbagili-Shabat^{17,18,1b}, Jonathan P. Segal^{19,20}, Rotem Sigall-Boneh^{17,21}, Harry Sokol^{22,1b}, Catherine L. Wall^{23,24}, Kevin Whelan^{5,1b}, Eytan Wine^{25,26,1b}, Henit Yanai^{27,28,1b}, Richard Hansen^{*,‡,29,1b}, Emma P. Halmos^{‡,10,1b}

¹Human Nutrition, School of Medicine, Dentistry & Nursing, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom

²Lab of Clinical Nutrition and Dietetics, Department of Nutrition and Dietetics, School of Physical Education, Sports Science and Dietetics, University of Thessaly, Trikala, Greece

³Translational Gastroenterology Unit, Oxford University Hospitals NHS Trust, Oxford, United Kingdom

⁴Department of Gastroenterology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom

⁵Department of Nutritional Sciences, King's College London, London, United Kingdom

⁶Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

⁷Pediatric Gastroenterology, Hepatology and Cystic Fibrosis Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy

⁸Department of Gastroenterology, The Queen Elizabeth Hospital and Basil Hetzel Institute, Woodville South, Adelaide, Australia

⁹Department of Paediatrics, University of Otago, Christchurch, Christchurch, New Zealand

¹⁰Department of Gastroenterology, Monash University & Alfred Health, Melbourne, Australia

¹¹Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel

¹²Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden

¹³Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

¹⁴Division of Gastroenterology, University of Ioannina, Ioannina, Greece

¹⁵Department of Gastroenterology, McMaster University, Hamilton, Canada

¹⁶Department of Paediatric Gastroenterology, Royal Hospital for Children & Young People, Edinburgh, United Kingdom

¹⁷Pediatric Gastroenterology and Nutrition Unit, The E. Wolfson Medical Center, Holon, Israel

¹⁸Department of Paediatric Gastroenterology and Nutrition, Amsterdam University Medical Centers, Emma Children's Hospital, Amsterdam, The Netherlands

¹⁹Department of Gastroenterology, Royal Melbourne Hospital, Parkville, Melbourne, Australia

²⁰Department of Medicine, University of Melbourne, Parkville, Melbourne, Australia

²¹Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology and Metabolism, University of Amsterdam, Amsterdam, The Netherlands

²²Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Paris, France

²³Department of Medicine, University of Otago, Christchurch, New Zealand

²⁴Nutrition and Dietetics, Health New Zealand, Christchurch, New Zealand

²⁵University of Alberta, Edmonton, Canada

²⁶The Hospital for Sick Children and University of Toronto, Toronto, Canada

²⁷IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel

²⁸Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

²⁹Division of Respiratory Medicine and Gastroenterology, School of Medicine, University of Dundee, Dundee, United Kingdom

*Corresponding author: Richard Hansen, Division of Respiratory Medicine and Gastroenterology, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, James Arrott Drive, Dundee, DD1 9SY, United Kingdom (rhansen002@dundee.ac.uk)

[#]Joint first authors.

[‡]Joint senior authors.

Key words: Crohn's disease; ulcerative colitis; diet; nutrition.

1. Introduction

Diet is gaining recognition amongst clinicians, researchers, and the inflammatory bowel disease (IBD) community as a potential modifier to change the course of the disease. The role of diet in the management of IBD has evolved beyond adjustment for nutritional needs and is now applied as therapy to influence disease activity and complications. With growing recognition of diet, there is a demand for high-quality dietary research to guide practice and consideration on where to best position diet in the treatment paradigm. This has led to the commissioning of this first European Crohn's and Colitis Organisation (ECCO) consensus on dietary management of IBD, with the goal of providing evidence-based recommendations to guide clinical practice.

2. Methodology

This consensus followed ECCO standardized methodology and was directed by four project coordinators, selected by the ECCO Guideline Committee to represent an adult gastroenterologist and ECCO guideline committee member (H.G.), a pediatric gastroenterologist (R.H.), and dietitians (V.S. and E.P.H.), all with expertise in diet and IBD. A panel of 25 experts was selected from a competitive pool of applicants that consisted of 12 IBD dietitians, eight adult gastroenterologists, and five pediatric gastroenterologists. Panel members were allocated to 1 of 5 working groups. One patient representative from the European Federation of Crohn's and Ulcerative Colitis Associations was assigned to each group.

The topics of the working groups were decided by the project coordinators to comprehensively cover the following: (1) Diet as therapy to induce remission of IBD; (2) Diet as therapy to maintain remission of IBD; (3) Dietary management of comorbidities and special conditions of IBD; (4) Nutritional assessment and optimization for IBD; and (5) Diet as prevention of IBD development. Each working group was led by a project coordinator and a fifth working group leader was recruited (M.C.E.L.). Within each working group, clinically relevant research questions were formulated using the Population, Intervention, Comparison, and Outcome (PICO) approach¹ when possible, in accordance with ECCO standard operating procedures for Oxford Centre for Evidence-Based Medicine-based guidelines. These informed systematic literature searches performed by a professional librarian (completed January 2024) using PubMed/Medline, Embase, and the Cochrane Central databases. Abstracts from each PICO were screened for relevance by 2 panel members. Full texts of potentially relevant abstracts were retrieved and evaluated for consensus inclusion by a panel member. Consensus statements and supporting text were drafted for each PICO and allocated a level of evidence (EL) score using the Oxford Centre for Evidence-Based Medicine.² When considering *Diet as prevention of IBD development* only prospective cohort studies were included in data analysis, with EL2 ascribed for articles best fitting with "inception cohort studies."

All statements underwent 3 voting rounds and feedback by panel members and patient representatives, followed by revisions. The second voting round was extended to all applicants to the consensus with opportunity for feedback, but consensus was calculated from panel member votes only. Panel members and patient representatives met in person or online in September and December 2024 for the final discussion and consensus

vote. Consensus was defined as >80% agreement amongst panel members and patient representatives and is presented for each statement. Only statements achieving consensus were included.

3. Translation and execution of dietary management

Statement 1: In the absence of a specific dietary intervention that is recommended by an IBD healthcare professional, healthy eating guidelines should be followed by people with IBD, as recommended for the general population. (EL5) (Consensus: 100%)

Statement 2: All people with IBD should have access to a dietitian with experience in IBD. (EL5) (Consensus: 96%)

To drive engagement with diet as a routine part of IBD care, to enable diet as both a primary and adjunctive therapy, and to facilitate high-quality dietary research, it is essential to include specialist dietetic input in clinical care and research. *Statement 2* is arguably the most important statement within this consensus. Recommendations for nutritional assessment and execution of dietary interventions are outlined through the statements of this consensus, based on evidence for its efficacy and safety. Where evidence is lacking, as indicated by EL5, mechanism-based reasoning should ensue without compromise to safety. Ideally, nutritional assessment should be performed by a dietitian, who can assess and correct abnormalities in nutrition and eating behavior. Where no such dietetic expertise is available, a health care professional with training in nutrition assessment and optimization should be consulted. A dietitian well-versed in IBD should execute and monitor IBD-specific dietary interventions, particularly diets of restrictive nature, as such diets carry nutritional and psychosocial risks and require skilled dietetic supervision.

4. Dietary management of patients with IBD

The dietary management of patients with IBD is categorized in 3 areas (Figure 1), including dietary therapy to induce and maintain remission of IBD, dietary management of comorbidities and special conditions of IBD, and nutritional assessment and optimization for IBD.

4.1 Dietary therapy to induce and maintain remission of IBD

Consensus evaluation of dietary therapies and supplements for both induction and maintenance of remission of IBD is presented in this section and are summarized in Table 1 and Table 2. Several areas of interest had insufficient evidence to make a recommendation. Most evidence for dietary interventions was of low quality, with few studies measuring endoscopic, radiological, or biochemical end points or durability of response. Hence, positioning dietary therapies in treatment algorithms is challenging. It is often appropriate to consider dietary intervention in conjunction with medical therapy. Descriptions of defined diets given recommendations for use in the management of IBD are summarized in Table 3.




Figure 1. Schematic of recommended dietary management for patients with inflammatory bowel disease.

4.1.1 Exclusive enteral nutrition and partial enteral nutrition

Statement 3.1: Exclusive enteral nutrition (EEN) is effective for the induction of clinical and endoscopic remission in children (EL1) and adults (EL2) with mild-to-moderate Crohn's disease (CD). (Consensus 96.6%)

Statement 3.2: Partial enteral nutrition (PEN) provided in high volumes could improve disease activity, although details of optimal dose are unclear. The use of $\leq 50\%$ PEN is not recommended for the induction of remission of CD. (EL3) (Consensus 90.0%)

Statement 3.3: Polymeric formulas for EEN and PEN are equally effective to elemental and semi-elemental formulas and should be recommended. (EL2) (Consensus 89.7%)

Statement 3.4: The use of EEN or PEN as induction therapy for ulcerative colitis is not recommended. (EL2) (Consensus 100%)

Exclusive enteral nutrition (EEN) is a treatment that replaces all food with oral nutrition supplements, usually for 6-8 weeks. Partial enteral nutrition (PEN) replaces a proportion of food with oral nutritional supplements.

The efficacy of EEN inducing remission of active Crohn's disease (CD) in pediatric and adult populations is supported by several systematic reviews and meta-analyses.³⁻¹³ A Cochrane review, including 27 studies and 1011 adult and pediatric participants with CD, showed high remission rates for both children (83%) and adults (43%), with no difference between enteral formulas, including fat content and elemental versus polymeric composition.¹⁰ While remission rates between elemental and polymeric formulas are comparable, polymeric formulas may be better tolerated.¹⁴ Exclusive enteral nutrition remission rates were comparable with corticosteroids (EEN: 83%, corticosteroids: 61%) for children but not for adults

(EEN: 45%, corticosteroids: 73%) in intention to treat analysis.¹⁰ However in per protocol analysis, there was equivalence between remission rates in adults too (relative risk [RR]: 0.93; 95% confidence interval [CI]: 0.75-1.14), suggesting the therapies are equally effective in adults when EEN is tolerated. The equal clinical efficacy of EEN and corticosteroids in the pediatric population, both for newly diagnosed and relapsing CD, has been reported elsewhere.^{6,12,13} Normalization of C-reactive protein (CRP) and fecal calprotectin did not differ between groups, while EEN was superior to corticosteroids for endoscopic and histological healing.^{5,12,13} Interestingly, recent pediatric studies have shown similar efficacy for remission induction for EEN and infliximab.^{15,16}

Exclusive enteral nutrition use in adults has become more common,^{10,15,17–20} with studies with good adherence demonstrating equal efficacy in adult and pediatric cohorts.⁴ Two randomized controlled trials (RCT) that compared EEN with corticosteroids reported excellent tolerance and similar efficacy between groups.^{21,22} Mucosal healing rates as high as 79% and a significant reduction in bowel-wall thickness have been reported for EEN in prospective observational studies of adult patients.^{17,23} Emerging data also support the use of EEN in abdominal abscesses, intestinal fistulae, and inflammatory intestinal strictures.^{24–27} There are additionally emerging retrospective data suggesting that EEN may augment response to advanced therapies, with a multicenter study of patients with ileal CD commencing advanced therapy demonstrating mucosal healing in 85.7% of those also receiving EEN for 16 weeks, compared with 23.7% receiving advanced therapy alone.²⁸

In pediatrics, PEN is likely less effective than EEN, although the proportion of enteral nutrition has varied between studies. The first trial comparing PEN and EEN in CD found lower clinical remission for PEN (15%) versus EEN (42%) after 6 weeks, although both reduced disease activity, with stronger benefits in EEN.²⁹ However, in a separate study when PEN accounted for 47% of caloric intake, remission was achieved

Table 1. Supporting evidence for dietary interventions to induce and maintain remission of CD and UC.

<i>Recommended</i>				
<i>Can be considered</i>				
<i>Not recommended</i>				
<i>Insufficient evidence to recommend</i>				
Dietary intervention	CD		UC	
	Induction of remission	Maintenance of remission	Induction of remission	Maintenance of remission
EEN				
PEN				
CDED + PEN				
CDED				
PN				
Mediterranean diet				
SCD				
Reduction of red meat				
Cow's milk protein elimination				
BFM				
High-fiber diet				
Low-fiber diet				
Low FODMAP diet				
Food-specific IgG-guided diet				
Low microparticle diet				
CD-TREAT				
AIP				
IBD-AID				
4-SURE diet				
UCED				
Gluten-free diet				
Intermittent fasting				

Abbreviations: 4-SURE, 4 strategies to sulfide reduction; AIP, autoimmune protocol; BFM, bifidobacterium-fermented milk; CD, Crohn's disease; CD-TREAT, Crohn's disease treatment-with-eating; CDED, the Crohn's disease exclusion diet; EEN, exclusive enteral nutrition; FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; IBD-AID, inflammatory bowel disease anti-inflammatory diet; IgG, immunoglobulin G; PEN, partial enteral nutrition; PN, parenteral nutrition; SCD, the specific carbohydrate diet; UC, ulcerative colitis; UCED, ulcerative colitis exclusion diet.

Table 2. Supporting evidence for dietary supplements to induce and maintain remission of CD and UC.

<i>Recommended</i>				
<i>Can be considered</i>				
<i>Not recommended</i>				
<i>Insufficient evidence to recommend</i>				
Dietary supplement	CD		UC	
	Induction of remission	Maintenance of remission	Induction of remission	Maintenance of remission
Curcumin ^a				
QingDai ^a				
Curcumin and QingDai ^a				
Psyllium				
Germinated barley				
Resistant starch				
Oat bran				
Wheat bran				
Non-starch polysaccharides				
Mastiha				
Prebiotics				
Vitamin D ^b				
Omega-3				
Glutamine				

^aOptimal dose and duration are unclear.

^bAlthough not recommended for induction or maintenance of remission, vitamin D supplementation is not contraindicated in IBD and supplementation may confer benefit, especially when deficiency is present.
Abbreviations: CD, Crohn's disease; UC, ulcerative colitis.

Table 3. Rationale and description of defined diets recommended in the management of IBD.

Dietary intervention	Description of diet and rationale	Key food inclusions/exclusions (not an exhaustive list)
EEN)	Total exclusion of food using a nutritionally complete liquid enteral nutrition formula reduces intestinal inflammation and promotes mucosal healing in CD	Inclusion: 100% of energy intake from polymeric (whole protein), semi-elemental (oligopeptide) or elemental (amino acid based) formula Exclusion: All foods, beverages (except water and enteral nutrition formula)
PEN	Partial replacement of food with enteral nutrition formula reduces intestinal inflammation in CD	Inclusion: 35%-50% of estimated energy requirements from polymeric, semi-elemental or elemental formula Exclusion: None
CD exclusion diet + PEN	Structured exclusion of food components (e.g., emulsifiers, maltodextrin, carrageenan, gluten) impairs intestinal barrier function, leading to dysbiosis, combined with PEN reduces intestinal inflammation in CD	Inclusion: 14 whole foods including chicken, eggs, rice, bananas, apples, potatoes; 50% of estimated energy requirements from enteral nutrition formula Exclusion: For food components—gluten, dairy, processed foods, additives and high-fat animal products
Mediterranean diet	High intake of plant-based foods rich in fiber, antioxidants, healthy fats, limited protein from meat supports a diverse microbiota and reduces inflammation in IBD	Inclusion: Fruits, vegetables, legumes, whole grains, olive oil, fish, nuts Exclusion: Red and processed meats, sugary drinks, ultra-processed foods
Low FODMAP diet	FODMAPs are fermentable short-chain carbohydrates responsible for increased intestinal water and colonic gas, decreased FODMAP intake reduces IBS-like symptoms in susceptible individuals	Inclusion: Defined food lists of low FODMAP foods, such as meat and fish, oats, rice, lactose-free milk, low FODMAP fruits and vegetables Exclusion: Defined list of high FODMAP foods, such as onion, garlic, wheat, legumes, apples, milk
Modified or low-fiber diet	A diet low in bulking fiber reduces risk of intestinal obstruction in people with stricturing CD	Inclusion: White bread, white rice, peeled well-cooked vegetables, banana, peeled apple, pureed legumes Exclusion: Wholegrain bread, brown rice, raw vegetables, edible fruit peel, whole legumes
Low oxalate diet	A low oxalate diet reduces risk of oxalate stone formation in people at risk of calcium oxalate nephrolithiasis	Inclusion: Most meats, grains, many fruits and vegetables, such as onion, potato, mushroom, avocado, banana, apple Exclusion: Nuts, nut butters, cocoa, rhubarb, beetroot, spinach, berries, soy products
Cinnamon- and benzoate-free diet	Elimination of foods containing cinnamon and benzoates reduces allergy-like responses associated with orofacial granulomatosis	Inclusion: Most meats, whole grains, fruits, vegetables, and dairy Exclusion: Cinnamon, benzoic acid, sodium benzoate, and processed foods containing these additives
Healthy eating patterns	A healthy eating pattern reduces risk of IBD development	Inclusion: Whole grains, fruits, vegetables, nuts, seeds, legumes and fish Exclusion: Red meat, processed meats, high-sugar foods, and beverages

Abbreviations: CD, Crohn's disease; EEN, exclusive enteral nutrition; IBD, inflammatory bowel disease; PEN, partial enteral nutrition.

by 50%, 76%, and 73% in PEN, EEN, and biologic groups, respectively, based on fecal calprotectin.¹⁶ When PEN provided 80%-90% of caloric intake, 87% clinical response, 65% remission, and improvements in biochemical outcomes were observed irrespective of disease location.³⁰ However, for a similar protocol only 42% completed the prescribed course due to lack of response (25%) and intolerance (23%).³¹

In adults, PEN that provides at least 50% of caloric intake alongside adalimumab led to remission rates and inflammatory marker improvements similar to EEN, outperforming regular diet.³²

Data on the use of EEN and PEN for the treatment of active ulcerative colitis (UC) are limited. A single small open label RCT suggests that EEN may reduce hospital stay and corticosteroid failure in patients with acute severe UC, but these findings require replication.³³

Partial enteral nutrition as maintenance therapy for CD has been evaluated by prospective trials, retrospective trials, and RCTs as reported in several meta-analyses and systematic reviews.³⁴⁻³⁷

The data are broadly supportive of PEN for maintenance of clinical remission in CD in adults and children. The most recent systematic review and meta-analysis, which consisted of 64 studies, including 11 RCTs, revealed efficacy of PEN as maintenance therapy when prescribed at higher doses.³⁵ The risk of clinical relapse was significantly reduced at intake >35% of energy requirements (35%-50% PEN, odds ratio (OR): 0.42;

95% CI, 0.27-0.65) and even lower with > 50% PEN (OR: 0.27; 95% CI, 0.08-0.88). A follow-up of 268 patients with CD demonstrated that maintenance PEN >900 kcal/day was associated with reduced risk of hospitalization (hazard ratio [HR]: 0.62; 95% CI, 0.44-0.87, $P = .007$).³⁸ Conversely, no studies with PEN <35% have described benefit.³⁹ Partial enteral nutrition may also aid corticosteroid weaning in refractory CD.⁴⁰

Most studies did not include endoscopic or biochemical endpoints.³⁵⁻³⁷ One prospective observational study did not find a difference between endoscopic outcomes of PEN compared with usual diet at 12 months (RR: 0.79; 95% CI, 0.57-1.10),⁴¹ although a prospective study from the same group did show a reduction

Statement 4.1: Partial enteral nutrition (PEN) could be considered for the maintenance of remission in Crohn's disease (EL2), including as an adjunct to medical therapy (EL3), with the most convincing evidence of efficacy for PEN comprising >35% daily energy requirements (EL2). However, details of optimal duration and psychological impact of long-term PEN are unknown. (Consensus 96%)

Statement 4.2 There is insufficient evidence to recommend PEN for the maintenance of remission of ulcerative colitis. (EL5) (Consensus 88%)

in 12-month endoscopic relapse rate in 40 participants post ileal or ileocolic resection (RR: 0.43; 95% CI, 0.21-0.89).⁴² The efficacy of polymeric and elemental formulations is comparable.⁴³

When considering PEN to augment response to medical therapy, this has been best studied in people receiving anti-tumor necrosis factor (TNF) therapy. One meta-analysis, including data from clinical trials and prospective and retrospective cohort studies evaluating PEN with infliximab or adalimumab, revealed the maintenance effect of the PEN group to be 70.5% (203/288) compared with 53.8% (306/569), yielding a pooled OR for long-term remission or response of 2.19 (95% CI, 1.49-3.22).³⁴ A meta-analysis focusing on three studies showed improved 12-month infliximab efficacy with PEN >600kcal/day clinical remission rates for CD compared with infliximab alone (74.5% [79/106] vs 49.2% [62/126], OR: 2.93; 95% CI, 1.66-5.17, $P < .01$).³⁴ However, there are limited data on endoscopic and biochemical outcomes, with details on immunogenicity and immunomodulator use also lacking.

There is no evidence to support PEN for maintaining remission in UC.

4.1.2 The Crohn's disease exclusion diet

Statement 5.1: The Crohn's disease exclusion diet (CDED) with partial enteral nutrition (PEN) is recommended for induction of remission in children (EL2) and could be considered in adults (EL3) with mild-to-moderate Crohn's disease (CD). (Consensus 100%)

Statement 5.2: There is insufficient evidence to support the use of the CDED without PEN as induction therapy for CD. (EL3) (Consensus 100%)

Statement 5.3: There is no evidence to support the use of the CDED, with or without PEN, as induction therapy for ulcerative colitis. (EL5) (Consensus 100%)

Statement 5.4: There is insufficient evidence to recommend the CDED for maintenance of remission of CD. (EL3) (Consensus 96%)

The CD exclusion diet (CDED), combined with PEN covering 50% of energy requirements, is a 6-week induction therapy (described as 'Phase 1'—further phases explained below) for treating pediatric and adult populations with CD. This 6-week diet comprises 50% PEN, using a polymeric oral nutritional supplement, mandatory inclusion of five foods of specified dose to be eaten daily, and an allowance of 14 foods that may be eaten. All other foods are disallowed.

The efficacy of CDED for inducing remission of active CD has been assessed in various studies.⁴⁴⁻⁴⁸ Randomized controlled trials data from pediatric participants with active CD revealed that CDED with 50% PEN was better tolerated and equally as effective as EEN in inducing remission at 6 weeks (CDED + PEN: 80%; EEN: 73.5%). Both therapies significantly reduced fecal calprotectin (CDED + PEN: median 3126-1744 µg/g, $p = 0.002$; EEN: 2647-1021 µg/g, $P = .011$).⁴⁹ Subsequent analysis showed that rapid response (94%) and remission (81%) based on fecal calprotectin levels within 3 weeks predicted sustained control at 6 weeks.⁵⁰ These data are supported by retrospective evidence comparing CDED with 50% PEN and EEN

(remission rate CDED + PEN: 75%; EEN: 66%).⁵¹ Those receiving CDED with 50% PEN had superior growth, although 80% of the cohort had 1-2 weeks of EEN prior to therapy.⁵¹ A prospective study revealed that CDED with PEN and EEN had similar clinical (CDED + PEN: 85%; EEN: 81%), endoscopic (CDED + PEN: 54%; EEN: 50%), and mucosal healing rates (CDED + PEN: 39%; EEN: 44%) after 6 weeks, although PEN covered 75% of energy needs.⁵² Preliminary data suggest that CDED with 50% PEN may be more effective for treatment-naïve children than those with prior biologic therapy.⁴⁵

In adults, an open-label pilot trial found similar 6-week remission rates between CDED with 1000kcal PEN (68%) and CDED alone (57%, $P = .46$).⁵³ An observational trial supported use of the CDED with 50% PEN, which induced remission in 77% and response in 83% of adults with CD.⁵⁴

For maintenance therapy, a step-down diet has been assessed, which involves reducing PEN to 25% of energy requirement and an expanded range of permitted foods for 6 weeks (Phase 2), then a restricted diet without PEN (Phase 3). This maintenance therapy has been assessed in two small studies of mild-to-moderate CD with follow-up to 24 weeks after the aforementioned 6-week induction diet. One of the studies in adults naïve to advanced therapy with mild-to-moderate CD (defined as Harvey Bradshaw Index [HBI] 5-14) compared CDED with 1000kcal PEN to CDED alone.⁵³ In the 20 participants who achieved remission at week 6, 80% were still in sustained clinical remission at week 24 (12 CDED + PEN; 8 CDED alone).⁵³ At week 24, 35% (14/40) of participants were also in endoscopic remission (simple endoscopic score-CD ≤ 3 ; 72.8% decrease from baseline in $n = 22$).⁵³ A real-world follow-up of patients treated with CDED to maintain remission demonstrated that remission was maintained in 83% (20/24) of patients at week 12.⁴⁴ However, there was significant heterogeneity, with 54.5% using concurrent medical therapy.

The only long-term analysis of Phase 3 CDED as maintenance therapy was a 52-week observational study in a limited number of children with CD in deep remission withdrawing from immunomodulator or anti-TNF monotherapy, whereby there was no difference in week-52 clinical remission between those who followed CDED (67% [5/9]) compared with a free diet (55.6% [5/7], $P = .63$).⁵⁵

4.1.3 Parenteral nutrition

Statement 6.1: While total parenteral nutrition is effective as induction therapy for IBD, with stronger evidence for Crohn's disease (CD) than ulcerative colitis (UC) (EL1), given the risk of harm, parenteral nutrition is not recommended. (EL3) (Consensus 90%)

Statement 6.2: Total parenteral nutrition is not recommended for maintenance of remission of CD (EL4) or UC. (EL5) (Consensus 100%)

Intravenous feeding, described as parenteral nutrition (PN) or total (exclusive) parenteral nutrition (TPN), has been investigated in the treatment of active IBD.

When given to people with active CD or UC, PN improved symptoms, weight, mucosal healing, and subsequent corticosteroid reduction and surgery avoidance in historic studies conducted before 1990.⁵⁶⁻⁶⁰ A systematic review and

meta-analysis of PN in treatment of IBD (15 studies qualitatively, 10 quantitatively) revealed improvements in disease activity and albumin but no increase in body weight. Ten of the studies assessed PN for treatment of active IBD, while the other studies focused on surgical outcomes.⁴ A controlled trial of PN with PEN in hospitalized patients with IBD demonstrated superior clinical response compared with a regular hospital diet, with benefits in high-sensitivity CRP, erythrocyte sedimentation rate (ESR), and albumin.⁶¹

Of the two studies that assessed PN in an active CD cohort, similar remission rates were observed for TPN compared with polymeric EEN and PN (71%, 58%, and 60%, respectively) with food in one trial,⁶² which was similar to the other, showing comparable efficacy of TPN and EEN for treating CD.⁶³ A retrospective sub-analysis of 12 participants with CD colitis compared TPN treatment alone with a cohort of 2 × 11 participants with moderate-to-severe UC receiving corticosteroids with TPN or a hospital diet, respectively, and showed that TPN led to symptom resolution and nutritional improvements in the participants with CD.⁶⁴ No TPN-related differences in outcomes were seen in the participants with UC.⁶⁴ Indeed, another study confirmed the equivalence of TPN and EEN for inducing remission in a population with UC.²¹ Regarding safety, a randomized study with similar efficacy outcomes of TPN and EEN among patients with IBD found higher liver dysfunction rates in the TPN group (TPN: 62%; EEN: 6%, $p=0.002$),⁶⁵ while the risks of catheter-related infections with TPN was previously described in a meta-analysis.⁶⁶ Given these risks and the efficacy equivalence to EEN, PN is not recommended as induction therapy for CD or UC.

For maintenance of remission, there is no evidence to support the use of TPN for CD or UC. TPN use in those with refractory CD led to high rates of 12-month clinical remission (61%), but corticosteroids were not discontinued and participants only received TPN for a mean 25.5 (± 1.1) days with no clear objective maintenance endpoints and no evidence of superiority over EEN or medical therapies.⁵⁹

4.1.4 The Mediterranean diet

Statement 7.1: There is insufficient evidence to recommend the Mediterranean diet (MD) as induction therapy for Crohn's disease (CD) or ulcerative colitis (UC). (EL3) (Consensus 100%)

Statement 7.2: The MD could be considered for maintenance of remission in UC as an adjunct to medical therapy. There is insufficient evidence to recommend the MD for maintenance of remission in CD. (EL3) (Consensus 83%)

The Mediterranean diet (MD), widely recognized for metabolic benefits, has shown mixed results in managing IBD.

A 12-week RCT in children with IBD revealed that the MD lowered inflammatory activity indices, CRP, and fecal calprotectin compared with those who remained on habitual diet, although the results were confounded by corticosteroid use.⁶⁷ A 6-month MD intervention in participants with IBD improved metabolic and inflammatory markers, although most participants were already in remission, limiting its utility as an induction therapy.⁶⁸ This limitation also affected another trial in CD

where the MD achieved modest symptomatic and biomarker responses, but 85% of participants had normal baseline fecal calprotectin levels ($<250 \mu\text{g/g}$).⁶⁹

For maintenance of remission, one prospective interventional study assessed 84 adult patients with UC and 58 with CD who followed the MD for 52 weeks.⁶⁸ Although the study revealed improvements in clinical and biochemical outcomes associated with dietary adherence, there were significant biases in the analysis, such as exclusion of participants who commenced corticosteroids.⁶⁸

A single-center prospective cohort study followed 693 patients with IBD (UC: $n=373$; CD: $n=320$) for a median of 27 months (interquartile range [IQR]: 22-29 months), using the prevención con dieta Mediterránea (PREMIMED) questionnaire to assess adherence to the MD in addition to assessing activity levels.⁷⁰ A sub-analysis of participants with UC showed that those who adhered to the MD were less likely to flare ($P = .034$), had lower fecal calprotectin ($P = 0.018$), and had reduced need for corticosteroids ($P = 0.023$). Median time to relapse was also greater in those who adhered to the MD (MD adherence: 14 months (IQR: 6.8-19.5); nonadherence: 5.5 months (IQR: 3.8-15), $P = 0.03$). A similar trend was found in participants with CD, although this did not reach statistical significance.

4.1.5 The specific carbohydrate diet

Statement 8.1: There is insufficient evidence to support the use of the specific carbohydrate diet (SCD) as induction therapy for Crohn's disease (CD) or ulcerative colitis (UC). (EL3) (Consensus 96.2%)

Statement 8.2: There is insufficient evidence to recommend the SCD for maintenance of remission of CD or UC. (EL4) (Consensus 100%)

The specific carbohydrate diet (SCD) excludes disaccharides and polysaccharides found in grains, legumes, starchy vegetables, dairy, and manufactured food.

For induction therapy with the SCD, initial small retrospective studies of up to 26 children with mild-to-moderate IBD showed improvements in disease activity indices and CRP.⁷¹⁻⁷³ However, prospective analysis of the SCD revealed variable results. Three small pediatric observational studies of up to 12 participants showed clinical improvements over 12 weeks, although results were mixed over 26 months.⁷⁴⁻⁷⁶ In another small trial of children with mild-to-moderate CD, 12 weeks of the SCD improved disease activity indices and CRP in 4 participants, as did a modified SCD and a whole-food diet in 4 and 2 participants, respectively.⁷⁷ In a large trial of 191 adults randomized to the SCD or the MD, both cohorts had improvements in symptoms but no differences in inflammatory biomarkers, including fecal calprotectin. Many participants had quiescent disease on study entry.⁶⁹ Adherence to the SCD remains challenging, with high drop-out rates in some studies due to adverse events or lack of response.⁷⁸

Studies assessing the SCD as maintenance therapy for IBD are small, heterogenous, and exclusive to the pediatric population. In 7 children with active CD following the SCD for 52 weeks, clinical response (HBI: 0.1 ± 0.4 and pediatric CD activity index: 5.4 ± 5.5 , $P = .016$ and $P = 0.027$, respectively) and mucosal response (assessed by capsule endoscopy; 2 children had mucosal healing) were maintained, with no patients

requiring changes to medical therapy.⁷⁴ Conversely, no significant benefits were seen in clinical or biochemical outcomes in pediatric participants with IBD (CD: $n=20$; UC: $n=6$) following the SCD over 3-48 months.⁷² Ten children were unable to tolerate the diet.

4.1.6 The semi-vegetarian diet

Theoretical and preliminary clinical data suggest that the semi-vegetarian diet (SVD) may be of benefit for maintaining IBD remission, although data are currently too limited and heterogeneous to draw conclusions. The SVD includes rice, vegetables, fruit, potatoes, fish once per week, meat every 2 weeks, and regular exercise. Sweets, bread, cheese, margarine, fast foods, carbonated drinks, juices, alcohol, and smoking are discouraged. A Japanese group studied the role of SVD in 3 CD and 2 UC open-label populations (CD: $n=68$; UC: $n=107$), mostly initiated during a period of hospitalization.⁷⁹⁻⁸⁴ There was heterogeneity between clinical studies in clinical outcomes and use of endoscopy, with some studies undertaken only in responders. These studies demonstrated a reduction in clinical relapse in participants with CD (>90% remission at 2 years) and UC (25% relapse rate at 1-2 years) associated with normalization of CRP in approximately half of participants when measured. However, with the various changes advocated, it is difficult to attribute the benefits to SVD. No consensus was reached for the role of SVD in IBD management.

4.1.7 Red and processed meat

Statement 9: A reduction in the intake of red and processed meat could be considered for maintenance of remission in ulcerative colitis. (EL3) (Consensus 96%)

Meat, particularly red and processed meat, has been implicated in the pathogenesis of IBD, albeit most data exist for its association with UC.^{85,86} Furthermore, an average daily red meat intake of only 76 g has been associated with incident colorectal cancer,⁸⁷ which may be relevant to an IBD population with an already increased risk.⁸⁸ The role of meat in established IBD is not clear and its role in predicting relapse has been assessed, mostly through observational studies.

Two studies have assessed the contribution of meat intake to disease flare in a population of combined CD and UC in remission. This included association data from a longitudinal study conducted in two distinct geographic Dutch cohorts that revealed that patients with quiescent IBD (CD: $n=440$; UC: $n=284$) had lower intake of red meat than those who had a recent flare (38.1 ± 23.7 vs 46.2 ± 34.8 g/day, $p=0.028$).⁸⁹ This was consistent with the second study, a retrospective survey that assessed dietary patterns in patients with IBD. This study revealed that a diet low in processed meats, if also low in refined carbohydrates and high in fruits and vegetables, was associated with reduced disease activity indices.⁹⁰ Associations have also been observed between processed meat and all-cause mortality in a retrospective cohort of 5763 patients with IBD.⁹¹

For CD, studies have examined the role of meat intake in maintaining remission, as in the Food and CD Exacerbation Study (FACES), which assessed time to flare in people with quiescent status.⁹² A high red and processed meat intake did not decrease time to disease flare and there was no significant difference in relapse rates between the high meat diet group (62%) versus the low meat diet group (42%).⁹² However, this

internet-based study had much lower adherence rates in the low meat group (57.3% vs 98.5%). Lastly, in children with CD completing a course of EEN, reintroduction of meat was associated with an increase in fecal calprotectin.⁹³

For maintenance of UC remission, the link between red and processed meat was made in one prospective cohort study in 191 subjects with quiescent UC where intake increased risk of relapse when comparing the highest to lowest tertiles (OR: 5.19; 95% CI, 2.1-12.9).⁹⁴ This was reflected in a retrospective study of dietary patterns in patients with IBD showing an inverse association between consumption of processed meats and risk of active UC.⁹⁰

4.1.8 Reduction of dairy

Statement 10: Cow's milk protein elimination is not recommended as an adjunct induction therapy for ulcerative colitis. (EL3) (Consensus 100%)

Exclusion of cow's milk protein and dairy products in general is a common practice among people with IBD.⁹⁵ There are limited data to support the benefit of a dairy-free diet in the management of IBD. In an RCT in children with new-onset UC, a diet that eliminated cow's milk protein as an adjunct to induction treatment with corticosteroids, mesalamine, or both did not increase the proportion of children who achieved clinical remission when compared with an unrestricted diet.⁹⁶ No studies have been performed to explore the benefit of cow's milk elimination in disease outcomes in CD. However, the routine use of dairy-based nutritional supplements in the management of active CD with EEN contradicts any notions of a harmful role of cow's milk protein in CD.⁹⁷

The efficacy of *Bifidobacterium*-fermented milk (BFM) as a maintenance therapy in UC was investigated in two Japanese trials. While BFM was effective for symptomatic relief in the first pilot trial, results were not replicated in the larger, placebo-controlled trial in 195 patients.^{98,99} No studies were identified on maintaining remission in UC.

4.1.9 High- and low-fiber diets

Statement 11.1: There is no consistent evidence to make recommendations on the use of low- or high-fiber diets as induction therapy for IBD. (EL3) (Consensus 95.2%)

Statement 11.2: Neither low- nor high-fiber diets are recommended for maintenance therapy for Crohn's disease or ulcerative colitis. (EL3) (Consensus 96%)

It is currently unclear if the amount and type of fiber play important roles in the management of IBD.

One of the first retrospective case studies on fiber, published in 1979, demonstrated that hospital admissions were significantly lower and shorter in patients with CD who followed an unrefined, high-fiber diet.¹⁰⁰ In a study published in 1985, a low residue/fiber diet did not differ from a high residue/fiber diet when comparing clinical disease activity, need for hospitalization or surgery, new complications, nutritional status, or postoperative recurrence in adults with CD.¹⁰¹ A recent Cochrane systematic review found that the effect of a high-fiber

diet on induction of clinical remission in people with active CD was uncertain.¹⁰² Most studies focused on specific fiber supplementation, with one study focusing on the effect of a high-fiber diet, inclusive of wheat bran, on induction of remission in adults with active CD. This study revealed improved health-related quality of life (QoL) and gastrointestinal symptoms but did not demonstrate benefit in biochemical outcomes.¹⁰³ These data are consistent with a previous systematic review of RCTs, which concluded that there was no benefit of fiber supplementation for active CD and inconsistent data for UC.¹⁰⁴

For maintaining remission of IBD, there was no clear evidence that either high- or low-fiber diets predispose to disease flare. A sub-analysis within a meta-analysis,³⁶ including two RCTs,^{105,106} revealed that a high-fiber diet was not superior in maintaining clinical remission compared with a diet low in fiber and high in refined carbohydrates in 556 patients with clinically quiescent CD (RR: 1.04; 95% CI, 0.83-1.30). However, another RCT showed higher 1-year clinical relapse rates in patients with CD who followed a diet rich in fiber compared with a dietary protocol excluding symptom-triggering foods (100% vs 30%, $P < 0.05$).¹⁰⁷ This study lacked objective measures of inflammation. However, there was a similar observation in a cross-sectional study in 14 children with CD entering clinical remission following treatment with EEN, where median fiber intake during early food reintroduction was higher in those with higher fecal calprotectin levels compared with those with lower fecal calprotectin (median: 12.1 g/day; IQR: 11.2-19.9 vs median 9.9 g/day; IQR: 7.6-12.1, $P = 0.03$).⁹³ However, a prospective study of patients with CD showed no such association.¹⁰⁸ In a more recent crossover trial of 17 patients with UC in remission or with mild clinical disease, administration of a high-fiber and low-fat diet (median fiber intake: 25.6 g/day) for 4 weeks, compared with a “healthier” version of a typical American diet (median fiber intake: 18.1 g/day), improved patients’ QoL scores but did not demonstrate improved biochemical outcomes.¹⁰⁹

The role of fiber in risk of surgery and hospitalization is also unclear, with two large prospective studies showing differing results.^{110,111} In the first study of over 5000 adults from the UK Biobank, fiber intake in the highest quartile was negatively associated with surgery after a mean follow-up of 11.2 years (HR: 0.63; 95% CI, 0.44-0.89, $P = .009$), with a protective effect seen from fiber sourced from fruit and vegetables on sensitivity analysis.¹¹¹ In contrast, in a study of over 1000 patients with quiescent IBD, no significant associations were observed between fiber intake and hospitalization with a median 3-year follow-up (HR: 1.016; 95% CI, 0.99-1.05, $P = 0.294$).¹¹⁰ Fiber restriction in the context of symptomatic strictures in CD is detailed in *Dietary management of comorbidities and special conditions of IBD*.

4.1.10 The low FODMAP diet

Statement 12: The low FODMAP diet is not recommended for maintenance of remission in Crohn's disease (EL2) and there is no evidence to support its use for maintenance of remission in ulcerative colitis. (Consensus 100%)

The low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet is a therapeutic diet

commonly utilized for treatment of irritable bowel syndrome (IBS).

In a meta-analysis including 4 RCTs evaluating the low FODMAP diet to maintain remission in quiescent CD compared with normal diet, there was no impact on inflammatory markers after remission was achieved with conventional therapy.¹¹² No studies were identified that examined the ability of the low FODMAP diet to maintain remission in UC.

4.1.11 Food-specific immunoglobulin G-guided diet

Statement 13: A food-specific IgG-guided diet is not recommended as induction therapy for IBD. (EL3) (Consensus 100%)

People with IBD may have specific food intolerances. The clinical utility of measurement of serum immunoglobulin G (IgG) to guide food elimination has been studied, with no studies to date supporting this practice.

In active disease, one open-label study using a food-specific IgG-guided diet in CD showed improved clinical disease activity and ESR but no changes in albumin or CRP.¹¹³ A subsequent trial with a sham diet as comparator arm found modest improvements in CD activity and QoL, but no changes in inflammatory biomarkers.¹¹⁴ Similar subjective markers, such as abdominal pain, were measured in a crossover study that showed no specific improvements from an IgG-guided diet compared with a sham diet in CD; however, 45% of patients dropped out due to poor compliance.¹¹⁵ In UC, IgG-guided diets improved Mayo scores, body mass index (BMI), and albumin, but not endoscopic outcomes.¹¹⁶

Following induction therapy with EEN, one study evaluated food reintroduction based on IgG, including a retrospective study of 64 adults where no difference in relapse rates were seen between those following IgG exclusion and those on unrestricted diet (relapse rate from IgG diet: 12.5% [4/32]; relapse rate from normal diet: 25% [8/32]).¹¹⁷ No studies were identified on maintaining remission in UC.

4.1.12 A low microparticle diet

Statement 14: A low microparticle diet is not recommended as induction therapy for Crohn's disease. (EL2) (Consensus 100%)

Microparticles, including titanium dioxide and aluminosilicates, are used as food additives.

Two RCTs explored the effect of a low microparticle diet on disease activity in adults with active CD. In the first trial of 20 patients with active corticosteroid-treated CD, a 4-month low microparticle diet significantly reduced CD activity index compared with a control group.¹¹⁸ However, these preliminary data were not replicated in a subsequent larger, single-blinded, multicenter, placebo-controlled trial.¹¹⁹

4.1.13 Other diets targeting active IBD

Statement 15.1: There is insufficient evidence to support the use of the CD Treatment-with-EATing (CD TREAT) diet as induction therapy for Crohn's disease (CD) or ulcerative colitis (UC). (EL3) (Consensus 100%)

Statement 15.2: There is insufficient evidence to support the use of the Autoimmune Protocol diet (AIP) (EL4), IBD-Anti-Inflammatory Diet (AID) (EL4), 4-strategies-to-Sulfide-Reduction (4 SURE diet) (EL4), or UC exclusion diet (UCED) (EL2) as induction therapy for CD, UC, or both. (Consensus 100%)

Statement 15.3: There is no evidence to make recommendations on the benefit of a gluten-free diet for induction of remission in IBD. (EL5) (Consensus 100%)

The CD Treatment-with-EATing (CD-TREAT) diet is a food-based therapy designed to replicate the composition and microbial effects of EEN. While early studies, including an animal model of ileitis and a small open-label trial of 5 pediatric patients, showed promising anti-inflammatory benefits and fecal calprotectin reduction, larger controlled trials are needed to confirm these findings.¹²⁰ There were no published studies that evaluated CD-TREAT as maintenance therapy.

Targeting both CD and UC, the autoimmune protocol (AIP) diet is an extension of the Paleolithic diet that is high in meat but eliminates grains, legumes, certain vegetables, dairy, nuts, seeds, and certain sugars, oils, and food additives. In an open-label study in 9 CD and 6 UC patients, QoL, disease activity indices, and fecal calprotectin improved. Among those with follow-up endoscopy, 6 of 7 patients showed improvement after 11 weeks.^{121,122}

The IBD-Anti-Inflammatory Diet (IBD-AID) is a step-down diet that restricts foods and textures across all food groups. In a small open-label study with 22 adults, *Clostridia* and *Bacteroides* increased, but clinical outcomes were not measured.¹²³ A retrospective series of 40 adults with IBD (of whom 13 did not attempt the diet) demonstrated symptom improvement and medication reduction in 11 participants.¹²⁴

Targeting UC, the 4-strategies-to-Sulfide-REduction (4-SURE) diet reduces total and sulphur-containing proteins and sulphur- and nitrate-containing additives, whilst increasing resistant starch and non-starch polysaccharides. An 8-week study in 28 patients with active UC showed clinical response in 48%, improved fecal calprotectin (from 400 to 175 µg/g, $P = .02$), and endoscopic improvement in 36%. Fecal short-chain fatty acids (SCFA) increased by 69%, and QoL improved by 10 points ($P < .001$).¹²⁵

The UC Exclusion Diet (UCED) aims to not only reduce total and sulphur-rich protein but also to reduce saturated and polyunsaturated fats and all food additives while including tryptophan, pectin, and resistant starch. An improved disease activity index was observed in 37.5% (9/24) of children with active disease following the UCED after 6 weeks.¹²⁶ A subsequent trial in adults comparing UCED to fecal microbiota transplantation revealed that a greater proportion of participants on UCED achieved clinical remission (40%) and endoscopic improvement (27%). Mucosal healing was seen in 4/15 in the UCED group.¹²⁷

Large controlled trials are needed before formal recommendations on these diets can be made.

Although the literature search encompassed search terms to evaluate the role of both a gluten-free diet and intermittent

fasting on IBD disease activity, no relevant studies were found. A weak signal of sustained remission to 26-52 weeks was found in a meta-analysis combining studies of various dietary strategies in quiescent UC,¹²⁸ but serious imprecisions were identified in all studies and individual study results were of low or very low certainty. Pooling studies with distinct interventions for meta-analysis is also of limited clinical utility.

4.2 Dietary supplements to induce and maintain remission of IBD

Statement 16.1: Curcumin could be used as an adjunct therapy to mesalamine for induction of remission in mild-to-moderate ulcerative colitis (UC). (EL3) However, the optimal formulation, duration, and dose are unclear, and due to potential toxicity, medical supervision is advised. (EL5) (Consensus 100%)

Statement 16.2: There is evidence to support curcumin for maintenance of remission in UC, although the optimal formulation, duration, and dose are unclear, with risk of toxicity at high doses. Curcumin is not recommended for maintenance therapy in Crohn's disease. (EL3) (Consensus 96%)

Statement 16.3: QingDai with or without curcumin may be considered as an adjunct for induction of remission of mild-to-moderate UC. (EL3) Due to potential toxicity, medical supervision is advised (EL5). (Consensus 100%)

Consensus evaluation for dietary supplements to induce and maintain remission of IBD are described below and detailed in Table 2.

4.2.1 Curcumin and QingDai

Curcumin, the active compound of turmeric and QingDai (QD, also known as indigo naturalis) is a plant-based compound. Both have been studied in adults with UC.

Meta-analyses and a systematic review suggest that combining curcumin with mesalamine may help induce remission in patients not responding to mesalamine alone. The dosages and formulations of curcumin varied in the studies, ranging from 550 mg to 4 g per day, with treatment durations between 4 weeks and 6 months.¹²⁹⁻¹³¹

Four studies (2 RCTs, 1 case series, and 1 observational study) examined curcumin supplementation at doses of 2-3 g/day between 9 weeks and 49 months as an adjunct maintenance therapy for IBD.^{130,132-134} In post-operative CD, 3 g/day curcumin in addition to azathioprine in 31 subjects was not effective in preventing post-operative disease recurrence compared with placebo and azathioprine (curcumin: 67.7%; placebo: 58.1%, $p = 0.60$).¹³³ In fact, higher rates of severe disease recurrence occurred in the curcumin group (curcumin: 54.8%; placebo: 25.8%, $P = .034$). In UC, one trial found 2 g/day curcumin with oral mesalamine was more effective at maintaining remission at 6 months compared with placebo and mesalamine (curcumin: 4.44, 95% CI, 0.54-15.15; placebo: 15.15, 95% CI, 8.19-32.71, $P = 0.049$),¹³⁰ with a relapse rate at 6 months of 4% (curcumin) versus 18% (placebo) (RR: 0.24; 95% CI, 0.05-1.09, $P = .06$).¹³⁵ This treatment effect was not sustained at 12 months,¹³⁰ with comparable relapse rates of 22% (curcumin) versus 32% (placebo) (RR: 0.70; 95% CI, 0.35-1.40, $P = 0.31$).¹³⁵

Some reports suggest curcumin has potential hepatotoxicity.¹³⁶ Curcumin may interact with medications, including anti-coagulants and diabetes drugs, and may modulate estrogen receptors.^{136–140} It would therefore seem sensible that curcumin be used under clinical supervision with monitoring of liver biochemistry, particularly for long-term and high-dose use.

QingDai has shown efficacy in treating active moderate-to-severe UC in two Japanese RCTs.^{141,142} A European trial demonstrated that a combination of curcumin and QD (CurQD) activated the mucosal aryl hydrocarbon receptor pathway and was superior to placebo in inducing clinical remission and achieving endoscopic improvement in those with moderate-to-severe UC, including biologic-experienced patients.¹⁴³ Similar results were observed in a multicenter retrospective cohort of 88 UC patients; 48% of these had prior biologic or small-molecule therapy. Patients received 1.5 g of QD and 1.5 g of curcumin for an 8-week induction phase.¹⁴⁴ Side effects were rare and included headaches, elevated liver enzymes, and cases of intussusception or pulmonary hypertension.^{141–144} Clinical supervision would seem appropriate, with dose adjustments for headaches, liver enzyme tests 1 month after starting, and periodic testing every 3–6 months. Further research is needed to determine the optimal dosing, duration, and positioning of CurQD in UC management.

4.2.2 Fiber supplements

Statement 17.1: There is insufficient evidence to recommend psyllium, germinated barley, resistant starch, oat bran, wheat bran, and non-starch polysaccharides for induction therapy in ulcerative colitis (UC) (EL3), and there is no evidence for induction therapy in Crohn's disease (CD). (Consensus 100%)

Statement 17.2: There is insufficient evidence to recommend psyllium, germinated barley, oat bran, mastiha, or QingDai supplements for maintenance of remission in CD or UC. (EL3) (Consensus 100%)

A wide range of fiber supplements have been examined for induction of remission, maintenance of remission, or both in IBD. Assessment with objective markers of disease activity is limited.

Derived from the husk of *Plantago ovata*, psyllium (also known as ispaghula) is predominantly composed of the non-starch polysaccharide arabinoxylan and has shown some promise in symptom management for patients with UC, but lacks robust evidence for remission induction.¹⁴⁵ In a small ($n=36$) double-blinded, placebo-controlled crossover trial of 3.5 g/day ispaghula husk for maintenance of remission, 4/36 participants relapsed within 4 months (ispaghula husk: $n=1$ [3%]; placebo: $n=3$ [8%], P value not reported).¹⁴⁶ In an open-label, parallel-group, multicenter trial, 20 g/day *Plantago* seeds were compared with 1.5 g/day mesalamine or combined therapy for 12 months.¹⁴⁷ Although numerically fewer relapses were observed in the combination group, no differences in the probability of maintaining remission at 12 months was observed upon examination of treatment failure rates (Mantel-Cox test, $P = 0.67$; Breslow test, $P = 0.58$). No studies evaluated psyllium as maintenance therapy for CD.

Wheat bran is a fiber that contains 46% non-starch polysaccharides. In a small intervention study, wheat bran provided daily for 18 months was well tolerated and reduced bile acid

fecal excretion among juvenile UC patients but showed no effect on disease activity parameters.¹⁴⁸

The only other fiber supplement assessed, germinated barley fiber, led to reduced frequency of diarrhea in patients with UC and may also reduce levels of inflammatory markers when provided at 20–30 g/day. However, there was no published comparison to control or placebo.^{149–152} There were insufficient data from two prospective open-label trials of 105 adults with quiescent UC who received 20–90 g/d germinated barley as an adjunct to conventional therapy.^{149,153} While significant treatment effects were observed in one study up to 12 months (lower disease activity scores, lower withdrawal rates, reduced corticosteroid use, and lower cumulative recurrence rates compared with control; all $P < 0.05$)¹⁵³ and symptomatic benefit was observed in both trials, germinated barley warrants further evaluation in trials of longer duration with objective end points before a clear recommendation can be made.^{149,153}

A recent systematic review with a meta-analysis on the effect of resistant starches on active IBD was impeded by significant methodological challenge.¹⁵⁴ Outcomes from two prospective trials suggest that oat bran is ineffective at maintaining remission as an adjunct therapy in quiescent UC.^{155,156}

Mastiha, a traditional herb, as an adjunct to conventional medical therapy was not superior to placebo at maintaining remission in quiescent IBD (placebo: 23.5%; mastiha: 17.6%, $P = .549$).¹⁵⁷ There were no studies evaluating supplementation with indigo naturalis or QingDai in the maintenance of remission in quiescent UC or CD.

4.2.3 Prebiotics

Statement 18.1: Prebiotics are not recommended as induction therapy for Crohn's disease (CD). (EL2) (Consensus 100%)

Statement 18.2: There is insufficient evidence to recommend prebiotics as induction therapy for ulcerative colitis (UC). (EL3) (Consensus 100%)

Statement 18.3: Prebiotics are not recommended for maintenance of remission in CD or UC. (EL3) (Consensus 100%)

Prebiotics are a class of nondigestible nutrients that undergo selective fermentation by host microorganisms into bioactive molecules (such as SCFA), which confer a health benefit.¹⁵⁸

Individual studies of prebiotics have suggested potential benefits, but further research is required to confirm their efficacy and optimal use.^{159–164}

The prebiotic effects of the common laxative lactulose (10 g/day) were explored in a 4-month pilot study of patients with active CD ($n=17$) and UC ($n=14$). Lactulose did not have any beneficial effects on clinical activity indices, endoscopic scores, or immunohistochemical parameters but also did not detrimentally alter stool frequency.¹⁶⁵

In quiescent disease, a systematic review and meta-analysis of prebiotic use in IBD demonstrated that in a pooled analysis, prebiotics did not reduce risk of UC flare (RR: 0.84; 95% CI, 0.57–1.26, 4 studies; $n=332$).¹⁶⁶ Germinated barley foodstuff trended towards prevention of clinical relapse (RR: 0.40; 95% CI, 0.15–1.03, $n=59$), while inulin, oat bran, and *P. ovata* showed no difference compared with controls.¹⁶⁶ For CD, inulin and lactulose were no different than controls for induction of remission, and fructo-oligosaccharides were no different than controls for

maintenance of remission.¹⁶⁶ The overall certainty of evidence was very low, with larger studies needed to draw firm conclusions.

4.2.4 Vitamin D, omega-3, and glutamine

Statement 19.1: There is insufficient evidence to recommend vitamin D for induction therapy of IBD. (EL2) (Consensus 100%)

Statement 19.2: Omega-3 fatty acid (EL2) and glutamine (EL3) supplementation are not recommended for induction therapy in IBD. (Consensus 100%)

Statement 19.3: Omega-3 fatty acid and vitamin D supplementation are not recommended for maintenance of remission in Crohn's disease or ulcerative colitis. (EL1) (Consensus 100%)

A recent Cochrane review on the utility of vitamin D in active IBD, which assessed 22 RCTs with 1874 participants, could not draw any conclusions on clinical response for UC as the certainty of evidence was low. There were no data on efficacy for induction of remission in CD.¹⁶⁷ This review and four other meta-analyses consistently did not support vitamin D for maintenance of remission of IBD.^{167–174}

A Cochrane review of six studies assessed omega-3 fatty acids for induction of remission in IBD. One small study showed positive benefits, while others suggested minor benefits for secondary outcomes.¹⁷⁵ However, small sample sizes and poor study quality prevented definitive conclusions. A more recent systematic review of 83 RCTs (41 751 participants), including 13 studies in active IBD, concluded that long-term supplementation with omega-3, omega-6, and total polyunsaturated fatty acids (PUFA) had minimal effect on IBD activity.¹⁶⁸ Meta-analysis data also did not support use of these supplements in maintenance of remission.^{167–174}

A systematic review of glutamine for treating active IBD analyzed 7 studies that used oral, enteral, or parenteral

administration. The results showed no significant changes in anthropometry, biochemical parameters, or disease activity.¹⁷⁶

Although there are potential health benefits for optimizing these nutrients, their impact on IBD disease activity has not been proven.

4.3 Dietary management of comorbidities and special conditions of IBD

Management of IBD involves more than controlling the inflammatory disease process. Diet plays an important role in treating complications of IBD and concerns unrelated to inflammation.

4.3.1 IBS-like symptoms

Statement 20.1: In adults with quiescent IBD and IBS-like symptoms, a low FODMAP diet is recommended to treat persistent gastrointestinal symptoms. (EL1) (Consensus: 100%)

Up to one-third of people with IBD in remission have IBS-like symptoms,¹⁷⁷ which is approximately 3-fold more than the general population.

A low FODMAP diet has the greatest efficacy for managing IBS compared with other dietary interventions¹⁷⁸ and is currently recommended in IBS management guidelines, if general lifestyle and dietary advice fail.¹⁷⁹ Two meta-analyses evaluated the efficacy of a low FODMAP diet for treatment of overall symptoms in adults with IBD in remission.^{112,180} The most recent meta-analysis, which included four RCTs,^{181–184} showed that a low FODMAP diet improved overall gut symptoms compared with a controlled diet (RR: 0.47; 95% CI, 0.33–0.66).¹¹² Improvements were seen in people with CD and UC. There were no differences observed between IBS subtypes, which are classified according to predominant bowel habits. These data are supported by observational trials^{185,186} and studies that showed a worsening of symptoms with FODMAP provocation on a background low FODMAP diet in the same population.^{187,188} There are limited data on the effects of a low FODMAP diet in children with IBS-like symptoms.¹⁸⁹

Table 4. Example foods and supplements containing fermentable, viscous, and bulking fiber (not an exhaustive list).

Food group	Foods containing fermentable fiber	Foods containing viscous fiber	Foods containing bulking fiber
Grains	<ul style="list-style-type: none"> Wheat breads Wheat pasta 	<ul style="list-style-type: none"> Oats Barley 	<ul style="list-style-type: none"> Whole-grain breads Bran-based cereals Barley Quinoa Brown rice
Vegetables	<ul style="list-style-type: none"> Onion Garlic Potato (particularly cooked and cooled) 	<ul style="list-style-type: none"> Vegetable peel (eg, potato skin) 	<ul style="list-style-type: none"> Raw vegetables (eg, salads) Broccoli Cauliflower Corn Celery Vegetable peel (eg, potato skin)
Fruit	<ul style="list-style-type: none"> Apple Pear Stone fruit (eg, apricots, plums) Banana (particularly green) 	<ul style="list-style-type: none"> Apple Pear Stone fruit (eg, apricots, plums) 	<ul style="list-style-type: none"> Edible fruit peel (eg, apple peel) Edible seeds (eg, passionfruit) Dried fruit
Meat/alternatives	<ul style="list-style-type: none"> Legumes (whole and pureed, eg, baked beans, chickpeas, lentils) 	<ul style="list-style-type: none"> Legumes (whole and pureed, eg, baked beans, chickpeas, lentils) 	<ul style="list-style-type: none"> Whole legumes (eg, baked beans, lentils and chickpeas) Whole nuts and seeds
Dairy/alternatives			
Fiber supplements	<ul style="list-style-type: none"> Inulin 	<ul style="list-style-type: none"> Psyllium 	<ul style="list-style-type: none"> Cellulose

Dietary guidance and monitoring with a dietitian are suggested for appropriate application and customization to prevent ongoing over-restriction of diet.

Statement 20.2: In people with quiescent IBD and IBS-like symptoms, there is insufficient evidence to support the use of high-fiber foods, fiber supplements, or a low-fiber diet to treat persistent gastrointestinal symptoms. (EL3) (Consensus: 100%)

Fiber is the only other dietary component that has been assessed in people with quiescent IBD and persistent gastrointestinal symptoms. However, there are limited quality data supporting the efficacy of high-fiber foods,^{103,155} fiber supplements,¹⁴⁶ and a low-fiber diet¹⁰¹ in reducing IBS-like symptoms.

4.3.2 Strictures

Statement 21.1: While there are no data supporting a modified or low-fiber diet to manage stricturing Crohn's disease (CD), mechanism-based reasoning suggests that a diet low in bulking fiber in people with stricturing CD and obstructive symptoms might reduce the risk of developing intestinal obstruction. (EL5) (Consensus: 100%)

People with stricturing CD are at risk of intestinal obstruction. Obstructive symptoms typically include abdominal pain, nausea, vomiting, abdominal distension, absence of gas and stool passage, or combinations thereof.

It has long been convention to suggest a low bulking fiber diet to reduce the risk of intestinal obstruction. This is solely mechanism-based reasoning, utilizing anecdotal associations of obstructive symptoms and intestinal obstruction with high-fiber foods. No studies have investigated the role of a modified or low-fiber diet in preventing intestinal obstruction. However, it is common practice to suggest a low bulking fiber diet in people with stricturing CD and obstructive symptoms. There is no consensus on the definition of a low bulking fiber diet; a proposed categorization of food based on functional gastrointestinal effects¹⁹⁰ is detailed in Table 4. Although it is not common practice to restrict fermentable and viscous fibers to reduce risk of intestinal obstruction, many foods contain a mix of fiber types (Table 4). Dietary guidance and monitoring to customize dietary treatment and ensure nutritional adequacy are suggested, preferably with a dietitian experienced in IBD.

Statement 21.2: Exclusive enteral nutrition could be considered to treat inflammatory strictures in Crohn's disease. (EL3) (Consensus: 100%)

Two observational studies that included people with stricturing CD who completed 12 weeks of EEN revealed a decrease in bowel-wall thickness and an increase in luminal cross-sectional area,^{25,191} indicating that EEN could reduce risk of intestinal obstruction in people with inflammatory strictures. This is consistent with retrospective studies. One case-control study revealed that 13/51 (25%) participants treated with at least 2 weeks of preoperative EEN avoided their planned surgery,

compared with participants who received no nutrition support, who all proceeded to surgery.¹⁹² Another study of 87 participants with complicated CD (48 with stricturing disease) revealed that participants who received 4 weeks of EEN were 4-fold less likely to require surgery.²⁶ There are limited quality data supporting the use of EEN to prevent intestinal obstruction.

4.3.3 Preoperative nutritional care

Statement 22.1: Exclusive enteral nutrition provided for at least 2 weeks might reduce the inflammatory burden in people with Crohn's disease who are awaiting surgical intervention and might prevent the planned surgery. (EL4) (Consensus: 96%)

Many people with IBD will require surgery during their disease course. Provision of nutrition support preoperatively is recognized to improve postoperative outcomes and is incorporated in protocols for colorectal surgery.¹⁹³ Research assessing the role of preoperative nutrition on clinical and surgical outcomes in people with IBD have been limited mostly to people with CD who have received EEN.

Preoperative EEN for at least 2 weeks can reduce the disease burden¹⁹⁴ and therefore reduce the extent and even requirement for surgery.^{26,192,195,196}

Statement 22.2: To reduce risk of postoperative complications in people with Crohn's disease who are awaiting surgical intervention, provision of preoperative nutrition is recommended, with most evidence supporting 4 weeks of exclusive enteral nutrition (EEN). (EL3) A minimum of 10 days of oral nutritional supplementation might be considered if EEN is not feasible. (EL4) (Consensus: 100%)

A meta-analysis of five retrospective and observational trials that evaluated the effect of preoperative nutrition compared with standard care without nutrition support in people with CD undergoing surgery showed that at least 4 weeks of EEN or TPN reduced the risk of postoperative complications (OR: 0.26; 95% CI, 0.07-0.99).¹⁹⁷ A sub-analysis indicated that this reduced risk was largely associated with EEN.^{196,198} Subsequent retrospective and observational trials on EEN for at least 2 weeks have supported this finding.^{195,199,200} This included retrospective studies in children and adults with CD undergoing surgery, indicating that even PEN reduced the risk of postoperative complications compared with no nutritional support.^{194,201,202} One of the studies provided 10-14 days of nutrition support as part of a perioperative home management program, which also involved nutrition screening, endurance training, pre- and postoperative drug review, and patient education.²⁰² Furthermore, limited observational data suggest that EEN leads to a reduction in inflammatory markers, such as cytokines,^{203,204} CRP,^{192,198-200,205} and CD clinical disease activity scores.¹⁹⁵ Although one comparative trial showed no differences in postoperative complications from EEN compared with no nutritional support, EEN was given only to high-risk patients in this trial.²⁰⁶ Since this meta-analysis, there has been limited-quality evidence supporting the use of PN over standard care for the prevention of

postoperative complications.²⁰⁷ Clinical decisions on type and duration of preoperative nutrition depend on timing of surgery, clinical risk, access to a dietitian, other dietary requirements (eg, for malnutrition, obesity, strictures, pregnancy), and preferences of the person with IBD.

Statement 22.3: There are insufficient data to define the optimal preoperative nutrition care in reducing risk of postoperative complications in people with ulcerative colitis. (EL4) (Consensus: 100%)

There are limited data on preoperative nutrition in people with UC. A retrospective study in people with UC undergoing surgery showed similar rates of postoperative complications, excluding line infections, in those provided EEN compared with PN.²⁰⁸ However, another trial in people with acute severe UC on corticosteroids who were randomized to receive either EEN or PN showed that EEN was superior to PN in preventing postoperative infection in a subset of 20 patients who had undergone colectomy.²⁰⁹

4.3.4 Intestinal resection

Statement 23.1: There are insufficient data to support a low-fat diet for the treatment of bile-acid diarrhea in people with Crohn's disease who have undergone intestinal resection involving the terminal ileum. (EL4) (Consensus: 100%)

There is no specific dietary advice in the setting of intestinal resection and re-anastomosis. However, in people with CD who have undergone resection involving the terminal ileum, there is an increased risk of ileal malabsorption of vitamin B12 and bile acids, with subsequent development of vitamin B12 deficiency and type I bile-acid diarrhea, respectively. Assessment and correction of vitamin B12 deficiency is described under *Nutritional assessment and optimization for IBD*.

Bile-acid diarrhea is caused by the dysregulation of bile-acid recycling within the enterohepatic circulation, leading to delivery of unabsorbed bile acids to the colon where they increase stimulating fluid, mucus, or sodium secretion.²¹⁰ Data on the role of diet in treating bile-acid diarrhea in people with CD after an ileal resection are limited. An observational trial of EEN with a low-fat elemental formula for 8-15 days in 6 patients (4 with CD) with bile-acid diarrhea following an ileal resection led to reduced fecal bile-acid output, weight, and frequency.²¹¹ Whether the improvement in bile-acid diarrhea was due to the low-fat composition or another component of the EEN formula is unknown. Two other observational studies of patients with bile-acid diarrhea in the absence of IBD, with or without bile-acid sequestrants, revealed improvements in gastrointestinal symptoms with a low-fat diet.^{212,213} Given the chronic nature of bile-acid diarrhea, use of ongoing EEN is not feasible. Calcium oxalate nephrolithiasis is over 2-fold more common in people with CD following intestinal resection than those without prior intestinal surgery.²¹⁴

Statement 23.2: In people with Crohn's disease who have undergone intestinal resection and have a history of calcium oxalate nephrolithiasis, mechanism-based reasoning suggests that adequate hydration, increased dietary calcium, supplementary calcium citrate, a low oxalate diet, or combinations thereof might reduce oxalate absorption and oxalate stone formation. (EL5) (Consensus: 100%)

A case-control study revealed that in patients with CD, two-thirds of whom had undergone an ileal resection, had higher intestinal absorption and urinary excretion of oxalate compared with healthy controls.²¹⁵ However, there were no studies specifically in people with IBD assessing dietary treatment of oxalate stones. Mechanism-based reasoning suggests that adequate hydration, increased dietary calcium, supplementary calcium citrate, and a low oxalate diet will reduce oxalate absorption and oxalate stone formation. This is supported by trials assessing a low-oxalate diet in those with idiopathic hyperoxaluria.²¹⁶

4.3.5 Stomas

Statement 24: In people with IBD and an ileostomy, fiber intake could increase ileostomy output, but likely not above what is considered normal volume. (EL3) (Consensus: 100%)

Many people with IBD will require a temporary or permanent stoma. Diet may influence the content of stoma bags.

The impact of dietary fiber on stoma output has been investigated in six randomized controlled crossover trials, predominately in people with UC with an ileostomy, although these trials included small numbers and were not sufficiently blinded. Compared with diets with <20 g dietary fiber, a diet containing ≥28 g dietary fiber from fruits, vegetables, grains,^{217,218} inclusion of oat-bran bread,²¹⁹ rye bread,²²⁰ brewer's spent grain,²²¹ or potato or kidney bean flakes²²² increased ileostomy total and dry weight. However, all ileostomy outputs remained within what is generally accepted as normal volume. No other symptoms were examined. In two similar crossover trials in people with IBD and an ileostomy, fiber supplementation with 3.3 g of psyllium husk and 5 g guar gum, but not psyllium seed, provided three times daily increased wet ileostomy output compared with no fiber supplementation.^{223,224} Guar gum doubled ileostomy output, reduced output viscosity, and increased stoma bag emptying frequency compared with usual diets,²²⁴ although background fiber intake was not evaluated.

Survey data indicate that constipation, defined as the absence of stool evacuation ≥2 days with abdominal discomfort, flatulence, and painful passage of stool, is common and occurs in up to 29% of people with a colostomy, although only a small proportion of participants surveyed had IBD.^{225,226} Lifestyle modification counselling, including recommending 20-35 g/day fiber and 2-3 L/day fluids led to symptom resolution in 50%-60% of people with a colostomy and constipation, although this did not benefit the small sample of people with IBD.^{225,226} No contraindications for fiber or fluid were identified,^{225,226} and

it is common practice to encourage adequate fiber and fluid intake as part of a healthy diet.

4.3.6 Ileal pouch-anal anastomoses

Statement 25.1: In people with ulcerative colitis and an ileal pouch-anal anastomosis, fermentable fiber might improve pouch function but there is insufficient evidence to support non-fermentable fiber to improve pouch function. (EL4) (Consensus: 100%)

Many people with UC and an ileal pouch-anal anastomosis (IPAA) associate certain foods with a worsening of symptoms and restrict their diet.²²⁷ However, data informing the role of diet in pouch function, pouchitis development, and pouchitis treatment are limited.

Pouch function: Fiber directly or indirectly has been the most studied for its effect on pouch function in people with UC and an IPAA. There may be symptomatic benefits from fermentable fiber (Table 4), as two placebo-controlled crossover studies showed that the fermentable fiber supplements inulin²²⁸ and fructo-oligosaccharides²²⁹ improved clinical disease activity scores and reduced stool frequency. Dietary sources of fermentable fiber may act similarly, as suggested by an open-label study showing improved pouch function in 6/12 symptomatic patients who were provided a specific diet to increase oligosaccharides and to regulate total and sulphur-containing dietary protein.²³⁰ Assessment of the inverse (via reduction in dietary fermentable fibers) in an open-label study of a low FODMAP diet in 5 patients showed variable results.²³¹ There is no evidence of a discernible effect of non-fermentable fiber on pouch function, as methylcellulose did not provide symptomatic benefit in an open-label crossover study.²³² **Pouchitis development:**

Statement 25.2: In people with ulcerative colitis and an ileal pouch-anal anastomosis, adherence to a Mediterranean diet and daily fruit intake might be associated with a reduced risk of pouchitis development. There are insufficient data on diet in treatment of pouchitis. (EL4) (Consensus: 100%)

The impact of specific nutrients, food groups, and dietary patterns on pouchitis development has been assessed. The only factor associated with previous pouchitis was oligosaccharide intake, as shown in a cross-sectional study.²³³ Lower fruit consumption is associated with pouchitis development in observational and case-control studies.^{234,235} While a prospective cohort study in participants with IPAA did not reveal any specific dietary pattern associated with pouchitis development,²³⁶ an observational study associated adherence to a MD with lower fecal calprotectin levels.²³⁷ This associated benefit did not clearly reduce risk of pouchitis development over 8 years of follow-up.²³⁷

Pouchitis treatment: EEN may reduce bowel frequency and clinical disease activity scores, as shown in an open-label study of 7 people with pouchitis,²³⁸ although clinical symptom

improvement from EEN might not be consistent.²³⁹ Improvements in a modified clinical disease activity score were demonstrated in 15 people with pouchitis following the CDED over 24 weeks, although 7 people withdrew from the study before completion.²⁴⁰

No improvement of bowel frequency was seen with green tea polyphenol in a retrospective study of people with pouchitis.²⁴¹

4.3.7 Short-bowel syndrome

Statement 26.1: In people with Crohn's disease and short-bowel syndrome, isotonic high sodium oral rehydration solutions might help maintain good hydration. (EL4) (Consensus: 100%)

Studies assessing the role of oral dietary therapies in people with short-bowel syndrome (SBS) or intestinal failure, specifically in CD, are lacking. As such, clinical practice in people with CD and SBS is usually based on research in cohorts that did not include people with CD or included people with SBS due to CD and other etiologies. The role of oral rehydration solutions, macronutrient absorption, and glutamine supplementation has been investigated. Parenteral nutrition strategies in people with CD and SBS are beyond the scope of this consensus.

Dehydration, both from reduced absorption and increased losses from diarrhea, is common in people with SBS. Isotonic oral nutritional solutions are often used to enhance fluid absorption. Various oral rehydration solutions have been tested in people with CD and SBS, albeit mostly in small series or case reports, with a focus on short-term physiological studies. Isotonic high sodium oral rehydration solutions may help to replace luminal sodium losses in SBS.^{242–248}

Statement 26.2: In people with Crohn's disease and short-bowel syndrome, a diet with a higher fat: carbohydrate ratio containing medium-chain triglycerides might decrease energy losses in those with colon in continuity. (EL3) (Consensus: 100%)

Macronutrient absorption has been assessed in people with SBS with and without a colon. In those with a colon, unblinded crossover studies revealed that fecal energy losses were less after following a diet with a higher fat: carbohydrate ratio.^{249,250} However, there were conflicting findings on the differences being due to fat versus carbohydrate excretion. These results may be because of a difference in those who had fat maldigestion or malabsorption, which is common with SBS and poses a risk of deficiencies in fat-soluble vitamins and essential fatty acids.²⁵¹ The type of fat ingested may be of importance, as indicated in a randomized crossover study of 7 people with SBS and a colon, whereby inclusion of medium-chain compared with only long-chain triglyceride consumption, provided in both food and enteral nutrition, led to improved energy absorption.²⁵² Medium-chain triglycerides can be absorbed directly in the small bowel without requiring micelle formation and the presence of bile. In those without a

functioning colon, the fat: carbohydrate ratio did not affect absorption in several studies.^{250,252,253} Type of fat matter also did not affect absorption, as shown in another crossover study of 7 people with a high jejunostomy that compared an elemental diet containing medium-chain triglycerides to a polymeric formula containing only long-chain triglycerides.²⁵³

Statement 26.3: In people with Crohn's disease and short-bowel syndrome, oral or subcutaneous glutamine does not improve markers of intestinal growth, function, and adaption. (EL3) (Consensus: 100%)

Supplementation (oral or subcutaneous) with the amino acid glutamine, often in combination with growth hormone, has been examined for possible benefits on intestinal growth, function, and adaption. Double-blinded, placebo-controlled crossover studies have shown no convincing effects on intestinal morphology, gastrointestinal transit, D-xylose absorption, or stool losses. However, the studies had small sample sizes and a mix of those with and without a colon.^{254–256}

4.3.8 Orofacial granulomatosis

Statement 27.1: A cinnamon- and benzoate-free diet might assist in the management of perioral manifestations of Crohn's disease, within the spectrum of orofacial granulomatosis, to reduce lip and oral inflammation and lip enlargement. There is insufficient evidence to support other dietary restrictions, although exclusive enteral nutrition might have a role. (EL4) (Consensus: 96%)

Orofacial granulomatosis (OFG) is an uncommon condition characterized by lip swelling that may have associated perioral erythema and intra-oral changes (ulceration or fissuring). While OFG can be isolated, some individuals also have or will subsequently develop CD. Given the low prevalence of OFG, most research on the role of diet as treatment has provided low-level evidence, and only short-term outcomes have been reported.

The most commonly researched diet in OFG has been a cinnamon- and benzoate-free diet. In a retrospective study of 32 people with OFG, of whom 9 also had inflammation identified on ileocolonoscopy, a large proportion had improved lip and oral inflammatory activity after following the diet for 8 weeks.²⁵⁷ The findings of this study were consistent with three single case reports that showed reduced gingival inflammation and enlargement following several weeks of a cinnamon-free or benzoate-free (or both) diet.^{258–260}

Restriction of phenolic acid and monosodium glutamate has also been examined. A low phenolic acid diet led to improved symptoms in 7/10 people with OFG (1 person had concurrent CD)²⁶¹ and two case reports of people with isolated OFG achieved responses after exclusion of monosodium glutamate.^{262,263} A 6-week course of EEN with an elemental formula in a series of 22 children with OFG, (12 with concurrent CD) led to improved lip appearance and

clinical disease activity scores in those with and without concurrent CD.²⁶⁴

Statement 27.2: Allergy testing to predict dietary response for orofacial granulomatosis may not be valuable. (EL3) (Consensus: 96%)

Many conditions that affect the orofacial region have an allergy-basis, including the proposed etiology of OFG. Indeed, 73% of 264 people with OFG within a large cohort of people with oral diseases had urticaria on allergy patch testing, with more than half reacting to benzoic acid, 38% to cinnamaldehyde, and many to related food additives, perfumes, and flavourings.²⁶⁵ Subsequent dietary restrictions resulted in subjective improvements in more than a third of those with OFG.²⁶⁵ In contrast, there were variable results on the predictive value of allergy testing for dietary response.²⁶⁶

4.3.9 Perinatal nutrition

The nutritional management of women with IBD and their infants throughout the prenatal, antenatal, and infant periods was covered in a 2023 ECCO consensus on perinatal care in IBD and therefore has not been revisited within this consensus.²⁶⁷

4.4 Nutritional assessment and optimization for IBD

Consensus evaluation of the evidence for nutritional assessment and optimization for IBD is outlined as anthropometric, micro-nutrient, and dietary approaches.

4.4.1 Anthropometry

Statement 28: Malnutrition and sarcopenia are negatively associated with clinical outcomes in IBD. Screening to identify the need for nutritional assessment is recommended. (EL3) (Consensus: 96.6%)

Malnutrition (including both undernutrition and overnutrition) arises from an imbalance between nutrient intake and requirements, leading to abnormal body composition and diminished physical and mental function.²⁶⁸ This imbalance can lead to nutritional deficiencies and sarcopenia, characterized by low muscle mass and decreased muscle strength or physical performance, and increased visceral fat associated with chronic disease, including cardiovascular and metabolic conditions. Malnutrition is highly prevalent in IBD, during active disease and remission,²⁶⁹ and is associated with increased hospitalizations, disease flares, need for surgery, and postoperative complications.^{270–278} Furthermore, malnutrition and sarcopenia are correlated with disease activity and elevated levels of fecal calprotectin.²⁷⁷ Identification of malnutrition involves using a validated screening tool that is both effective and easy to use. Nutritional assessment in IBD at diagnosis and in patients who are at risk of malnutrition is particularly important, necessitating the use of various anthropometric measurements and

assessment of body composition (Table 5). Body composition measurements, such as reduced muscle mass and excessive visceral adipose tissue, are independently associated with negative clinical outcomes.^{272,273,277,279–285} A detailed nutritional assessment paradigm is presented in Figure 2.

Statement 29: Body mass index does not accurately represent body composition in people with IBD. Longitudinal assessment of nutritional status using body mass index in combination with assessments of body composition, muscle function, or both is recommended. (EL3) (Consensus: 93.3%)

Historically, nutritional assessment has relied solely on weight and BMI. However, these have limitations in nutritional assessment of people with IBD and are often misleading in people who are overweight and obese but are actually malnourished.^{271,286} Weight and BMI also do not accurately predict body composition.^{286–288} As sarcopenia is not exclusively linked to undernutrition and can occur in people who are overweight and obese, this can lead to undiagnosed sarcopenia in IBD. Additionally, body composition measurements reveal a high prevalence of nutritional risk in people with IBD in clinical remission that may not be captured by BMI alone.^{286,289} Therefore, incorporating additional anthropometric measures to evaluate body composition and muscle function is important in clinical practice decisions for IBD management. The Global

Table 5. Advantages and disadvantages of tools assessing body composition.

Tool	Advantages	Disadvantages	Marker of sarcopenia	Marker of visceral adiposity
Body mass index	Free, rapid, easy to measure and track	Does not provide information about body composition, can misclassify malnutrition, cannot detect sarcopenia	Poor	Moderate
Unintentional weight loss	Free, easy to measure and track, indicates recent nutritional changes	Does not provide information about body composition, cannot detect sarcopenia	Poor	Poor
MUAC	Inexpensive, rapid, easy to measure	Does not accurately reflect body composition, cannot detect sarcopenia, less sensitive to changes of nutritional status	Poor	Poor
MAMC	Inexpensive, provides more detailed information about muscle mass than MUAC, practical indicator of muscle mass when combined with triceps skinfold	Requires triceps skinfold measurement to calculate, more time-consuming, interpretation requires age and gender-specific reference values, limited in accuracy compared with more advanced techniques	Poor	N/A
Waist circumference	Inexpensive, rapid, easy to measure, practical indicator of visceral adiposity	Does not accurately reflect muscle composition, cannot detect sarcopenia	N/A	Good
Handgrip strength	Moderate cost, noninvasive, easy to perform, can detect sarcopenia by assessing muscle strength, sensitive to changes of nutritional status	Interpretation requires age and gender-specific reference values	Good with muscle mass measure	N/A
Quadriceps muscle strength	Moderate cost, noninvasive, can detect sarcopenia by assessing muscle strength of lower body	Requires specialized equipment and training, interpretation requires age and gender-specific reference values	Good with muscle mass measure	N/A
Bioimpedance	Moderate cost, noninvasive, rapid, easy to use, generally portable, can detect sarcopenia by measuring body composition, sensitive to changes of nutritional status	Requires specialized equipment and training, might be less accurate especially in certain populations (eg, obese or cachectic patients)	Good with muscle strength measure	N/A
DEXA	Highly accurate for body composition assessment, can detect sarcopenia, can measure bone density, can assess visceral adiposity	Expensive, requires specialized equipment and training, very low dose of radiation	Reference method	Reference method
CT	Can detect sarcopenia by measuring body composition, providing precise measurements of skeletal muscle mass, can assess visceral adiposity	Expensive, requires specialized equipment and training, high dose of radiation	Reference method	Reference method
MRI	Can detect sarcopenia by measuring body composition, can assess visceral adiposity, provides detailed images without radiation exposure	Very expensive, limited availability and time consuming, requires specialized equipment and training	Reference method	Reference method
Ultrasound	Moderate cost, portable, noninvasive, provides imaging of muscle and subcutaneous fat layers without radiation exposure	Requires specialized equipment and training, less accurate for body composition assessment, validation studies are required before a recommendation for sarcopenia detection can be made	N/A	Moderate

Table assessment tools summary are based on these references.^{1–7}

Abbreviations: BMI, body mass index; CT, computed tomography; DEXA, dual energy X-ray absorptiometry; MAMC, mid-upper arm muscle circumference; MRI, magnetic resonance imaging; MUAC, mid-upper arm circumference; N/A, not applicable.




Figure 2. Recommended nutritional assessment algorithm for patients with inflammatory bowel disease at diagnosis and established disease.

Table 6. Definition of anemia according to WHO criteria (2024).⁸

Age or sex group	Mild to moderate anemia (hemoglobin g/L)	Severe anemia (hemoglobin g/L)
Children, 6-23 months	<105	<70
Children, 24-59 months	<110	<70
Children, 5-11 years	<115	<80
Girls, 12-14 years (non-pregnant)	<120	<80
Boys, 12-14 years	<120	<80
Women, 15-65 years (non-pregnant)	<120	<80
Men, 15-65 years	<130	<80
First trimester pregnancy	<110	<70
Second trimester pregnancy	<105	<70
Third trimester pregnancy	<110	<70

Leadership Initiative on Malnutrition (GLIM) includes reduction in muscle mass as one of the phenotypic criteria for diagnosing malnutrition.²⁶⁸ According to GLIM, techniques such as dual-energy X-ray absorptiometry, bioelectrical impedance analysis, ultrasound, computed tomography, and magnetic resonance imaging are recommended for assessing muscle mass. Additionally, GLIM recommends grip strength as a measure of muscle function due to its practicality and accessibility, particularly since muscle function often declines more rapidly than muscle size, making grip strength a useful complementary tool.²⁶⁸

4.4.2 Micronutrients

Anemia, or reduction of hemoglobin, is common in IBD²⁹⁰⁻²⁹² and has a prevalence ranging from 6%-74%, with two-thirds of patients presenting with anemia at IBD diagnosis.^{290,293} Anemia leads to fatigue and negatively impacts patient QoL, cognitive functions, and IBD disease outcomes.²⁹⁰ Anemia in IBD is defined according to the World Health Organization criteria²⁹⁴ (Table 6). Anemia is commonly caused by deficiencies in

iron, folate, vitamin B12, or combinations thereof. Specific recommendations for iron, folate, and vitamin B12 monitoring in people with IBD and supplementation therapies for correction of deficiencies are described elsewhere^{293,295} and are beyond the scope of this consensus.

Statement 30: Hemoglobin and iron status should be monitored in all people with IBD. (EL2) (Consensus: 100%)

The most common forms of anemia in people with IBD are iron deficiency anemia (IDA), anemia of chronic disease (ACD), and anemia from combined causes. In patients with IBD, the diagnosis of IDA and ACD is challenging as they often overlap, particularly as iron deficiency relates to the degree of inflammation, which is commonly problematic in chronic disease. In patients without clinical, laboratory, endoscopic, or radiological signs of active inflammation, serum ferritin <30 µg/L

Table 7. Characterization of relevant micronutrients in IBD, food sources, deficiencies, and recommended monitoring.

Micronutrient	Role in body	Food sources	Symptoms of deficiency	Definition of deficiency	Populations to consider prophylactic supplementation	Monitoring
Iron^a	Formation of hemoglobin	High bioavailability: Meat, seafood, and poultry Low bioavailability: Iron-fortified breakfast cereals and breads, legumes, spinach, nuts and some dried fruits	Weakness, fatigue, lack of energy, and problems with concentration and memory	CRP <10 mg/L and ferritin <30 µg/L CRP >10 mg/L and ferritin <100 µg/L CRP not available TfS <16%	Pregnancy, infancy, those on vegetarian or vegan diets, those with anemia of chronic disease	At diagnosis and at least every 12 months in patients in remission, at least every 3 months in those with active disease
Folate^a	DNA replication, metabolism of amino acids, maturation of red blood cells	Green vegetables, legumes/legumes flours, whole grains, offal, folate-fortified foods	Fatigue, mouth ulcers, decreased appetite, pale skin, dizziness, poor appetite, diarrhea, irritability	Serum folate <7 nmol/L or 3 g/L	Those on restrictive diets, those on sulfasalazine or methotrexate, pregnancy/pregnancy planning	At diagnosis and annually
Vitamin B12^a	DNA synthesis, nerve myelin synthesis, cellular metabolism, maturation of red blood cells	Animal products, vitamin B12 fortified plant foods	Fatigue, diarrhea or constipation, poor concentration, frequent infections, poor appetite, numbness in extremities, depression	Variable definitions (148-185 pmol/L or 200-250 pg/mL; serum vitamin B12 poor marker), elevated methylmalonic acid	Those on vegan diet, those with ileal resection >20 cm	At diagnosis and annually
Vitamin D	Maintains bone health alongside calcium and phosphorus, supports gut absorption of calcium, magnesium, phosphorus	Cod liver oil, fatty fish, vitamin D supplemented foods and drinks	Osteopenia and osteoporosis	<50 nmol/L or <30 ng/dL	Those with limited sunlight exposure, those at far distance from the equator	At diagnosis and annually
Vitamin C	Tissue repair, formation of collagen, production of neurotransmitters, enhances non-haem iron absorption	Fruit, vegetables	Poor wound healing, easy bruising or bleeding, fatigue	30-80 µmol/L if CRP <10 mg/L	Those on restrictive or poor-quality diets	If deficiency suspected
Zinc	Cellular metabolism, immune function, protein and DNA synthesis, wound healing, and cell signaling and division	Meat, seafood	Alopecia, delayed growth (in children), frequent infections, hair loss, poor wound healing, loss of appetite, infertility, loss of taste and smell	<9 mmol/L (74 µg/dL; fasting) <8.4 mmol/L (postprandial)	Those on vegetarian or vegan diets, pregnancy and lactation, people with chronic diarrhea	At diagnosis and annually in people with Crohn's disease (not during active disease)
Calcium	Builds and maintains bones and teeth	Dairy, fish with edible bones, calcium-fortified dairy alternatives	Osteopenia and osteoporosis	Serum calcium markers poor indicator of deficiency	Those with active IBD, frequent or long-term corticosteroid use, children, those who restrict dairy	N/A
Magnesium	Energy production, maintains nerve and muscle function, immunity, maintains calcium regulation	Green vegetables, soybeans, nuts, spices, cocoa	Loss of appetite, nausea, vomiting, muscle spasms, abnormal heart rhythm	0.6-1.0 mmol/L	People with chronic or severe diarrhea	If deficiency suspected

^aFor supplementation guidelines refer to Gordon et al. 2024 ECCO guidelines on extraintestinal manifestations in IBD.⁹

indicates iron deficiency. In the presence of active inflammation (CRP > 10 mg/L), serum ferritin up to 100 µg/L indicates ACD. Transferrin saturation <16% is diagnostic of IDA when inflammatory markers are not available.²⁹⁶ If serum ferritin is 30-100 µg/L, a combination of iron deficiency and ACD is likely.^{293,295} The initial screening for anemia and iron deficiency should be performed in all patients with IBD through full blood count, serum ferritin, and CRP.²⁹³ If anemia is confirmed, red blood cell indices, such as red cell distribution width and mean corpuscular volume, reticulocyte count, differential blood cell count, serum ferritin, transferrin saturation, and CRP concentration should be measured. Based on the results and each patient's clinical situation, serum levels of vitamin B12, folic acid, haptoglobin, reticulocytes, lactate dehydrogenase, soluble transferrin receptor, creatinine, and urea could benefit clinical assessment. If the cause of anemia is still unclear despite an appropriate extensive workup, advice from a hematologist may be necessary. Patients in remission or with mild disease activity should be monitored every 6-12 months; such measurements should be performed at least every 3 months for those with moderate or severe disease activity. Serum levels of vitamin B12 and folic acid should be measured at least annually in patients at risk (eg, small-bowel disease or resection) or in the absence of thiopurine use in case of macrocytosis (Table 7).^{293,295,296} The long-term effects of anemia on IBD disease course are debated. However, pre-operative anemia is associated with poorer surgical outcomes (ie, a higher risk of postoperative morbidity and mortality and postsurgical complications).²⁹⁷ A recent Italian multicenter study conducted on 5416 adults with IBD revealed that severe anemia was linked to increased fatigue and poorer QoL. Despite this, only two-thirds of patients received adequate supplementation.²⁹⁰

Iron deficiency is the most common micronutrient deficiency in patients with IBD.²⁹⁰ Long-term iron deficiency can impact patient QoL and cognitive function, even in the absence of anaemia.²⁹² A systematic review of 39 studies conducted in pediatric IBD showed that iron deficiency is common, with iron deficiency in up to 95% of patients at diagnosis and up to 70% of patients continue to have iron deficiency after 2 years.²⁹⁶

Statement 31: Serum folate should be monitored in people with IBD, as they are at risk of deficiency. (EL2) (Consensus: 100%)

Folate (vitamin B9) is required for DNA replication, metabolism of amino acids, and maturation of red blood cells. Folate is found in legumes and legume flours, green vegetables, whole grains, offal, mussels, and folic acid fortified foods. Folate is absorbed in the duodenum and serum folate concentration is an indicator of recent folate status and intake. Although there is no consensus on the specific serum folate level indicating deficiency, the risk of megaloblastic anemia significantly increases below the serum folate cut-off value of 7 nmol/L.²⁹⁴ Systematic reviews of studies on children and adults with IBD suggest that folate deficiency is rare^{296,297} but that serum folate is significantly lower in those with IBD than controls.²⁹⁸ Furthermore, patients who live in countries without mandatory folic acid food fortification (e.g., Europe and Asia) were more likely to have lower serum folate than those living in countries with mandatory fortification (eg, United States, Africa).^{296,298}

Patients taking methotrexate should be supplemented with prophylactic folic acid as the drug inhibits folate uptake. Furthermore, to reduce the risk of neural tube defects, folic acid supplementation is recommended for at least 4 weeks pre-conception and continued for the first 12 weeks of pregnancy.²⁶⁷

Statement 32: People with Crohn's disease (CD) who have had an ileal resection > 20 cm, people with IBD who follow a vegan diet, or both are at high risk of vitamin B12 deficiency and prophylactic supplementation could be considered. Monitoring of vitamin B12 in people with CD and ileal involvement is recommended (EL3) (Consensus: 100%)

Vitamin B12 is essential for cellular metabolism, DNA and nerve myelin synthesis, and maturation of red blood cells. Vitamin B12 is found only in animal products and some vitamin B12 fortified foods. Vitamin B12 is stored in the liver but prolonged inadequate dietary intake or poor absorption depletes liver stores. Vitamin B12 requires gastric-produced intrinsic factor to support its absorption in the terminal ileum. Therefore, patients with prolonged active ileal CD, ileal resections, or both are at increased risk of deficiency compared against those with colonic CD or UC.^{299,300} Serum vitamin B12 is not a sensitive marker of deficiency³⁰⁰ and clinical symptoms of deficiency overlap with those of active IBD, making the diagnosis of vitamin B12 deficiency challenging. Methylmalonic acid, with or without holotranscobalamin (the metabolically active form of vitamin B12), could be used as a more sensitive marker of deficiency.³⁰⁰ Symptoms of vitamin B12 deficiency include fatigue, diarrhea, constipation, poor concentration, frequent infections, poor appetite, numbness in extremities, and depression. During conception and pregnancy, low serum vitamin B12 is associated with adverse pregnancy outcomes.²⁶⁷ Besides those with active ileal disease or resection, the prevalence of serum vitamin B12 deficiency in IBD is rare.^{296,297,299,300} A meta-analysis revealed that people with CD and ileal resection >20 cm were predisposed to vitamin B12 deficiency.³⁰¹ A multivariate analysis of a large retrospective observational study ($n=381$) revealed that the odds of vitamin B12 deficiency were higher in patients with ileal resection >20 cm (OR: 6.7; 95% CI, 3.0-15.0) or active ileal disease (OR: 3.9; 95% CI, 2.2-6.9).³⁰⁰ A systematic review found that those who follow a vegan diet are also at high risk of deficiency due to low oral intake of vitamin B12.³⁰² Prophylactic supplementation could be considered for patients at higher risk of deficiency. Oral, sublingual, or intramuscular vitamin B12 improves status (Table 7), although those with ileal resections may not respond as well to oral supplementation.²⁹⁹

Statement 33: Vitamin D insufficiency is common in people with IBD and may be associated with adverse disease outcomes. Monitoring of serum vitamin D is recommended (EL3) (Consensus: 100%)

Vitamin D, in conjunction with calcium, magnesium, and phosphate, is necessary to achieve and maintain optimal bone density. There are few dietary sources of vitamin D (cod liver

oil, fatty fish; Table 7); synthesis of vitamin D from ultraviolet radiation on the skin is the major contributor to maintenance of adequate status. In IBD, prevalence of deficiency in some countries varies by season, skin pigmentation, or sun exposure behaviors (Table 7) and as such prophylactic supplementation could be considered.^{303–305} While vitamin D deficiency is common both in the IBD and general population, optimal repletion strategies in those with IBD is not known. This is indicated by pediatric trials suggesting that vitamin D supplementation does not preclude vitamin D deficiency^{306,307} and a Canadian cohort study showing that pregnant women with IBD ($n=61$) receiving vitamin D supplements were more likely to be deficient than pregnant women without IBD ($n=574$).³⁰⁸ However, normalization of vitamin D status may be associated with improved inflammatory markers, lower risk of hospitalization and surgery, and fewer disease relapses in both adults and children with IBD.^{170,172,303}

Statement 34: Monitoring of micronutrient levels should be considered in people with IBD. Ideally, this should be performed during clinical and biochemical remission, because levels may be falsely altered during active disease (EL2) (Consensus: 100%)

Although limited data are available, active IBD is linked to low serum levels of vitamins and minerals,²⁹⁷ including iron, zinc, selenium, copper, manganese, folic acid, thiamine, and vitamins D, B12, A, C, E, K, and B6.²⁹⁷ Many of these nutrients are acute-phase reactants, making interpretation of findings challenging in the presence of elevated CRP.²⁹¹ Micronutrient deficiencies are more prevalent in hospitalized patients and in those with active IBD and long-standing CD.^{297,309,310} However, some reports suggest that micronutrient deficiencies persist even during disease remission.^{311,312} A systematic review and meta-analysis revealed zinc deficiency in approximately 50% of adults with IBD, particularly CD,³¹³ and commonly at diagnosis.²⁹⁶ Limited data are available on the clinical outcomes of zinc deficiency in IBD. Some studies suggest poorer clinical outcomes (higher risk of surgery and hospitalizations) in zinc-deficient individuals with IBD than in those with normal zinc levels.^{297,314,315} Similar data were reported in children.^{291,316} The efficacy of zinc supplementation is poorly understood. Small studies suggest that different zinc formulations may improve serum zinc levels and possibly clinical outcomes.^{297,317}

Although data on vitamins A, E, and C and selenium are limited, deficiency of these micronutrients seems to be rare.²⁹⁶

Overall, minimal data are available on the impact of trace elements on the course of IBD. Recently, a single-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy of an over-the-counter multivitamin and mineral supplement to reduce the risk of infection in 320 non-deficient patients with IBD in remission receiving immunomodulators, biologics, or both found no significant differences between supplemented and placebo groups over 24 weeks.³¹⁸

4.4.3 Diet

Beyond nutritional status of people with IBD, problems with eating behavior are common and can lead to nutritional inadequacies and excesses, in addition to negative effects on social eating and enjoyment. Dietary assessment is a core skill of all

dietitians, including identification of issues with eating behaviors followed by counselling on corrective strategies and monitoring behavior change. However, all clinicians can screen for dietary abnormalities. Table 8 describes such behavioral alarm features that may indicate dietary inadequacies, excesses, or both that warrant referral to a dietitian.

Gaps in dietary intake have been assessed in patients with CD and UC. Dietary components that require particular attention in an IBD population include total energy, iron, vitamin C, calcium, and dietary fiber.

Statement 35: Dietary intake is generally lower in active disease than in remission in people with Crohn's disease or ulcerative colitis (EL2). Assessment of dietary intake in people with IBD is recommended, as dietary restriction is common, often resulting in inadequate energy and nutrient intake. (EL3) (Consensus: 100%)

Energy intake, as estimated by dietary recall or food diaries, is lower in adults and children with CD and UC when compared with recommended intake^{319–321} and controls, regardless of disease activity.^{322–325} Intake for dietary fiber, vitamin A, vitamin D, vitamin K, thiamine, folate, calcium, magnesium, iron, zinc, phosphorus, and selenium are often inadequate for persons with CD or UC.^{323,324,326–334} Dietary assessment in children is of particular importance to ensure dietary recommendations are met and to prevent growth deficits.^{322,325,335,336}

While dietary restriction is common among all people with IBD, specific attention should be given to people with IBD and a stoma or an IPAA due to high rates of self-perceived intolerances.²²⁷ Indeed, survey data show that almost half (15/32) of people with IBD and a newly-established or well-established ileostomy avoided certain foods to prevent increased output, gas, odor, blockage, visible food in the stoma bag, or pain.³³⁷ Similar food restrictions were identified in people with an IPAA.²²⁷ As with other populations applying dietary restrictions, there may be a higher risk of micronutrient deficiencies, as suggested by a sub-analysis of 12 people with an established ileostomy not meeting certain reference nutrient intakes.³³⁷ Restrictive eating behavior is of particular concern in people with IBD, as a fear of eating, food avoidance behavior, or disordered eating patterns are more frequently encountered than

Table 8. Dietary alarm features to indicate referral for dietary assessment.

High-risk behavior	Possible contribution to malnutrition
Skipping meals	Not meeting nutritional requirements or overeating at other times
Continual eating	Small food volumes leading to undereating or not stimulating satiety, enabling overeating
Inappropriate eating times (eg, overnight)	Avoidance of “normal” eating leading to under- or overeating
Extreme dietary restriction	Food restriction resulting in undereating or compensation with high-energy foods
Lack of diet variety	Nutritional gaps, limited variety, or including only high-energy foods
Poor knowledge of intake	Poor food choice leading to nutritional gaps or excesses
Fussy eating	Insufficient nutritional intake or including only high-energy foods
Disordered eating	Intentional or inappropriate food restriction (or both) or binge eating

observed in the general population; dietary assessment may help identify those at risk.^{338,339}

Management of increased nutritional requirements and correction of micronutrient deficiencies in women with IBD is reported elsewhere.³⁴⁰

Statement 36: Dietary intake of iron and vitamin C is often low in people with IBD. Assessment of iron and vitamin C intake is recommended. (EL3) (Consensus: 93.1%)

In the absence of IDA or ACD, adequate dietary iron intake helps maintain iron stores.³⁴¹ Dietary iron intake (high concentrations found in red meat; Table 7) is usually lower in people with active IBD, including children and pregnant women^{329,336,340,341} than in healthy persons, although there is inconsistency in whether dietary iron intake increases in people in remission.^{325,334,342} Given the higher iron requirements, cross-sectional studies found that girls³⁴³ and women^{321,332,344} of menstruating age are less likely than males to meet targets. Non-haem iron absorption is improved with dietary and supplementary vitamin C (dietary sources include fruit and vegetables; Table 7), however vitamin C intake is also lower in individuals with IBD compared to healthy people.^{329,331,332,334,336,341,345} Given the low consumption of iron and vitamin C in people with IBD, referral for dietary assessment should be considered in those identified as deficient during quiescent disease, particularly for menstruating women and those on restrictive diets, including vegetarians and vegans. Recommendations for people unable to meet recommended iron intake from food alone and needing iron supplementation are specified elsewhere.^{293,295}

Statement 37: Dietary calcium intake is often below recommendations for optimal bone health in people with IBD. Assessment of calcium intake is recommended. (EL3) (Consensus: 100%)

Osteopenia and osteoporosis are prevalent in people with IBD due to inflammation and corticosteroid use, which increases bone resorption.³⁴⁶ Adequate calcium intake is needed to promote bone mineralization. Compared with healthy populations, calcium intake is lower during active and inactive disease in people with IBD, including children and pregnant women, and is also lower than the recommended intake for optimal bone health.^{321,325,328,329,331–336,340,343,344} As milk products are rich in calcium, reduced calcium intake is even more prevalent in those who avoid dairy.^{331,334,344} Referral for dietary assessment should be considered in people with IBD who restrict dairy intake.

Statement 38: Assessment of dietary fiber intake is recommended in people with IBD, as intake is often below recommendations. (EL2) (Consensus: 96.4%)

Dietary fiber is important for normal laxation, gut health, and disease prevention. Compared with healthy people, those with IBD often have lower dietary fiber intake,^{320,325,331,336,340,342,343,347–350} varying between

8.8–22.7 g/day.^{321,324,325,327,329,331,342,351,352} This is well below most recommended guidelines of 25–30 g/day.^{309,320,321,324–327,331–333,340,343,344,346–349,351–354}

The data for adults and children are similar and disease phenotype or activity have minimal influence on intake.

Despite suggestions that fiber restriction may increase the risk of a flare in CD³⁴⁷ or UC³⁵⁰, many people with IBD minimize fiber to prevent a flare. The clinical practice of a targeted fiber restriction in people with IBD is indicated only for people with stricturing CD (see *Dietary management of comorbidities and special conditions of IBD*).

Where available, referral for dietary assessment of fiber should be considered in people with IBD who restrict fiber or plant-based foods (ie, fruit, vegetables, whole grains, legumes, nuts, and seeds) or those with suspected poor-quality diets.

5. The role of diet in IBD prevention

Diet is a key environmental factor that plays a role in the development of IBD (Figure 1). Identifying pre-disease dietary components that increase or decrease the risk of IBD development has been ascertained through epidemiological cohort studies that repeatedly assessed food intake via food frequency questionnaires or 24-h dietary recall in a large healthy population that was observed for several years or decades. Identifying people who develop illness, such as IBD, allows for assessment of baseline dietary risk factors. For the purpose of this review, only cohort studies conducted prospectively were assessed for consensus inclusion. This was done to minimize the inherent bias from data collected retrospectively.

5.1 Diet as prevention of IBD development

Prospective cohort studies have investigated associations between macronutrients, micronutrients, other food components, and more recently, dietary patterns, such as healthy eating patterns and classification for levels of food processing (Table 9). The association between breastfeeding and IBD development in the offspring is also included (Table 9).

Statement 39: Increased docosahexaenoic acid (n-3) is associated with lower risk of Crohn's disease and ulcerative colitis (UC). A high intake of arachidonic acid (n-6) is associated with UC. Increased oleic acid (n-9) and a high intake ratio of n-3: n-6 polyunsaturated fatty acids are associated with lower risk of UC. (EL2) (Consensus: 100%)

5.1.1 Food components

Several prospective cohort studies have assessed specific food components in the development of IBD.

Several studies have investigated the association between total fat, total long-chain fatty acids, and specific omega-3 (n-3), omega-6 (n-6), and omega-9 (n-9) long-chain fatty acids, in addition to intake ratios of n-3:n-6 and IBD development.

Total fat and long-chain fatty acids: The European Prospective Investigation into Cancer and Nutrition (EPIC), one of the largest and oldest European cohort studies, has broadly assessed the link between the intake of total fat and long-chain fatty acids and CD using matched controls.³⁵⁵ No associations were found.³⁵⁵

n-3: Only two studies assessed intake of total n-3 with the development of UC and CD, with neither study finding

Table 9. Associations of macronutrients, micronutrients, dietary patterns, and breastfeeding with development of CD and UC from prospective cohort studies.

Food component	Prospective cohort study	Participants (n)	Association with CD	Association with UC	Reference
<i>Macronutrients</i>					
Total fat and long-chain fatty acids	EPIC	229 702	None	-	10
<i>n</i> -3	EPIC	25 639		↓ DHA	11
<i>n</i> -3	NHS I and NHS II	238 130	None	None	12
<i>n</i> -3	EPIC	229 702	↓ DHA	-	10
<i>n</i> -3	EPIC	203 193	-	↓ DHA	11
<i>n</i> -6	DCH	57 053	-	↑ arachidonic acid	13
<i>n</i> -6	EPIC	25 639	-	↑ arachidonic acid	14
<i>n</i> -9	EPIC	25 639	-	↓ oleic acid	14
<i>n</i> -3: <i>n</i> -6 ratio	NHS I and NHS II	170 805	None	↓	15
<i>n</i> -3: <i>n</i> -6 ratio	NHS I and NHS II	238 130	↓ in certain genotypes	None	12
Fiber	NHS I and NHS II	170 776	↓ total fiber and fiber from fruit	None	16
Fiber	EPIC	401 326	None	None	17
Fiber	UK Biobank	470 669	↓ total fiber and fiber from fruit and bread	↓ fiber from cereal	18
<i>Micronutrients and polyphenols</i>					
Vitamin D	NHS I	72 719	None	↓	19
Vitamin D	E3N	67 572	None	None	20
Vitamin D	NHS I	359 728	None	None	21
Vitamin D	EPIC	260 686	-	None	22
Zinc	NHS I and NHS II	170 776	↓	None	23
Zinc	NutriNet Santé	359 728	↓	None	24
Iron	NHS I and NHS II	165 331	None	None	25
Iron	EPIC	260 686	-	None	22
Polyphenols	EPIC	401 326	↓ resveratrol	None	26
<i>Food groups</i>					
Dairy	Meta-analysis of 11 cohort studies	4 302 554	None (after adjusted for energy, BMI, and alcohol intake)	None (after adjusted for energy, BMI, and alcohol intake)	27
Fruit and vegetables	Meta-analyses of 3-4 cohort studies	211 767 fruit 211 540 vegetables	↓	↓	28
Meat	Meta-analysis of 11 cohort studies	4 302 554	None	None	27
Meat	PURE	116 087	None ^a	None ^a	29
Meat	DCH	56 468	-	-	30
Meat	EPIC	413 593	None	↑ total and red meat	31
Meat	NHS II	39 511	None	None	32
Meat	E3N	67 581	None	↑ animal protein	33
Alcohol	EPIC	262 451	None	None	34
Sweetened beverages	SMC/CoSM	83 042	None	None	35
Sweetened beverages	UK Biobank	121 490	↑ sugar-sweetened beverages	None	36
<i>Dietary patterns</i>					
Healthy Lifestyle Score	NHS I, NHS II, HPFS, EPIC and SMC/CoSM	208 070 primary cohort 482 229 validation cohort	↓ Healthy lifestyle score	↓ Healthy lifestyle score	37
Healthy Lifestyles Score	UK Biobank	429 515-430 384	↓ Healthy lifestyle score alone and in combination with polygenic risk scores	↓ Healthy lifestyle score alone and in combination with polygenic risk scores	38
Nutritional quality	EPIC	394 255	↓ UK Food Standards Agency modified nutrient profiling system score	None	39
Cardioprotective diet	UK Biobank	482 887	↓ cardioprotective diet score	↓ cardioprotective diet score	40
Mediterranean diet score	SMC/CoSM	83 147	↓ modified Mediterranean diet score	None	41

(Continued)

Table 9. Continued.

Food component	Prospective cohort study	Participants (n)	Association with CD	Association with UC	Reference
Several healthy eating scores	SMC/CoSM	83 147	↓ healthy eating scores	None	42
Mediterranean diet score	EPIC	366 351	None	None	43
Several healthy eating scores	Lifelines	125 445	↓ Lifelines diet score	↑ red meat, processed meat, and poultry	44
Healthy eating index	ABIS and MoBA	81 280	↓ Medium and high diet quality score	↓ Medium and high diet quality score	45
Healthy eating patterns	Meta-analysis of 6 studies including 4 case-control studies	264 211	↓ healthy eating pattern	None	46
Western dietary pattern	Meta-analysis of 6 studies including 2 cohorts	39 511-222 419	None (cohorts only)	None	47
EDIP score	NHS I, NHS II, and HPFS	208 834	↑ higher inflammatory score	None	48
EDIP score	PURE	28 428	None	None	29
EDIP score	EPIC	32 633	↑ higher inflammatory score	None	49
UPF	Meta-analysis of 5 studies	1 068 425	↑ UPF	None	50
Beastfeeding					
Breastfeeding	NSHD	3 322	None	None	51
Breastfeeding	DNBC, ABIS and MoBA	148 737-169 510	None	None	52

*Processed meat intake associated with increased risk of IBD but not when adjusted for CD or UC.

Abbreviations: ABIS, All Babies in Southeast Sweden cohort; MoBA, Norwegian Mother, Father, and Child cohort; BMI, body mass index; CD, Crohn's disease; DCH, Danish diet, cancer and health cohort; DHA, docosahexaenoic acid; DNBC, Danish National Birth Cohort; E3N, Étude épidémiologique des femmes de la Mutuelle Générale de l'éducation nationale; EDIP, empirical dietary inflammatory pattern; EPIC, European Prospective Investigation into Cancer and Nutrition; HPFS, Health Professional Follow-up Study; NHS, Nurses' Health Study; NSHD, the 1946 National Survey of Health & Development; n-3, omega-3 fatty acids; n-6, omega-6 fatty acids; n-9, omega-9 fatty acids; PURE, Prospective Urban Rural Epidemiology cohort; SMC/CoSM, Swedish Mammography Cohort/Cohort of Swedish Men; UC: ulcerative colitis; UPF, ultra-processed food.

associations.^{356,357} However, the individual *n*-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), commonly found in fish and shellfish, were assessed in four cohort studies,^{355–358} with variable results. Two EPIC studies showed a reduced risk of UC development with DHA intake.^{357,358} This included a study where DHA intake 0.13–0.80 g/day was associated with reduced risk of UC when corrected for total energy, cigarette smoking, and other long-chain fatty acids (OR: 0.17; 95% CI, 0.04–0.78).³⁵⁷ The second study showed similar results (OR: 0.23; 95% CI, 0.06–0.97, adjusted for various factors including age, gender, total energy, and the other fatty acids).³⁵⁸ Another study assessing risk for CD where consumption of 0.31–1.49 g/day DHA (corrected for smoking, total energy, BMI, dietary vitamin D) and the other fatty acids was associated with an over 16-fold reduction in the risk of developing CD (OR: 0.06; 95% CI, 0.01–0.72).³⁵⁵ EPA was not associated with UC risk.³⁵⁷

n-6: *n*-6 arachidonic acid, found in animal-derived foods, was associated with developing UC in a Danish cohort (OR: 4.16; 95% CI, 1.56–11.04, adjusted for gender, smoking, aspirin and NSAID use, and other fatty acids)³⁵⁹ and within the UK cohort of EPIC (OR: 6.09; 95% CI, 1.05–35.23); adjusted for total energy, aspirin use, cigarette smoking, social class, and the dietary intakes of linoleic acid and *n*-3 fatty acids.³⁶⁰

n-9: Consumption of oleic acid, a large constituent of olive oil, was associated with a lower risk of UC (OR 0.03 (0–0.56)).³⁶⁰

n-3: *n*-6 ratio: In the all-female Nurses' Health Study (NHS) I, the risk associations of *n*-3:*n*-6 ratio for UC and CD were explored.³⁶¹ Compared with the lowest quintile, women in the highest quintile of *n*-3:*n*-6 PUFA intake had a lower risk of developing UC but not CD (HR: 0.69; 95% CI, 0.49–0.98, adjusted for age, cohort, smoking, energy intake, BMI, oral contraceptive and postmenopausal hormone

therapy use, and NSAID and aspirin use).³⁶¹ Although no associations were seen for *n*-3:*n*-6 ratios, in a subsequent study including NHS I and NHS II, integration of targeted genetic profiling revealed a significantly reduced risk of UC from *n*-3: *n*-6 ratio intake in four genotypes (GG genotype of rs4646904 single nucleotide polymorphism (SNP), GT/TT genotype of rs1290617 SNP, GG genotype of rs3794987 SNP of CYP4F3 locus, and T-genotype of rs3834458 SNP of FADS2 locus). No such protective effect was seen in genotype analysis for CD.³⁵⁶

Statement 40: Increased dietary fiber intake is associated with lower risk of IBD, particularly from fruit and high-fiber bread for Crohn's disease and from high-fiber cereals for ulcerative colitis. (EL2) (Consensus: 96.7%)

Three studies investigated dietary fiber intake in the development of CD and UC.^{362–364} The impact of dietary fiber on all forms of IBD was investigated in one cohort, which showed a reduced risk of developing IBD in all quintiles of fiber intake in an adjusted model (highest quintile HR: 0.74; 95% CI, 0.58–0.93).³⁶⁴ The reduced risk was largely associated with fiber sourced from bread and cereal (highest quintiles—bread HR: 0.85; 95% CI, 0.75–0.96, cereal HR: 0.84; 95% CI, 0.71–0.99). When separated into IBD phenotypes, there were consistently no associations found between dietary fiber intake and UC development.^{362,363} A sub-analysis considering food sources of fiber found cereal fiber lowered the risk of developing UC (HR: 0.79; 95% CI, 0.64–0.98),³⁶⁴ but this was inconsistent with another study.³⁶²

Through a range of mechanisms, including antioxidant activity, polyphenols are nonessential nutrients that may have protective effects against development of many chronic diseases. The European Prospective Investigation into Cancer and Nutrition explored risk associations with intake of numerous non-nutrient bioactive polyphenols.³⁷⁴ There were no associations between risk of CD and intake of total polyphenols or total or individual flavonoids. There was a reduced risk with higher flavone intakes, which was significant for the trend across quartiles ($P = .03$). However, only the third quartile was statistically significant (OR: 0.33; 95% CI, 0.15-0.69, in only 12 cases) but not the fourth (OR: 0.61; 95% CI, 0.28-1.3, in 30 cases, lignans or total or individual phenolic acids).³⁷⁴ There was a reduced risk of CD with higher intake of resveratrol (OR: 0.40; 95% CI, 0.20-0.82, P for trend 0.02).³⁷⁴ Individual intake corresponding to the different quartiles associated with risk were not reported. There were no associations between intake of total polyphenols or intake of total or individual polyphenol classes with UC.

Statement 46: Healthy eating patterns are associated with lower IBD risk and therefore are recommended. These often include high consumption of fruits, vegetables, whole grains, nuts and seeds, legumes, and fish and low consumption of red meat, processed meats, and high-sugar foods and beverages. (EL2) (Consensus: 83.3%)

5.1.2 Dietary patterns

Rather than assessing the risk of IBD development with individual nutrients, consideration of more comprehensive dietary intake, either through food groups or the combination of food groups in dietary patterns, may be more indicative of interactions of foods as eaten together and possibly overall diet quality. Food groups describe the categorization of foods sharing similar nutritional properties, such as dairy (consisting of milk, yoghurt, and cheese, which are rich in calcium and protein). The removal of entire food groups with the specific intent of mitigating risk of IBD presents safety concerns and may potentially cause macronutrient or micronutrient deficiencies (or both), as in the case of dairy exclusion causing calcium deficiency. For this reason, any recommendation to exclude food groups from the diet should be done with caution. Several studies have investigated food groups and dietary patterns and their association with IBD development. *Food groups:* A recent meta-analysis of cohort studies reported reduced risk for both CD and UC in adults with higher dairy intake. However, this reduced risk did not appear to persist when adjusted for alcohol, BMI, and energy intake.³⁷⁵ A systematic review and meta-analysis reported inverse associations between fruit and vegetable intake with the development of CD, UC, and IBD,³⁷⁶ although many studies were case-control in design and findings were variable. Results from a large prospective cohort suggested that higher fruit intake was associated with a decreased risk of CD and no association with UC, but no adjustment was made for other dietary components or level of food processing.³⁶² Other prospective cohorts did not find an association.^{377,378} There were no clear associations between intake of meat (including

red, white, and processed meat),^{85,86,375,377,379,380} alcohol,³⁸¹ and sweetened beverages^{382,383} with development of IBD. Most published studies did not adjust for other dietary components or patterns, which limits generalizability.

Healthy dietary patterns: Studies utilizing a dietary pattern approach have the advantage of capturing the complex interactions between foods and nutrients. In recent years, multiple studies that focused on healthy dietary patterns, using different definitions, have been conducted on large cohorts with long-term follow-up, showing a seemingly protective effect between adherence to a healthy lifestyle (including diet) and risk of IBD. The largest of these assessments included the NHS that translated modifiable diet and other lifestyle factors into a "Healthy Lifestyle Score," which was higher for consumption of fruits, vegetables, nuts, dietary fibers, at least two servings of fish per week, nil-to-moderate alcohol consumption, low red meat consumption, maintaining a normal BMI, being a nonsmoker, and engaging in physical activity. The population attributable risk for a healthy lifestyle score was 61.1% (95% CI, 16.8-84.9%) for CD and 42.2% (95% CI, 1.7-70.9%) for UC.³⁸⁴ These data were validated in three large European cohorts, including the EPIC and the Swedish Mammography Cohort/ Cohort of Swedish Men cohorts, generating a population attributable risk of 48.8-60.4% and 56.3-46.8% for CD and UC, respectively.³⁸⁴ Data from the UK biobank suggest adherence to a healthy lifestyle score, which was calculated based on smoking status, BMI, sleep duration, physical activity, low alcohol consumption, and a diet including high consumption of fruits, vegetables, and whole grains, consumption of ≥ 2 servings of fish/week and low consumption of red meat, processed meat, and refined grains, could mitigate genetic risk of IBD. Individuals with a high genetic risk who adhered to a healthy lifestyle experienced an almost 50% reduction in the likelihood of developing CD and UC.³⁸⁵ This is consistent with studies using a UK-based dietary index showing that low nutritional quality scores are associated with increased risk of CD, although this was not the case with UC.³⁸⁶ Adherence to a cardioprotective diet was also inversely associated with the development of CD and UC.³⁸⁷

Commonly associated with health outcomes to prevent many chronic diseases, the MD has also been investigated in IBD prevention. Adherence to the MD was inversely associated with CD, but not UC, in large Swedish cohorts.^{388,389} However, this was inconsistent in other populations, likely confounded by inconsistencies in its definition.³⁹⁰ Moreover, other diet-quality scores, including healthy eating index, did not show consistent associations with CD or UC risk.^{390,391} Only one cohort group has investigated early-life impact on diet, following participants from birth, indicating that a high-quality diet at 1 year of age was inversely associated with the risk of CD and UC, suggesting that even short exposure to dietary habits may have significant effects on IBD risk.³⁹²

Unhealthy dietary patterns: As opposed to healthy eating patterns, the "Western diet" is often the model of an unhealthy diet. While there is no clear definition of a Western diet, it is often characterized as a diet high in fat, sugar, salt, animal protein, and low in dietary fibers. Meta-analyses of cohort and case-control studies have shown inconsistent results when comparing high and low categories of Western diet patterns, with no associations demonstrated when only cohort studies are included.^{390,391,393,394}

Statement 47: Ultra-processed food (UPF) intake is associated with the development of Crohn's disease but not ulcerative colitis. Intake of UPF should be limited consistent with healthy eating patterns. (EL1) (Consensus: 88.9%)

Foods associated with circulating inflammatory markers: Another method of assessing dietary patterns is to apply indices developed through associations of known inflammatory markers. This was the strategy undertaken in the development of the Empirical Diet Inflammatory Pattern (EDIP) score, which identified 18 inflammatory and anti-inflammatory foods associated with CRP and circulating cytokines, although the foods selected for study inclusion were ambiguous. Conflicting results between populations prevented conclusions on the association between EDIP and IBD risk.^{377,395,396}

There is a growing interest in the role of food processing in the pathophysiology of IBD. Ultra-processed food (UPF), defined by the Nova classification system,³⁹⁷ typically contains at least five ingredients, extracted from foods or derived from processing of food components, and can contain food additives. Several prospective cohort studies have investigated food processing on the risk of developing CD and UC. A meta-analysis of these studies, comprising five large cohorts of >1 million participants followed long-term across different geographical sites, showed that UPF intake was associated with an increased risk of subsequent CD (highest quartile 45%-51% versus lowest quartile 13%-21% of energy intake, OR: 1.71; 95% CI, 1.36-2.14).³⁹⁸ Low-processed diets were inversely associated with CD risk (OR: 0.71; 95% CI, 0.53-0.94).³⁹⁸ No associations were found with UC.³⁹⁸

There are several challenges that need consideration when following the recommendation made for UPF. Firstly, there is some ambiguity on the definition of UPF, which encompasses a large range of food, thus identifying some UPFs can be challenging. Secondly, no clear "safe" threshold for consumption of UPF has been identified, with some studies arbitrarily using 20% of energy intake or one serving/day as a reference. Thirdly, UPF differ greatly in their nutritional quality and there was no adjustment for diet quality in the published cohort studies. Due to these constraints, a recommendation of complete avoidance of UPF cannot be made. Recommendations for UPF intake are that they should be limited consistent with healthy eating patterns. Food availability and nutritional adequacy should not be compromised when giving recommendations for UPF intake, as complete avoidance is usually impractical.

5.1.3 Breastfeeding

Statement 48: There are well-recognized benefits of breastfeeding for the health of both the mother and infant but there is currently insufficient evidence supporting breastfeeding as a significant protector against subsequent IBD development. (EL2) (Consensus: 96.6%)

The health benefits of breastfeeding are well-recognized for both the infant and mother.³⁹⁹

The role of breastfeeding in preventing later development of IBD in the infant has been assessed in many studies. Although three meta-analyses concluded a benefit from breastfeeding,⁴⁰⁰⁻⁴⁰² this was mostly from case-control studies. Recommendations are based on four cohort studies to limit the biases inherent in case-control methodology.

The first cohort study that prospectively assessed breastfeeding and risk of IBD onset included data from British birth cohorts (MRC National Survey of Health & Development of 1946 and 1958 National Child Development Study) that followed participants to age 43 and 33 years, respectively, at the time of analysis.⁴⁰³ No associations were identified for risk of CD or UC development with any breastfeeding compared with no breastfeeding.⁴⁰³ The other collection of Scandinavian prospective birth cohorts from three countries (Norway 1999-2008, Sweden 1997-1999, Denmark 1996-2002) also found no difference between any duration of breastfeeding and development of CD or UC.⁴⁰⁴

Early-life factors and subsequent risk of pediatric IBD in the Scottish population from 1981-2017 were explored, where no difference between exclusive breastfeeding or exclusive formula feeding at 6 weeks was seen.⁴⁰⁵

6. Future directions

This first ECCO consensus on dietary management of IBD supports the role of diet in improving clinical outcomes for patients with IBD. The procedure for determining when and what dietary assessments and treatments should be implemented is detailed in Figure 1. Many evidence gaps within our IBD dietary management paradigm were identified through the consensus process. Advancing diet-focused IBD research would be facilitated by increasing the numbers of research dietitians and an increased provision of targeted financial support. Proposed research topics to further knowledge and improve clinical care for patients with IBD are described in Table 10. Ongoing dietary research is crucial to provide optimal dietary management in IBD.

The ECCO Consensus Papers are targeted at health care professionals only and are based on an international consensus process.

This process includes intensive literature research as explained in the methodology section and may not reflect subsequent scientific developments, if any, until the next update is prepared. Readers of the Consensus Papers acknowledge that research about medical and health issues is constantly evolving and diagnoses, treatments, and dose schedules for medications are being revised continually. Therefore, the ECCO encourages all readers to also consult the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations.

Any treatment decisions are to be made at the sole discretion and within the exclusive responsibility of the individual clinician and should not be based exclusively on the content of the ECCO Consensus Papers. The ECCO and/or any of its staff members and/or any consensus contributor may not be held liable for any information published in good faith in the ECCO Consensus Guidelines. ECCO makes no representations or warranties, express or implied, as to the accuracy or completeness of the whole or any part of the

Table 10. Proposed dietary research priorities for improvement of IBD knowledge and care.

Area	Research need	Example
Dietary therapy to induce and maintain remission of IBD	Develop and validate objective tools to assess dietary adherence and investigate the impact of compliance on treatment outcomes	Design prospective studies using metabolomic and isotope-based biomarkers and digital dietary tracking tools to quantify adherence and correlation with clinical, inflammatory, and microbiome-based outcomes in dietary interventions for IBD
	Elucidate the biological pathways through which EEN induces remission in CD	Conduct integrated multi-omic studies in both human patients and complementary animal/in vitro models to investigate how EEN modulates gut microbiota, microbial metabolites, mucosal immunity, and epithelial barrier function
	Assess the efficacy and mechanisms of whole-food dietary interventions in induction and maintenance of remission in IBD, including the exclusion of UPF, gluten and specific components identified as inflammatory in preclinical models	Randomized controlled trials comparing whole-food diets that exclude UPFs and specific components—such as emulsifiers, artificial sweeteners, gluten, and sugar/refined carbohydrates
	Investigate the efficacy of combining dietary therapy with advanced pharmacological treatments to enhance induction of remission	Randomized controlled trials evaluating dietary interventions (eg, CDED, whole-food diets, EEN) as adjuncts to biologics or small molecules
	Development of strategies to maintain remission	Development of existing dietary strategies that have shown promise, but currently with insufficient evidence to make a firm recommendation, such as CDED as maintenance therapy, PEN in CD, low red and ultra-processed meat in UC, Vegetarian diet in IBD, Mediterranean diet in UC
Dietary management of comorbidities and special conditions of IBD	Prevention of postoperative complications	Assessment of 10 days of oral nutritional supplementation and 2 weeks EEN, as part of the ERAS program, in people with IBD awaiting surgery
	Improvement of pouch function and prevention of pouchitis	Development and assessment of dietary therapies in people with UC and an ileal pouch-anal anastomosis
Nutritional assessment and optimization of IBD	Treatment of persistent gastrointestinal symptoms	Development and assessment of therapies in adults and children with quiescent IBD that minimize dietary burden
	Practical nutritional assessment	Identification of the optimal nutrition assessment tools for use by clinicians and people with IBD
Diet as prevention of IBD development	Longitudinal nutritional assessment	Research that reports longitudinal nutritional status assessment data using BMI in combination with assessments of body composition, muscle function, or both
	Mechanism(s) of diet conferring protection or risk of IBD development	Preclinical studies to evaluate the effects of well-defined diets on IBD pathogenesis
	Optimal diet for preventing IBD	Evaluation of a well-defined diet in healthy people followed for many years

Abbreviations: CD, Crohn's disease; CDED, the Crohn's disease exclusion diet; EEN, exclusive enteral nutrition; IBD, inflammatory bowel disease; PEN, partial enteral nutrition; UC, ulcerative colitis; UPF, ultra-processed foods.

Consensus Papers. The ECCO does not accept, and expressly disclaims, responsibility for any liability, loss, or risk that may be claimed or incurred as a consequence of the use or application of the whole or any part of the Consensus Papers.

When the Consensus Papers mention trade names, commercial products, or organizations, this does not constitute any endorsement by ECCO and/or any consensus contributor.

Acknowledgements and disclaimer

We would like to thank and acknowledge the ECCO Office for logistical and coordination support. We thank Alina Gedek, Anna Thiel, Fadi Ifram, and Bogomil Yotov for project management, Paul Freudenberg and Nadine Steubesand for the literature search, and Torsten Karge for support with informatics and the online Guidelines platform.

We gratefully thank the following European Federation of Crohn's and Ulcerative Colitis Associations patient representatives who proactively collaborated in the development of this Consensus Paper: Josef Busuttil, Isabella Grosu, Magdalena Sajak-Szczerba, Vera Slyk, and Vasiliki Rafaela Vakouftsi.

We would like to thank and acknowledge the following ECCO National Representatives, who acted as external reviewers and provided suggestions on the recommendations and supporting text to this document: Andreas Blesl, Ante Bogut, Mihai Mircea Diculescu, Piotr Eder, Tatiana Jovic, Lone Larsen, Diana Martins, Sara Onali, Konstantinos Soufleris, Svetlana Turcan, Sophie Vieujean, and Yamile Zabana. We would also like to thank the following additional reviewers, who provided their feedback during the second online voting round: Mohamed Alboraie, Mariangela Allocca, Aurelien Amiot, Konstantinos Argyriou, David Armstrong, Pearl Avery, Belen

Beltran, Lorenzo Bertani, Maiara Brusco De Freitas, Maria Cappello, Flavio Caprioli, Francesco Colombo, Tiago Curdia Goncalves, Wladyslaw Czuber-Dochan, Vishwa Mohan Dayal, Gabriele Dragoni, Robert Karol Dudkowiak, Nikolas Dussias, Simona Gatti, Amy Gittins, Andres Jose Gomez Aldana, Ahmed Gouda, Antonietta Gerarda Gravina, Nathan Grellier, Dan Griffith, Raluca Roxana Grigorescu, Natasha Haskey, Ioana Alexandra Husar-Sburlan, Nicola Imperatore, Tommaso Innocenti, Tarkan Karakan, Meropi Kontogianni, Ramit Magen Rimom, Sara Massironi, Verena Melo, Sarah Melton, Erasmo Miele, Ravi Misra, Giammarco Mocchi, Konstantina Morogianni, Olga Maria Nardone, Lorenzo Norsa, Daniele Noviello, Anthony O'Connor, Salvatore Oliva, Raquel Oliveira, Raffaele Pellegrino, Gianluca Pellino, Tamar Pfeffer-Gik, Michal Prokopic, Giuseppe Ribaldone, Erin Russell, Gabriela Sancisi, Philipp Oliver Schreiner, Tobias Schwerd, Neha D. Shah, Anne Thomann, Murat Toruner, Gina Trakman, Edyta Tulewicz-Marti, Williams Turpin, Karen Van Hoeve, Pauline Van Ouytsel, Chiara Vigano, Judith Wellens, Nicolette Wierdsma, CK Yao and Alessandra Zilli.

Funding

None declared.

Conflicts of interest

The ECCO has diligently maintained a disclosure policy of potential conflicts of interests (CoI). The conflict of interest declaration is based on a form used by the International Committee of Medical Journal Editors (ICMJE). The CoI statement is not only stored at the ECCO Office and the editorial office of JCC but is also open to public scrutiny on the ECCO website (<https://www.ecco-ibd.eu/about-ecco/ecco-disclosures.html>), providing a comprehensive overview of potential CoIs of authors.

References

- Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. *ACP J Club*. 1995;123:A12-A13.
- Howick J, Chalmers I, Glasziou P, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). Oxford Centre for Evidence-Based Medicine. 2011. Accessed March 14, 2024. <https://www.cebm.ox.ac.uk/resources/levels-of-evidence/explanation-of-the-2011-ocbm-levels-of-evidence/>
- Ajabnoor SM, Forbes A. Effect of fat composition in enteral nutrition for Crohn's disease in adults: a systematic review. *Clin Nutr*. 2019;38:90-99.
- Comeche JM, Caballero P, Gutierrez-Hervas A, et al. Enteral nutrition in patients with inflammatory bowel disease. systematic review, meta-analysis, and meta-regression. *Nutrients*. 2019;11:2657
- Ding Z, Ninan K, Johnston BC, et al. Microbiota signatures and mucosal healing in the use of enteral nutrition therapy v. corticosteroids for the treatment of children with Crohn's disease: a systematic review and meta-analysis. *Br J Nutr*. 2023;130:1385-1402.
- Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. *Aliment Pharmacol Ther*. 2007;26:795-806.
- Fernández-Banares F, Cabré E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. *JPEN J Parenter Enteral Nutr*. 1995;19:356-364.
- Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. *Am J Gastroenterol*. 2007;102:412-429; quiz 468.
- McVeigh L, Payne A. Inducing remission in paediatric Crohn's disease using nutritional therapies—A systematic review. *J Hum Nutr Diet*. 2020;33:170-186.
- Narula N, Dhillon A, Zhang D, et al. Enteral nutritional therapy for induction of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2018;4:Cd000542.
- Sohouli MH, Fatahi S, Farahmand F, et al. Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn's disease. *Aliment Pharmacol Ther*. 2022;56:384-395.
- Swaminath A, Feathers A, Ananthakrishnan AN, et al. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. *Aliment Pharmacol Ther*. 2017;46:645-656.
- Yu Y, Chen KC, Chen J. Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease: a meta-analysis. *World J Pediatr*. 2019;15:26-36.
- Wall CL, Gearry RB, Day AS. Polymeric formula is more palatable than elemental formula to adults with Crohn's disease. *E-SPEN Journal*. 2014;9:e200-e203.
- Kakkadasam Ramaswamy P, Gold Coast Inflammatory Bowel Diseases Research Group. Exclusive enteral nutrition with oral polymeric diet helps in inducing clinical and biochemical remission in adults with active Crohn's disease. *JPEN J Parenter Enteral Nutr*. 2022;46:423-432.
- Lee D, Baldassano RN, Otley AR, et al. Comparative effectiveness of nutritional and biological therapy in North American children with active Crohn's disease. *Inflamm Bowel Dis*. 2015;21:1786-1793.
- Diao N, Liu X, Lin M, et al. Exclusive enteral nutrition orchestrates immunological balances as early as week 4 in adult patients of Crohn's disease: a pilot, open-label study. *Nutrients*. 2023;15:5091.
- Guo Z, Gong J, Li Y, et al. Mucosal microRNAs expression profiles before and after exclusive enteral nutrition therapy in adult patients with Crohn's disease. *Nutrients*. 2016;8:519.
- Guo Z, Wu R, Zhu W, et al. Effect of exclusive enteral nutrition on health-related quality of life for adults with active Crohn's disease. *Nutr Clin Pract*. 2013;28:499-505.
- Xu Y, Guo Z, Cao L, et al. Isolated colonic Crohn's disease is associated with a reduced response to exclusive enteral nutrition compared to ileal or ileocolonic disease. *Clin Nutr*. 2019;38:1629-1635.
- González-Huix F, de León R, Fernández-Bañares F, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. *Gut*. 1993;34:778-782.
- Zoli G, Carè M, Parazza M, et al. A randomized controlled study comparing elemental diet and steroid treatment in Crohn's disease. *Aliment Pharmacol Ther*. 1997;11:735-740.
- Yamamoto T, Nakahigashi M, Umegae S, et al. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. *Inflamm Bowel Dis*. 2005;11:580-588.
- Yan D, Ren J, Wang G, et al. Predictors of response to enteral nutrition in abdominal enterocutaneous fistula patients with Crohn's disease. *Eur J Clin Nutr*. 2014;68:959-963.
- Yang Q, Gao X, Chen H, et al. Efficacy of exclusive enteral nutrition in complicated Crohn's disease. *Scand J Gastroenterol*. 2017;52:995-1001.

26. Zheng XB, Peng X, Xie XY, et al. Enteral nutrition is associated with a decreased risk of surgical intervention in Crohn's disease patients with spontaneous intra-abdominal abscess. *Rev Esp Enferm Dig.* 2017;109:834-842.
27. Zhu Y, Xu L, Liu W, et al. Safety and efficacy of exclusive enteral nutrition for percutaneously undrainable abdominal abscesses in Crohn's disease. *Gastroenterol Res Pract.* 2017;2017:6360319.
28. Wang W, Yin A, Wang J, et al. Real-world evidence of combined treatment of biologics and exclusive enteral nutrition in patients with ileum-dominant Crohn's disease: A multicenter study. *Clin Nutr.* 2024;43:1291-1298.
29. Johnson T, Macdonald S, Hill SM, et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. *Gut.* 2006;55:356-361.
30. Gupta K, Noble A, Kachelries KE, et al. A novel enteral nutrition protocol for the treatment of pediatric Crohn's disease. *Inflamm Bowel Dis.* 2013;19:1374-1378.
31. Davidson N, Rutsky J, Bricker JB, et al. 6- and 12-month outcomes after 90:10 enteral nutrition induction therapy in pediatric Crohn's disease. *J Pediatr Gastroenterol Nutr.* 2022;75:70-75.
32. Zhou S, Huang Z, Hou W, et al. Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease. *Inflamm Res.* 2024;73:199-209.
33. Sahu P, Kedia S, Vuyyuru SK, et al. Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. *Aliment Pharmacol Ther.* 2021;53:568-576.
34. Hirai F, Takeda T, Takada Y, et al. Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. *J Gastroenterol.* 2020;55:133-141.
35. Jatkowska A, White B, Gkikas K, et al. Partial enteral nutrition in the management of crohn's disease: a systematic review and meta-analysis. *J Crohns Colitis.* 2024;19:jjae177.
36. Limketkai BN, Godoy-Brewer G, Parian AM, et al. Dietary interventions for the treatment of inflammatory bowel diseases: an updated systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2023;21:2508-2525. e10.
37. Yang H, Feng R, Li T, et al. Systematic review with meta-analysis of partial enteral nutrition for the maintenance of remission in Crohn's disease. *Nutr Res.* 2020;81:7-18.
38. Watanabe O, Ando T, Ishiguro K, et al. Enteral nutrition decreases hospitalization rate in patients with Crohn's disease. *J Gastroenterol Hepatol.* 2010; 25:S134-S137.
39. Gkikas K, Gerasimidis K, Milling S, et al. Dietary strategies for maintenance of clinical remission in inflammatory bowel diseases: are we there yet? *Nutrients.* 2020;12:2018.
40. Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease? *Scand J Gastroenterol.* 2001;36:383-388.
41. Yamamoto T, Nakahigashi M, Saniabadi AR, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: a prospective study. *Inflamm Bowel Dis.* 2007;13:1493-1501.
42. Yamamoto T, Nakahigashi M, Umegae S, et al. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: A prospective, non-randomized, parallel, controlled study. *Aliment Pharmacol Ther.* 2007;25:67-72.
43. Akobeng AK, Zhang D, Gordon M, MacDonald JK. Enteral nutrition for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev.* 2018;8:CD005984.
44. Fliss-Isakov N, Aviv Cohen N, Bromberg A, et al. Crohn's disease exclusion diet for the treatment of Crohn's disease: real-world experience from a tertiary center. *J Clin Med.* 2023;12:5428.
45. Jijón Andrade MC, Pujol Muncunill G, Lozano Ruf A, et al. Efficacy of Crohn's disease exclusion diet in treatment-naïve children and children progressed on biological therapy: a retrospective chart review. *BMC Gastroenterol.* 2023;23:225.
46. Sigall Boneh R, Sarbagili Shabat C, Yanai H, et al. Dietary therapy with the Crohn's disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy. *J Crohns Colitis.* 2017;11:1205-1212.
47. Sigall-Boneh R, Pfeffer-Gik T, Segal I, et al. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. *Inflamm Bowel Dis.* 2014;20:1353-1360.
48. Urlep D, Benedik E, Brecelj J, Orel R. Partial enteral nutrition induces clinical and endoscopic remission in active pediatric Crohn's disease: results of a prospective cohort study. *Eur J Pediatr.* 2020;179:431-438.
49. Levine A, Wine E, Assa A, et al. Crohn's disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. *Gastroenterology.* 2019;157:440-450 e8.
50. Sigall Boneh R, Van Limbergen J, Wine E, et al. Dietary therapies induce rapid response and remission in pediatric patients with active Crohn's disease. *Clin Gastroenterol Hepatol.* 2021;19:752-759.
51. Niseteo T, Sila S, Trivić I, et al. Modified Crohn's disease exclusion diet is equally effective as exclusive enteral nutrition: real-world data. *Nutr Clin Pract.* 2022;37:435-441.
52. Urlep D, Orel R, Kunstek P, Benedik E. Treatment of active Crohn's disease in children using partial enteral nutrition combined with a modified Crohn's disease exclusion diet: a pilot prospective cohort trial on clinical and endoscopic outcomes. *Nutrients.* 2023;15:4676.
53. Yanai H, Levine A, Hirsch A, et al. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. *Lancet Gastroenterol Hepatol.* 2022;7:49-59.
54. Szczubielek M, Pomorska K, Korólczyk-Kowalczyk M, et al. Effectiveness of Crohn's disease exclusion diet for induction of remission in Crohn's disease adult patients. *Nutrients.* 2021;13:4112.
55. Stein R, Daniel SG, Baldassano RN, et al. Outcomes and predictors of sustained remission after drug withdrawal in pediatric Crohn disease. *J Pediatr Gastroenterol Nutr.* 2022;75:608-615.
56. Elson CO, Layden TJ, Nemchausky BA, et al. An evaluation of total parenteral nutrition in the management of inflammatory bowel disease. *Dig Dis Sci.* 1980;25:42-48.
57. Kushner RE, Shapir J, Sitrin MD. Endoscopic, radiographic, and clinical response to prolonged bowel rest and home parenteral nutrition in Crohn's disease. *JPEN J Parenter Enteral Nutr.* 1986;10:568-573.
58. Mullen JL, Hargrove WC, Dudrick SJ, et al. Ten years experience with intravenous hyperalimentation and inflammatory bowel disease. *Ann Surg.* 1978;187:523-529.
59. Ostro MJ, Greenberg GR, Jeejeebhoy KN. Total parenteral nutrition and complete bowel rest in the management of Crohn's disease. *JPEN J Parenter Enteral Nutr.* 1985;9:280-287.
60. Shiloni E, Coronado E, Freund HR. Role of total parenteral nutrition in the treatment of Crohn's disease. *Am J Surg.* 1989;157:180-185.
61. Mańkowska-Wierzbicka D, Karczewski J, Swora-Cwynar E, et al. The clinical importance of 21-day combined parenteral and enteral nutrition in active inflammatory bowel disease patients. *Nutrients.* 2019;11:2246.
62. Greenberg GR, Fleming CR, Jeejeebhoy KN, et al. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. *Gut.* 1988;29:1309-1315.

63. Wright RA, Adler EC. Peripheral parenteral nutrition is no better than enteral nutrition in acute exacerbation of Crohn's disease: a prospective trial. *J Clin Gastroenterol.* 1990;12:396-399.
64. Seo M, Okada M, Yao T, et al. The role of total parenteral nutrition in the management of patients with acute attacks of inflammatory bowel disease. *J Clin Gastroenterol.* 1999;29:270-275.
65. Abad-Lacruz A, González-Huix F, Esteve M, et al. Liver function tests abnormalities in patients with inflammatory bowel disease receiving artificial nutrition: a prospective randomized study of total enteral nutrition vs total parenteral nutrition. *JPEN J Parenter Enteral Nutr.* 1990;14:618-621.
66. Comerlato PH, Stefani J, Viana LV. Mortality and overall and specific infection complication rates in patients who receive parenteral nutrition: systematic review and meta-analysis with trial sequential analysis. *Am J Clin Nutr.* 2021;114:1535-1545.
67. El Amrousy D, Elashry H, Salamah A, et al. Adherence to the Mediterranean diet improved clinical scores and inflammatory markers in children with active inflammatory bowel disease: a randomized trial. *J Inflamm Res.* 2022;15:2075-2086.
68. Chicco F, Magri S, Cingolani A, et al. Multidimensional impact of Mediterranean diet on IBD patients. *Inflamm Bowel Dis.* 2021;27:1-9.
69. Lewis JD, Sandler RS, Brotherton C, et al. DINE-CD Study Group. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn's disease. *Gastroenterology.* 2021;161:837-852.e9.
70. Garcia-Mateo S, Martinez-Dominguez SJ, Gargallo-Puyuelo CJ, et al. Healthy lifestyle is a protective factor from moderate and severe relapses and steroid use in inflammatory bowel disease: a prospective cohort study. *Inflamm Bowel Dis.* 2024;31:95-104.
71. Burgis JC, Nguyen K, Park KT, Cox K. Response to strict and liberalized specific carbohydrate diet in pediatric Crohn's disease. *World J Gastroenterol.* 2016;22:2111-2117.
72. Obih C, Wahbeh G, Lee D, et al. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. *Nutrition.* 2016;32:418-425.
73. Suskind DL, Wahbeh G, Gregory N, et al. Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. *J Pediatr Gastroenterol Nutr.* 2014;58:87-91.
74. Cohen SA, Gold BD, Oliva S, et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. *J Pediatr Gastroenterol Nutr.* 2014;59:516-521.
75. Suskind DL, Cohen SA, Brittnacher MJ, et al. Clinical and fecal microbial changes with diet therapy in active inflammatory bowel disease. *J Clin Gastroenterol.* 2018;52:155-163.
76. Wahbeh GT, Ward BT, Lee DY, et al. Lack of mucosal healing from modified specific carbohydrate diet in pediatric patients with Crohn disease. *J Pediatr Gastroenterol Nutr.* 2017;65:289-292.
77. Suskind DL, Lee D, Kim YM, et al. The specific carbohydrate diet and diet modification as induction therapy for pediatric Crohn's disease: a randomized diet controlled trial. *Nutrients.* 2020;12:3749.
78. Kaplan HC, Opipari-Arrigan L, Yang J, et al. ImproveCareNow Pediatric IBD Learning Health System. personalized research on diet in ulcerative colitis and Crohn's disease: a series of n-of-1 diet trials. *Am J Gastroenterol.* 2022;117:902-917.
79. Chiba M, Abe T, Tsuda H, et al. Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. *World J Gastroenterol.* 2010;16:2484-2495.
80. Chiba M, Nakane K, Tsuji T, et al. Relapse prevention by plant-based diet incorporated into induction therapy for ulcerative colitis: a single-group trial. *Perm J.* 2019;23:18-220.
81. Chiba M, Tsuji T, Nakane K, Komatsu M. High amount of dietary fiber not harmful but favorable for Crohn disease. *Perm J.* 2015;19:58-61.
82. Chiba M, Tsuji T, Nakane K, et al. High remission rate with infliximab and plant-based diet as first-line (IPF) therapy for severe ulcerative colitis: single-group trial. *Perm J.* 2020;24:1-10.
83. Chiba M, Tsuji T, Nakane K, et al. Induction with infliximab and a plant-based diet as first-line (IPF) therapy for Crohn disease: a single-group trial. *Perm J.* 2017;21:17-009.
84. Chiba M, Tsuji T, Nakane K, et al. Relapse-free course in nearly half of Crohn's disease patients with infliximab and plant-based diet as first-line therapy: a single-group trial. *Perm J.* 2022;26:40-53.
85. Dong C, Chan SSM, Jantchou P, et al. Meat intake is associated with a higher risk of ulcerative colitis in a large European prospective cohort study. *J Crohns Colitis.* 2022;16:1187-1196.
86. Jantchou P, Morois S, Clavel-Chapelon F, et al. Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study. *Am J Gastroenterol.* 2010;105:2195-2201.
87. Bradbury KE, Murphy N, Key TJ. Diet and colorectal cancer in UK Biobank: a prospective study. *Int J Epidemiol.* 2020;49:246-258.
88. Porter RJ, Arends MJ, Churchhouse AMD, Din S. Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines. *J Crohns Colitis.* 2021;15:2131-2141.
89. Peters V, Spooren C, Pierik MJ, et al. Dietary intake pattern is associated with occurrence of flares in IBD patients. *J Crohns Colitis.* 2021;15:1305-1315.
90. Limketkai BN, Hamideh M, Shah R, et al. Dietary patterns and their association with symptoms activity in inflammatory bowel diseases. *Inflamm Bowel Dis.* 2022;28:1627-1636.
91. Chen H, Fu T, Dan L, et al. Meat consumption and all-cause mortality in 5763 patients with inflammatory bowel disease: a retrospective cohort study. *EClinicalMedicine.* 2022;47:101406.
92. Albenberg L, Brensinger CM, Wu Q, et al. A diet low in red and processed meat does not reduce rate of Crohn's disease flares. *Gastroenterology.* 2019;157:128-136.e5.
93. Gkikas K, Logan M, Nichols B, et al. Dietary triggers of gut inflammation following exclusive enteral nutrition in children with Crohn's disease: a pilot study. *BMC Gastroenterol.* 2021;21:454.
94. Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. *Gut.* 2004;53:1479-1484.
95. Gerasimidis K, McGrogan P, Hassan K, Edwards CA. Dietary modifications, nutritional supplements and alternative medicine in paediatric patients with inflammatory bowel disease. *Aliment Pharmacol Ther.* 2008;27:155-165.
96. Strisciuglio C, Giannetti E, Martinelli M, et al. Does cow's milk protein elimination diet have a role on induction and maintenance of remission in children with ulcerative colitis? *Acta Paediatr.* 2013;102:e273-8-e278.
97. Logan M, Gkikas K, Svolos V, et al. Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease-new insights into dietary disease triggers. *Aliment Pharmacol Ther.* 2020;51:935-947.
98. Ishikawa H, Akedo I, Umeki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. *J Am Coll Nutr.* 2003;22:56-63.
99. Matsuoka K, Uemura Y, Kanai T, et al. Efficacy of bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. *Dig Dis Sci.* 2018;63:1910-1919.
100. Heaton KW, Thornton JR, Emmett PM. Treatment of Crohn's disease with an unrefined-carbohydrate, fibre-rich diet. *Br Med J.* 1979;2:764-766.

101. Levenstein S, Prantera C, Luzzi C, D'Ubaldi A. Low residue or normal diet in Crohn's disease: a prospective controlled study in Italian patients. *Gut*. 1985;26:989-993.
102. Limketkai BN, Iheozor-Ejiofor Z, Gjuladin-Hellon T, et al. Dietary interventions for induction and maintenance of remission in inflammatory bowel disease. *Cochrane Database Syst Rev*. 2019;2:CD012839.
103. Brotherton CS, Taylor AG, Bourguignon C, Anderson JG. A high-fiber diet may improve bowel function and health-related quality of life in patients with Crohn disease. *Gastroenterol Nurs*. 2014;37:206-216.
104. Wedlake L, Slack N, Andreyev HJ, Whelan K. Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials. *Inflamm Bowel Dis*. 2014;20:576-586.
105. Lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. a randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). *Scand J Gastroenterol*. 1996;31:778-785.
106. Ritchie JK, Wadsworth J, Lennard-Jones JE, Rogers E. Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease. *Br Med J (Clin Res Ed)*. 1987;295:517-520.
107. Jones VA, Workman E, Freeman AH, et al. Crohn's disease: maintenance of remission by diet. *Lancet*. 1985;2:177-180.
108. Naqvi SA, Taylor LM, Panaccione R, et al. Dietary patterns, food groups and nutrients in Crohn's disease: associations with gut and systemic inflammation. *Sci Rep*. 2021;11:1674.
109. Fritsch J, Garces L, Quintero MA, et al. Low-fat, high-fiber diet reduces markers of inflammation and dysbiosis and improves quality of life in patients with ulcerative colitis. *Clin Gastroenterol Hepatol*. 2021;19:1189-1199.e30.
110. Ahsan M, Koutroumpakis F, Rivers CR, et al. High sugar-sweetened beverage consumption is associated with increased health care utilization in patients with inflammatory bowel disease: a multiyear, prospective analysis. *J Acad Nutr Diet*. 2022;122:1488-1498.e1.
111. Deng M, Dan L, Ye S, et al. Higher fiber intake is associated with reduced risk of related surgery among individuals with inflammatory bowel disease in a prospective cohort study. *J Nutr*. 2023;153:2274-2282.
112. Peng Z, Yi J, Liu X. A low-FODMAP diet provides benefits for functional gastrointestinal symptoms but not for improving stool consistency and mucosal inflammation in ibd: a systematic review and meta-analysis. *Nutrients*. 2022;14:2072.
113. Rajendran N, Kumar D. Food-specific IgG4-guided exclusion diets improve symptoms in Crohn's disease: a pilot study. *Colorectal Dis*. 2011;13:1009-1013.
114. Gunasekera V, Mendall MA, Chan D, Kumar D. Treatment of Crohn's Disease with an IgG4-guided exclusion diet: a randomized controlled trial. *Dig Dis Sci*. 2016;61:1148-1157.
115. Bentz S, Hausmann M, Piberger H, et al. Clinical relevance of IgG antibodies against food antigens in Crohn's disease: a double-blind cross-over diet intervention study. *Digestion*. 2010;81:252-264.
116. Jian L, Anqi H, Gang L, et al. Food exclusion based on IgG antibodies alleviates symptoms in ulcerative colitis: a prospective study. *Inflamm Bowel Dis*. 2018;24:1918-1925.
117. Wang G, Ren J, Li G, et al. The utility of food antigen test in the diagnosis of Crohn's disease and remission maintenance after exclusive enteral nutrition. *Clin Res Hepatol Gastroenterol*. 2018;42:145-152.
118. Lomer MC, Harvey RS, Evans SM, et al. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn's disease. *Eur J Gastroenterol Hepatol*. 2001;13:101-106.
119. Lomer MC, Grainger SL, Ede R, et al. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. *Eur J Gastroenterol Hepatol*. 2005;17:377-384.
120. Svolos V, Hansen R, Nichols B, et al. Treatment of active Crohn's disease with an ordinary food-based diet that replicates exclusive enteral nutrition. *Gastroenterology*. 2019;156:1354-1367.e6.
121. Chandrasekaran A, Groven S, Lewis JD, et al. An autoimmune protocol diet improves patient-reported quality of life in inflammatory bowel disease. *Crohn's Colitis*. 2019;1:otz019.
122. Konijeti GG, Kim N, Lewis JD, et al. Efficacy of the autoimmune protocol diet for inflammatory bowel disease. *Inflamm Bowel Dis*. 2017;23:2054-2060.
123. Olendzki B, Bucci V, Cawley C, et al. Dietary manipulation of the gut microbiome in inflammatory bowel disease patients: pilot study. *Gut Microbes*. 2022;14:2046244.
124. Olendzki BC, Silverstein TD, Persuitte GM, et al. An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. *Nutr J*. 2014;13:5.
125. Day AS, Yao CK, Costello SP, et al. Therapeutic potential of the 4 strategies to Sulfide-Reduction (4-SURE) diet in adults with mild to moderately active ulcerative colitis: an open-label feasibility study. *J Nutr*. 2022;152:1690-1701.
126. Sarbagili-Shabat C, Albenberg L, Van Limbergen J, et al. A novel UC exclusion diet and antibiotics for treatment of mild to moderate pediatric ulcerative colitis: a prospective open-label pilot study. *Nutrients*. 2021;13:3736.
127. Sarbagili Shabat C, Scaldaferrì F, Zittan E, et al. Use of faecal transplantation with a novel diet for mild to moderate active ulcerative colitis: The CRAFT UC randomised controlled trial. *J Crohn's Colitis*. 2022;16:369-378.
128. Herrador-López M, Martín-Masot R, Navas-López VM. Dietary interventions in ulcerative colitis: a systematic review of the evidence with meta-analysis. *Nutrients*. 2023;15:4194.
129. Banerjee R, Pal P, Penmetsa A, et al. Novel bioenhanced curcumin with mesalamine for induction of clinical and endoscopic remission in mild-to-moderate ulcerative colitis: a randomized double-blind placebo-controlled pilot study. *J Clin Gastroenterol*. 2021;55:702-708.
130. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. *Clin Gastroenterol Hepatol*. 2006;4:1502-1506.
131. Lang A, Salomon N, Wu JC, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. *Clin Gastroenterol Hepatol*. 2015;13:1444-1449.e1.
132. Ben-Horin S, Kopylov U, Salomon N. Curcumin-QingDai combination as treatment for moderate-severe ulcerative colitis. *Case Rep Gastroenterol*. 2022;16:563-568.
133. Bommelaer G, Laharie D, Nancey S, et al. POPCUR study group. Oral curcumin no more effective than placebo in preventing recurrence of Crohn's disease after surgery in a randomized controlled trial. *Clin Gastroenterol Hepatol*. 2020;18:1553-1560.e1.
134. Suskind DL, Wahbeh G, Burpee T, et al. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. *J Pediatr Gastroenterol Nutr*. 2013;56:277-279.
135. Kumar S, Ahuja V, Sankar MJ, et al. Curcumin for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2012;10:CD008424.
136. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver injury associated with turmeric-a growing problem: ten cases from the drug-induced liver injury network [DILIN]. *Am J Med*. 2023;136:200-206.

137. Goulart RA, Barbalho SM, Rubira CJ, et al. Curcumin therapy for ulcerative colitis remission: systematic review and meta-analysis. *Expert Rev Gastroenterol Hepatol*. 2020;14:1171-1179.
138. Lombardi N, Crescioli G, Maggini V, et al. Acute liver injury following turmeric use in Tuscany: an analysis of the Italian phytovigilance database and systematic review of case reports. *Br J Clin Pharmacol*. 2021;87:741-753.
139. Sharifi-Rad J, Rayess YE, Rizk AA, et al. Turmeric and its major compound curcumin on health: bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications. *Front Pharmacol*. 2020;11:01021.
140. Zheng T, Wang X, Chen Z, et al. Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta-analysis of randomized controlled trials. *J Gastroenterol Hepatol*. 2020;35:722-729.
141. Ben-Horin S, Salomon N, Karampekios G, et al. Curcumin-QingDai combination for patients with active ulcerative colitis: a randomized, double-blinded, placebo-controlled trial. *Clin Gastroenterol Hepatol*. 2024;22:347-356.e6.
142. Naganuma M, Sugimoto S, Mitsuyama K, et al. INDIGO Study Group. Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis. *Gastroenterology*. 2018;154:935-947.
143. Uchiyama K, Takami S, Suzuki H, et al. Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: an investigator-initiated multicenter double-blind clinical trial. *PLoS One*. 2020;15:e0241337.
144. Yanai H, Salomon N, Lahat A, et al. Real-world experience with curcumin-QingDai combination for patients with active ulcerative colitis: a retrospective multicentre cohort study. *Aliment Pharmacol Ther*. 2023;58:175-181.
145. Baghizadeh A, Davati A, Heidarloo AJ, et al. efficacy of Plantago major seed in management of ulcerative colitis symptoms: a randomized, placebo controlled, clinical trial. *Complement Ther Clin Pract*. 2021;44:101444.
146. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. *Scand J Gastroenterol*. 1991;26:747-750.
147. Fernández-Bañares F, Hinojosa J, Sánchez-Lombrana JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). *Am J Gastroenterol*. 1999;94:427-433.
148. Ejderhamn J, Hedenborg G, Strandvik B. Long-term double-blind study on the influence of dietary fibres on faecal bile acid excretion in juvenile ulcerative colitis. *Scand J Clin Lab Invest*. 1992;52:697-706.
149. Faghfoori Z, Shakerhosseini R, Navai L, et al. Effects of an oral supplementation of germinated barley foodstuff on serum CRP level and clinical signs in patients with ulcerative colitis. *Health Promot Perspect*. 2014;4:116-121.
150. Kanauchi O, Mitsuyama K, Homma T, et al. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. *Int J Mol Med*. 2003;12:701-704.
151. Kanauchi O, Suga T, Tochihiro M, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. *J Gastroenterol*. 2002;37:67-72.
152. Mitsuyama K, Saiki T, Kanauchi O, et al. Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. *Aliment Pharmacol Ther*. 1998;12:1225-1230.
153. Hanai H, Kanauchi O, Mitsuyama K, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. *Int J Mol Med*. 2004;13:643-647.
154. Montroy J, Berjawi R, Lalu MM, et al. The effects of resistant starches on inflammatory bowel disease in preclinical and clinical settings: a systematic review and meta-analysis. *BMC Gastroenterol*. 2020;20:372.
155. Hallert C, Björck I, Nyman M, et al. Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. *Inflamm Bowel Dis*. 2003;9:116-121.
156. Nyman M, Nguyen TD, Wikman O, et al. Oat bran increased fecal butyrate and prevented gastrointestinal symptoms in patients with quiescent ulcerative colitis-randomized controlled trial. *Crohn's Colitis* 360. 2020;2:otaa005.
157. Papada E, Amerikanou C, Torović L, et al. Plasma free amino acid profile in quiescent Inflammatory Bowel Disease patients orally administered with Mastiha (Pistacia lentiscus); a randomised clinical trial. *Phytomedicine*. 2019;56:40-47.
158. Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol*. 2017;14:491-502.
159. Akram W, Garud N, Joshi R. Role of inulin as prebiotics on inflammatory bowel disease. *Drug Discov Ther*. 2019;13:1-8.
160. Amiriani T, Rajabli N, Faghani M, et al. Effect of Lactocare® Synbiotic on disease severity in ulcerative colitis: a randomized placebo-controlled double-blind clinical trial. *Middle East J Dig Dis*. 2020;12:27-33.
161. Anderson JL, Hedin CR, Benjamin JL, et al. Dietary intake of inulin-type fructans in active and inactive Crohn's disease and healthy controls: a case-control study. *J Crohn's Colitis*. 2015;9:1024-1031.
162. Astó E, Méndez I, Audivert S, et al. The Efficacy of probiotics, prebiotic inulin-type fructans, and synbiotics in human ulcerative colitis: a systematic review and meta-analysis. *Nutrients*. 2019;11:293.
163. Dore MP, Bibbò S, Fresi G, et al. Side effects associated with probiotic use in adult patients with inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. *Nutrients*. 2019;11:2913.
164. Lomer MCE, Wilson B, Wall CL. British Dietetic Association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease. *J Hum Nutr Diet*. 2023;36:336-377.
165. Hafer A, Kramer S, Duncker S, et al. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. *BMC Gastroenterol*. 2007;7:36.
166. Limketkai BN, Godoy-Brewer G, Shah ND, et al. Prebiotics for induction and maintenance of remission in inflammatory bowel disease: systematic review and meta-analysis. *Inflamm Bowel Dis*. 2024;31:1220-1230.
167. Wallace C, Gordon M, Sinopoulou V, Limketkai BN. Vitamin D for the treatment of inflammatory bowel disease. *Cochrane Database Syst Rev*. 2023;10:CD011806.
168. Ajabnoor SM, Thorpe G, Abdelhamid A, Hooper L. Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: a systematic review and meta-analysis of randomized controlled trials. *Eur J Nutr*. 2021;60:2293-2316.
169. Guo X, Liu C, Huang Y. Efficacy and safety of Vitamin D adjuvant therapy for ulcerative colitis: a meta-analysis. *Comput Math Methods Med*. 2022;2022:6836942.
170. Guzman-Prado Y, Samson O, Segal JP, et al. Vitamin D therapy in adults with inflammatory bowel disease: a systematic review and meta-analysis. *Inflamm Bowel Dis*. 2020;26:1819-1830.

171. Lev-Tzion R, Griffiths AM, Leder O, Turner D. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2014;2014:CD006320.
172. Li J, Chen N, Wang D, et al. Efficacy of vitamin D in treatment of inflammatory bowel disease: A meta-analysis. *Medicine (Baltimore)*. 2018;97:e12662.
173. Turner D, Shah PS, Steinhart AH, et al. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. *Inflamm Bowel Dis*. 2011;17:336-345.
174. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2009;1:CD006320.
175. De Ley M, de Vos R, Hommes DW, Stokkers P. Fish oil for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2007;4:CD005986.
176. Severo JS, da Silva Barros VJ, Alves da Silva AC, et al. Effects of glutamine supplementation on inflammatory bowel disease: a systematic review of clinical trials. *Clin Nutr ESPEN*. 2021;42:53-60.
177. Ozer M, Bengi G, Colak R, et al. Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life. *Medicine (Baltimore)*. 2020;99:e20067.
178. Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. *Gut*. 2022;71:1117-1126.
179. Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. *Gut*. 2021;70:1214-1240.
180. Zhan YL, Zhan YA, Dai SX. Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. *Clin Nutr*. 2018;37:123-129.
181. Bodini G, Zanella C, Crespi M, et al. A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. *Nutrition*. 2019;67-68:110542.
182. Cox SR, Lindsay JO, Fromentin S, et al. Effects of Low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. *Gastroenterology*. 2020;158:176-188.e7.
183. Halmos EP, Christophersen CT, Bird AR, et al. Consistent prebiotic effect on gut microbiota with altered fodmap intake in patients with Crohn's disease: a randomised, controlled cross-over trial of well-defined diets. *Clin Transl Gastroenterol*. 2016;7:e164.
184. Pedersen N, Ankersen DV, Felding M, et al. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. *World J Gastroenterol*. 2017;23:3356-3366.
185. Testa A, Imperatore N, Rispo A, et al. Beyond irritable bowel syndrome: the efficacy of the low fodmap diet for improving symptoms in inflammatory bowel diseases and celiac disease. *Dig Dis*. 2018;36:271-280.
186. Wiecek M, Panufnik P, Kaniewska M, et al. Low-FODMAP diet for the management of irritable bowel syndrome in remission of IBD. *Nutrients*. 2022;14:4562.
187. Cox SR, Prince AC, Myers CE, et al. Fermentable carbohydrates [FODMAPs] exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial. *J Crohns Colitis*. 2017;11:1420-1429.
188. Melgaard D, Sørensen J, Riis J, et al. Efficacy of FODMAP elimination and subsequent blinded placebo-controlled provocations in a randomised controlled study in patients with ulcerative colitis in remission and symptoms of irritable bowel syndrome: a feasibility study. *Nutrients*. 2022;14:1296.
189. Brown S, Wall CL, Frampton C, et al. The low FODMAP diet for children with inflammatory bowel disease and overlapping functional gastrointestinal symptoms—a case series. *Recent Prog Nutr*. 2023;03:1-6.
190. So D, Gibson PR, Muir JG, Yao CK. Dietary fibres and IBS: translating functional characteristics to clinical value in the era of personalised medicine. *Gut*. 2021;70:2383-2394.
191. Hu D, Ren J, Wang G, et al. Exclusive enteral nutritional therapy can relieve inflammatory bowel stricture in Crohn's disease. *J Clin Gastroenterol*. 2014;48:790-795.
192. Heerasing N, Thompson B, Hendy P, et al. Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease. *Aliment Pharmacol Ther*. 2017;45:660-669.
193. Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for perioperative care in elective colorectal surgery: enhanced recovery after surgery (ERAS®) society recommendations: 2018. *World J Surg*. 2019;43:659-695.
194. Harris RE, Duncan H, Buchanan E, et al. Prehabilitation: the impact of preoperative exclusive enteral nutrition on paediatric patients with Crohn disease. *J Pediatr Gastroenterol Nutr*. 2020;70:503-507.
195. Costa-Santos MP, Palmela C, Torres J, et al. Preoperative enteral nutrition in adults with complicated Crohn's disease: effect on disease outcomes and gut microbiota. *Nutrition*. 2020;70:100009.
196. Li Y, Zuo L, Zhu W, et al. Role of exclusive enteral nutrition in the preoperative optimization of patients with Crohn's disease following immunosuppressive therapy. *Medicine (Baltimore)*. 2015;94:e478.
197. Brennan GT, Ha I, Hogan C, et al. Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn's disease patients: a meta-analysis. *Eur J Gastroenterol Hepatol*. 2018;30:997-1002.
198. Li G, Ren J, Wang G, et al. Preoperative exclusive enteral nutrition reduces the postoperative septic complications of fistulizing Crohn's disease. *Eur J Clin Nutr*. 2014;68:441-446.
199. Ge X, Tang S, Yang X, et al. The role of exclusive enteral nutrition in the preoperative optimization of laparoscopic surgery for patients with Crohn's disease: A cohort study. *Int J Surg*. 2019;65:39-44.
200. Yamamoto T, Nakahigashi M, Shimoyama T, Umegae S. Does preoperative enteral nutrition reduce the incidence of surgical complications in patients with Crohn's disease? A case-matched study. *Colorectal Dis*. 2020;22:554-561.
201. Meade S, Patel KV, Lubner RP, et al. A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre. *Aliment Pharmacol Ther*. 2022;56:646-663.
202. Xu H, Yao D, Huang Y, et al. Perioperative surgical home model improves outcomes in crohn's disease patients undergoing disease-related surgery. *Gastroenterol Res Pract*. 2020;2020:4293420.
203. Feng Y, Li Y, Mei S, et al. Exclusive enteral nutrition ameliorates mesenteric adipose tissue alterations in patients with active Crohn's disease. *Clin Nutr*. 2014;33:850-858.
204. Wang H, Zuo L, Zhao J, et al. Impact of preoperative exclusive enteral nutrition on postoperative complications and recurrence after bowel resection in patients with active crohn's disease. *World J Surg*. 2016;40:1993-2000.
205. Gong J, Wei Y, Gu L, et al. Outcome of surgery for coloduodenal fistula in Crohn's disease. *J Gastrointest Surg*. 2016;20:976-984.
206. Beaupel N, Brouquet A, Abdalla S, et al. Preoperative oral polymeric diet enriched with transforming growth factor-beta 2 (Modulen) could decrease postoperative morbidity after surgery for complicated ileocolonic Crohn's disease. *Scand J Gastroenterol*. 2017;52:5-10.

207. Ayoub F, Kamel AY, Ouni A, et al. Pre-operative total parenteral nutrition improves post-operative outcomes in a subset of Crohn's disease patients undergoing major abdominal surgery. *Gastroenterol Rep (Oxf)*. 2019;7:107-114.
208. Salinas H, Dursun A, Konstantinidis I, et al. Does preoperative total parenteral nutrition in patients with ulcerative colitis produce better outcomes? *Int J Colorectal Dis*. 2012;27:1479-1483.
209. González-Huix F, Fernández-Bañares F, Esteve-Comas M, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. *Am J Gastroenterol*. 1993;88:227-232.
210. Barkun AN, Love J, Gould M, et al. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. *Can J Gastroenterol*. 2013;27:653-659.
211. Nelson LM, Carmichael HA, Russell RI, Atherton ST. Use of an elemental diet (vivonex) in the management of bile acid-induced diarrhoea. *Gut*. 1977;18:792-794.
212. Jackson A, Lalji A, Kabir M, et al. The efficacy of a low-fat diet to manage the symptoms of bile acid malabsorption—outcomes in patients previously treated for cancer. *Clin Med (Lond)*. 2017;17:412-418.
213. Watson L, Lalji A, Bodla S, et al. Management of bile acid malabsorption using low-fat dietary interventions: a useful strategy applicable to some patients with diarrhoea-predominant irritable bowel syndrome? *Clin Med (Lond)*. 2015;15:536-540.
214. Fagagnini S, Heinrich H, Rossel JB, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. *PLoS One*. 2017;12:e0185193.
215. Siener R, Ersten C, Speller J, et al. Intestinal oxalate absorption, enteric hyperoxaluria, and risk of urinary stone formation in patients with Crohn's disease. *Nutrients*. 2024;16:264.
216. Gupta M, Gallante B, Bamberger JN, et al. Prospective randomized evaluation of idiopathic hyperoxaluria treatments. *J Endourol*. 2021;35:1844-1851.
217. Ellegård L, Bosaeus I. Sterol and nutrient excretion in ileostomists on prudent diets. *Eur J Clin Nutr*. 1991;45:451-457.
218. Ellegård L, Bosaeus I, Andersson H. Will recommended changes in fat and fibre intake affect cholesterol absorption and sterol excretion? An ileostomy study. *Eur J Clin Nutr*. 2000;54:306-313.
219. Zhang JX, Hallmans G, Andersson H, et al. Effect of oat bran on plasma cholesterol and bile acid excretion in nine subjects with ileostomies. *Am J Clin Nutr*. 1992;56:99-105.
220. Zhang JX, Lundin E, Hallmans G, et al. Effect of rye bran on excretion of bile acids, cholesterol, nitrogen, and fat in human subjects with ileostomies. *Am J Clin Nutr*. 1994;59:389-394.
221. Zhang JX, Lundin E, Andersson H, et al. Brewer's spent grain, serum lipids and fecal sterol excretion in human subjects with ileostomies. *J Nutr*. 1991;121:778-784.
222. Langkilde AM, Andersson H, Schweizer TF, Torsdottir I. Nutrients excreted in ileostomy effluents after consumption of mixed diets with beans or potatoes. I. Minerals, protein, fat and energy. *Eur J Clin Nutr*. 1990;44:559-566.
223. Gelissen IC, Brodie B, Eastwood MA. Effect of Plantago ovata (psyllium) husk and seeds on sterol metabolism: studies in normal and ileostomy subjects. *Am J Clin Nutr*. 1994;59:395-400.
224. Higham SE, Read NW. The effect of ingestion of guar gum on ileostomy effluent. *Br J Nutr*. 1992;67:115-122.
225. Krokowicz L, Bobkiewicz A, Borejsza-Wysocki M, et al. A prospective, descriptive study to assess the effect of dietary and pharmacological strategies to manage constipation in patients with a stoma. *Ostomy Wound Manage*. 2015;61:14-22.
226. Kuczynska B, Bobkiewicz A, Studniarek A, et al. Conservative measures for managing constipation in patients living with a colostomy. *J Wound Ostomy Continence Nurs*. 2017;44:160-164.
227. Cohen AB, Lee D, Long MD, et al. Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. *Dig Dis Sci*. 2013;58:1322-1328.
228. Welters CF, Heineman E, Thunnissen FB, et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. *Dis Colon Rectum*. 2002;45:621-627.
229. Alles MS, Katan MB, Salemans JM, et al. Bacterial fermentation of fructooligosaccharides and resistant starch in patients with an ileal pouch-anal anastomosis. *Am J Clin Nutr*. 1997;66:1286-1292.
230. Ardalán ZS, Yao CK, Green K, et al. A novel Monash Pouch diet in patients with an ileoanal pouch is tolerable and has favorable metabolic luminal effects. *JGH Open*. 2023;7:942-952.
231. Croagh C, Shepherd SJ, Berryman M, et al. Pilot study on the effect of reducing dietary FODMAP intake on bowel function in patients without a colon. *Inflamm Bowel Dis*. 2007;13:1522-1528.
232. Thirlby RC, Kelly R. Pectin and methyl cellulose do not affect intestinal function in patients after ileal pouch-anal anastomosis. *Am J Gastroenterol*. 1997;92:99-102.
233. Ardalán ZS, Livingstone KM, Polzella L, et al. Perceived dietary intolerances, habitual intake and diet quality of patients with an ileoanal pouch: associations with pouch phenotype (and behaviour). *Clin Nutr*. 2023;42:2095-2108.
234. Godny L, Maharshak N, Reshef L, et al. Fruit consumption is associated with alterations in microbial composition and lower rates of pouchitis. *J Crohns Colitis*. 2019;13:1265-1272.
235. Ianco O, Tulchinsky H, Lusthaus M, et al. Diet of patients after pouch surgery may affect pouch inflammation. *World J Gastroenterol*. 2013;19:6458-6464.
236. Barnes EL, Beniwal-Patel P, Deepak P, et al. Dietary patterns are not associated with disease activity among patients with inflammatory conditions of the pouch in a prospective cohort. *Crohns Colitis* 360. 2023;5:otad039.
237. Godny L, Reshef L, Pfeffer-Gik T, et al. Adherence to the Mediterranean diet is associated with decreased fecal calprotectin in patients with ulcerative colitis after pouch surgery. *Eur J Nutr*. 2020;59:3183-3190.
238. McLaughlin SD, Culkun A, Cole J, et al. Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis. *J Crohns Colitis*. 2013;7:460-466.
239. Yamamoto T. Elemental diet therapy for pouchitis following restorative proctocolectomy for ulcerative colitis. *J Crohns Colitis*. 2013;7:e155.
240. Fliss Isakov N, Kornblum J, Zemel M, et al. The effect of the Crohn's disease exclusion diet on patients with pouch inflammation: an interventional pilot study. *Clin Gastroenterol Hepatol*. 2023;21:1654-1656.e3.
241. Mehta M, Ahmed S, Dryden G. Refractory pouchitis improves after administration of the green tea polyphenol EGCG: a retrospective review. *Int J Colorectal Dis*. 2018;33:83-86.
242. Camilleri M, Prather CM, Evans MA, Andresen-Reid ML. Balance studies and polymeric glucose solution to optimize therapy after massive intestinal resection. *Mayo Clin Proc*. 1992;67:755-760.
243. Crow M, Meyer GW. "Cholera solution" in short bowel syndrome. *South Med J*. 1978;71:1303-1304.
244. Gerson CD, Janowitz HD. Glucose therapy in short-bowel syndrome. *Lancet*. 1971;2:1098.
245. Griffin GE, Fagan EF, Hodgson HJ, Chadwick VS. Enteral therapy in the management of massive gut resection complicated by chronic fluid and electrolyte depletion. *Dig Dis Sci*. 1982;27:902-908.
246. Kendall MJ, Hawkins CF. Oral glucose in reduction of jejunostomy effluent. *Lancet*. 1971;2:411-412.

247. Laustsen J, Fallingborg J. Enteral glucose-polymer-electrolyte solution in the treatment of chronic fluid and electrolyte depletion in short-bowel syndrome. *Acta Chir Scand*. 1983;149:787-788.
248. Nightingale JM, Lennard-Jones JE, Walker ER, Farthing MJ. Oral salt supplements to compensate for jejunostomy losses: comparison of sodium chloride capsules, glucose electrolyte solution, and glucose polymer electrolyte solution. *Gut*. 1992;33:759-761.
249. Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel. *Lancet*. 1994;343:373-376.
250. Nordgaard I, Hansen BS, Mortensen PB. Importance of colonic support for energy absorption as small-bowel failure proceeds. *Am J Clin Nutr*. 1996;64:222-231.
251. Jeppesen PB, Christensen MS, Høy CE, Mortensen PB. Essential fatty acid deficiency in patients with severe fat malabsorption. *Am J Clin Nutr*. 1997;65:837-843.
252. Jeppesen PB, Mortensen PB. The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. *Gut*. 1998;43:478-483.
253. McIntyre PB, Fitchew M, Lennard-Jones JE. Patients with a high jejunostomy do not need a special diet. *Gastroenterology*. 1986;91:25-33.
254. Scolapio JS. Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomized, controlled study. *JPEN J Parenter Enteral Nutr*. 1999;23:309-312. discussion 12-3.
255. Scolapio JS, McGreevy K, Tennyson GS, Burnett OL. Effect of glutamine in short-bowel syndrome. *Clin Nutr*. 2001;20:319-323.
256. Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. *Gut*. 2000;47:199-205.
257. White A, Nunes C, Escudier M, et al. Improvement in orofacial granulomatosis on a cinnamon- and benzoate-free diet. *Inflamm Bowel Dis*. 2006;12:508-514.
258. Eubanks BN, Seykora CM, Bandino JP. Granulomatous cheilitis preceding gastrointestinal manifestations of Crohn's disease. *Am J Dermatopathol*. 2023;45:482-486.
259. Marttala A, Sihvonen E, Kantola S, et al. Diagnosis and treatment of orofacial granulomatosis. *J Dent Child (Chic)*. 2018;85:83-87.
260. Ward VM, Dua S, Morrison GA. Oro-facial granulomatosis: a laryngeal presentation. *J Laryngol Otol*. 2001;115:923-924.
261. Campbell HE, Escudier MP, Milligan P, et al. Development of a low phenolic acid diet for the management of orofacial granulomatosis. *J Hum Nutr Diet*. 2013;26:527-537.
262. Oliver AJ, Rich AM, Reade PC, et al. Monosodium glutamate-related orofacial granulomatosis. Review and case report. *Oral Surg Oral Med Oral Pathol*. 1991;71:560-564.
263. Sweatman MC, Tasker R, Warner JO, et al. Oro-facial granulomatosis. Response to elemental diet and provocation by food additives. *Clin Allergy*. 1986;16:331-338.
264. Mutalib M, Bezanti K, Elawad M, Kiparissi F. The role of exclusive enteral nutrition in the management of orofacial granulomatosis in children. *World J Pediatr*. 2016;12:421-424.
265. Wray D, Rees SR, Gibson J, Forsyth A. The role of allergy in oral mucosal diseases. *QJM*. 2000;93:507-511.
266. Campbell HE, Escudier MP, Patel P, et al. Review article: cinnamon- and benzoate-free diet as a primary treatment for orofacial granulomatosis. *Aliment Pharmacol Ther*. 2011;34:687-701.
267. Godny L, Svols V, Williams AJ, et al. Multidisciplinary perinatal care in IBD. *J Crohns Colitis*. 2023;17:663-680.
268. Cederholm T, Jensen GL, Correia M, et al. GLIM Working Group. GLIM criteria for the diagnosis of malnutrition—A consensus report from the global clinical nutrition community. *Clin Nutr*. 2019;38:1-9.
269. Wei W, Yan P, Wang F, et al. Malnutrition defined by the global leadership initiative on malnutrition (GLIM) criteria in hospitalized patients with ulcerative colitis and its association with clinical outcomes. *Nutrients*. 2023;15:3572.
270. Abd-El-Aziz MA, Hübner M, Demartines N, et al. Simple clinical screening underestimates malnutrition in surgical patients with inflammatory bowel disease—an ACS NSQIP analysis. *Nutrients*. 2022;14:932.
271. Adams DW, Gurwara S, Silver HJ, et al. Sarcopenia is common in overweight patients with inflammatory bowel disease and may predict need for surgery. *Inflamm Bowel Dis*. 2017;23:1182-1186.
272. Bamba S, Inatomi O, Takahashi K, et al. Assessment of body composition from CT images at the level of the third lumbar vertebra in inflammatory bowel disease. *Inflamm Bowel Dis*. 2021;27:1435-1442.
273. Bedard K, Taylor L, Rajabali N, et al. Handgrip strength and risk of malnutrition are associated with an increased risk of hospitalizations in inflammatory bowel disease patients. *Therap Adv Gastroenterol*. 2023;16:17562848231194395.
274. Berger M, Yamada A, Komaki Y, et al. Low skeletal muscle index adjusted for body mass index is an independent risk factor for inflammatory bowel disease surgical complications. *Crohns Colitis*. 2020;2:otaa064.
275. Cushing KC, Kordbacheh H, Gee MS, et al. Sarcopenia is a novel predictor of the need for rescue therapy in hospitalized ulcerative colitis patients. *J Crohns Colitis*. 2018;12:1036-1041.
276. Grillot J, D'Engremont C, Parmentier AL, et al. Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn's disease. *Clin Nutr*. 2020;39:3024-3030.
277. Holt DQ, Moore GT, Strauss BJ, et al. Visceral adiposity predicts post-operative Crohn's disease recurrence. *Aliment Pharmacol Ther*. 2017;45:1255-1264.
278. Liu S, Ding X, Maggiore G, et al. Sarcopenia is associated with poor clinical outcomes in patients with inflammatory bowel disease: a prospective cohort study. *Ann Transl Med*. 2022;10:367.
279. Cravo ML, Velho S, Torres J, et al. Lower skeletal muscle attenuation and high visceral fat index are associated with complicated disease in patients with Crohn's disease: an exploratory study. *Clin Nutr ESPEN*. 2017;21:79-85.
280. Galata C, Hodapp J, Weiß C, et al. Skeletal muscle mass index predicts postoperative complications in intestinal surgery for Crohn's disease. *JPEN J Parenter Enteral Nutr*. 2020;44:714-721.
281. Ge X, Xia J, Wu Y, et al. Sarcopenia assessed by computed tomography is associated with colectomy in patients with acute severe ulcerative colitis. *Eur J Clin Nutr*. 2022;76:410-418.
282. Nagayoshi K, Mizuuchi Y, Zhang J, et al. Strong impact of sarcopenic state defined by skeletal muscle mass index on postoperative complication of Crohn's disease patients. *Surg Open Sci*. 2023;15:54-59.
283. Thiberge C, Charpentier C, Gillibert A, et al. Lower subcutaneous or visceral adiposity assessed by abdominal computed tomography could predict adverse outcome in patients with crohn's disease. *J Crohns Colitis*. 2018;12:1429-1437.
284. Zhang T, Ding C, Xie T, et al. Skeletal muscle depletion correlates with disease activity in ulcerative colitis and is reversed after colectomy. *Clin Nutr*. 2017;36:1586-1592.
285. Zhang W, Zhu W, Ren J, et al. Skeletal muscle percentage: a protective factor for postoperative morbidity in Crohn's disease patients with severe malnutrition. *J Gastrointest Surg*. 2015;19:715-721.
286. Bin CM, Flores C, Alvares-da-Silva MR, Francesconi CF. Comparison between handgrip strength, subjective global assessment,

- anthropometry, and biochemical markers in assessing nutritional status of patients with Crohn's disease in clinical remission. *Dig Dis Sci*. 2010;55:137-144.
287. Bryant RV, Ooi S, Schultz CG, et al. Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2015;41:895-906.
 288. Nguyen AL, Herath M, Burns M, et al. The value of whole-body dual-energy x-ray absorptiometry in assessing body composition in patients with inflammatory bowel disease: a prospective study. *Eur J Gastroenterol Hepatol*. 2024;36:52-61.
 289. He S, Huang Y, Peng Y, et al. Association between body fat composition and disease duration, clinical activity, and intravenous corticosteroid-induced response in inflammatory bowel disease. *Lipids Health Dis*. 2023;22:106.
 290. Bergamaschi G, Castiglione F, D'Incà R, et al. Prevalence, pathogenesis and management of anemia in inflammatory bowel disease: an ig-ibd multicenter, prospective, and observational study. *Inflamm Bowel Dis*. 2023;29:76-84.
 291. Ehrlich S, Mark AG, Rinawi F, et al. micronutrient deficiencies in children with inflammatory bowel diseases. *Nutr Clin Pract*. 2020;35:315-322.
 292. Rempel J, Grover K, El-Matary W. Micronutrient deficiencies and anemia in children with inflammatory bowel disease. *Nutrients*. 2021;13:236.
 293. Dignass AU, Gasche C, Bettenworth D, et al. European Crohn's and Colitis Organisation [ECCO]. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. *J Crohns Colitis*. 2015;9:211-222.
 294. World Health Organization. Iron deficiency anemia, assessment, prevention and control. 2015.
 295. Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. *J Crohns Colitis*. 2024;18:1-37.
 296. Fritz J, Walia C, Elkadri A, et al. A systematic review of micronutrient deficiencies in pediatric inflammatory bowel disease. *Inflamm Bowel Dis*. 2019;25:445-459.
 297. Valvano M, Capannolo A, Cesaro N, et al. Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. *Nutrients*. 2023;15:3824.
 298. Pan Y, Liu Y, Guo H, et al. Associations between folate and vitamin B12 levels and inflammatory bowel disease: a meta-analysis. *Nutrients*. 2017;9:382.
 299. Gomollón F, Gargallo CJ, Muñoz JF, et al. Oral cyanocobalamin is effective in the treatment of vitamin b12 deficiency in crohn's disease. *Nutrients*. 2017;9:308.
 300. Ward MG, Kariyawasam VC, Mogan SB, et al. Prevalence and risk factors for functional vitamin b12 deficiency in patients with Crohn's disease. *Inflamm Bowel Dis*. 2015;21:2839-2847.
 301. Battat R, Kopylov U, Szilagyi A, et al. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. *Inflamm Bowel Dis*. 2014;20:1120-1128.
 302. Bakaloudi DR, Halloran A, Rippin HL, et al. Intake and adequacy of the vegan diet. A systematic review of the evidence. *Clin Nutr*. 2021;40:3503-3521.
 303. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. *Inflamm Bowel Dis*. 2013;19:1921-1927.
 304. Bours PH, Wielders JP, Vermeijden JR, van de Wiel A. Seasonal variation of serum 25-hydroxyvitamin D levels in adult patients with inflammatory bowel disease. *Osteoporos Int*. 2011;22:2857-2867.
 305. Kojecky V, Adamikova A, Klimek P. Vitamin D supplementation in inflammatory bowel disease: the role of dosage and patient compliance. *Bratisl Lek Listy*. 2016;117:148-151.
 306. Gordon RJ, Wells R, Johansen C, et al. Efficacy and safety of high-dose cholecalciferol in patients with inflammatory bowel disease receiving infliximab. *J Pediatr Gastroenterol Nutr*. 2022;74:476-483.
 307. Pappa HM, Mitchell PD, Jiang H, et al. Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens. *J Clin Endocrinol Metab*. 2014;99:3408-3417.
 308. Lee S, Metcalfe A, Raman M, et al. Pregnant women with inflammatory bowel disease are at increased risk of vitamin d insufficiency: a cross-sectional study. *J Crohns Colitis*. 2018;12:702-709.
 309. Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer RJ. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. *Am J Clin Nutr*. 1998;67:919-926.
 310. Li X, Hu Y, Shi X, et al. Prevalence and relevant factors of micronutrient deficiencies in hospitalized patients with inflammatory bowel disease. *Nutrition*. 2022;99-100:111671.
 311. Hengstermann S, Valentini L, Schaper L, et al. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. *Clin Nutr*. 2008;27:571-578.
 312. MacMaster MJ, Damianopoulou S, Thomson C, et al. A prospective analysis of micronutrient status in quiescent inflammatory bowel disease. *Clin Nutr*. 2021;40:327-331.
 313. Zupo R, Sila A, Castellana F, et al. Prevalence of zinc deficiency in inflammatory bowel disease: a systematic review and meta-analysis. *Nutrients*. 2022;14:4052.
 314. Brownson E, Saunders J, Jatkowska A, et al. Micronutrient status and prediction of disease outcome in adults with inflammatory bowel disease receiving biologic therapy. *Inflamm Bowel Dis*. 2024;30:1233-1240.
 315. Siva S, Rubin DT, Gulotta G, et al. Zinc deficiency is associated with poor clinical outcomes in patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2017;23:152-157.
 316. Santucci NR, Alkhoury RH, Baker RD, Baker SS. Vitamin and zinc status pretreatment and posttreatment in patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. 2014;59:455-457.
 317. de Moura MSB, Soares NRM, Barros SÉL, et al. Zinc gluconate supplementation impacts the clinical improvement in patients with ulcerative colitis. *Biometals*. 2020;33:15-27.
 318. Laheij RLH, van Knippenberg YMW, Heil ALJ, et al. The efficacy of an over-the-counter multivitamin and mineral supplement to prevent infections in patients with inflammatory bowel disease in remission with immunomodulators and/or biological agents: a randomized, double-blind, placebo-controlled clinical trial. *Inflamm Bowel Dis*. 2024;30:1510-1516.
 319. Benjamin J, Makharia GK, Kalaivani M, Joshi YK. Nutritional status of patients with Crohn's disease. *Indian J Gastroenterol*. 2008;27:195-200.
 320. Costa CO, Carrilho FJ, Nunes VS, et al. A snapshot of the nutritional status of Crohn's disease among adolescents in Brazil: a prospective cross-sectional study. *BMC Gastroenterol*. 2015;15:172.
 321. Walton M, Alaunyte I. Do patients living with ulcerative colitis adhere to healthy eating guidelines? A cross-sectional study. *Br J Nutr*. 2014;112:1628-1635.
 322. Diederik K, Krom H, Koole JCD, et al. Diet and anthropometrics of children with inflammatory bowel disease: a comparison with the general population. *Inflamm Bowel Dis*. 2018;24:1632-1640.
 323. Ghoshal UC, Shukla A. Malnutrition in inflammatory bowel disease patients in northern India: frequency and factors influencing its development. *Trop Gastroenterol*. 2008;29:95-97.

324. Lambert K, Pappas D, Miglioretto C, et al. Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease. *Aliment Pharmacol Ther.* 2021;54:742-754.
325. Tsiountsioura M, Wong JE, Upton J, et al. Detailed assessment of nutritional status and eating patterns in children with gastrointestinal diseases attending an outpatients clinic and contemporary healthy controls. *Eur J Clin Nutr.* 2014;68:700-706.
326. Aghdassi E, Wendland BE, Stapleton M, et al. Adequacy of nutritional intake in a Canadian population of patients with Crohn's disease. *J Am Diet Assoc.* 2007;107:1575-1580.
327. Cioffi I, Imperatore N, Di Vincenzo O, et al. Evaluation of nutritional adequacy in adult patients with Crohn's disease: a cross-sectional study. *Eur J Nutr.* 2020;59:3647-3658.
328. Pierote NR, Braz AF, Barros SL, et al. Effect of mineral status and glucocorticoid use on bone mineral density in patients with Crohn's disease. *Nutrition.* 2018;48:13-17.
329. Rizzello F, Gionchetti P, Spisni E, et al. Dietary habits and nutrient deficiencies in a cohort of European Crohn's disease adult patients. *Int J Mol Sci.* 2023;24:1494.
330. Soares-Mota M, Silva TA, Gomes LM, et al. High prevalence of vitamin A deficiency in Crohn's disease patients according to serum retinol levels and the relative dose-response test. *World J Gastroenterol.* 2015;21:1614-1620.
331. Sousa Guerreiro C, Cravo M, Costa AR, et al. A comprehensive approach to evaluate nutritional status in Crohn's patients in the era of biologic therapy: a case-control study. *Am J Gastroenterol.* 2007;102:2551-2556.
332. Taylor L, Almutairdi A, Shommu N, et al. Cross-sectional analysis of overall dietary intake and Mediterranean dietary pattern in patients with Crohn's disease. *Nutrients.* 2018;10:1761.
333. Urbano AP, Sasaki LY, Dorna MS, et al. Nutritional intake according to injury extent in ulcerative colitis patients. *J Hum Nutr Diet.* 2013;26:445-451.
334. Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. *JPEN J Parenter Enteral Nutr.* 2007;31:311-319.
335. Pons R, Whitten KE, Woodhead H, et al. Dietary intakes of children with Crohn's disease. *Br J Nutr.* 2009;102:1052-1057.
336. Sila S, Trivić I, Pavić AM, et al. Nutritional status and food intake in pediatric patients with inflammatory bowel disease at diagnosis significantly differs from healthy controls. *Eur J Pediatr.* 2019;178:1519-1527.
337. England C, Mitchell A, Atkinson C. Diet after ileostomy study: an observational study describing dietary intake and stoma-related symptoms in people with an ileostomy. *J Hum Nutr Diet.* 2023;36:1600-1612.
338. David JG, Chute D, Reed B, et al. Assessing the prevalence of and risk factors for disordered eating attitudes and behaviors in adolescents with inflammatory bowel disease. *Inflamm Bowel Dis.* 2022;28:143-145.
339. Peters JE, Basnayake C, Hebbard GS, et al. Prevalence of disordered eating in adults with gastrointestinal disorders: A systematic review. *Neurogastroenterol Motil.* 2022;34:e14278.
340. Olendzki BC, Hsiao BS, Weinstein K, et al. Dietary intake of pregnant women with and without inflammatory bowel disease in the United States. *Nutrients.* 2023;15:2464.
341. Lomer MC, Kodjabashia K, Hutchinson C, et al. Intake of dietary iron is low in patients with Crohn's disease: a case-control study. *Br J Nutr.* 2004;91:141-148.
342. Ripoli J, Miszputen SJ, Ambrogini Jr., O, Carvalho L. Nutritional follow-up of patients with ulcerative colitis during periods of intestinal inflammatory activity and remission. *Arq Gastroenterol.* 2010;47:49-55.
343. Strisciuglio C, Cenni S, Serra MR, et al. Effectiveness of Mediterranean diet's adherence in children with inflammatory bowel diseases. *Nutrients.* 2020;12:3206.
344. Vidarsdottir JB, Johannsdottir SE, Thorsdottir I, et al. A cross-sectional study on nutrient intake and -status in inflammatory bowel disease patients. *Nutr J.* 2016;15:61.
345. Vagianos K, Clara I, Carr R, et al. What are adults with inflammatory bowel disease (IBD) eating? A closer look at the dietary habits of a population-based Canadian IBD cohort. *JPEN J Parenter Enteral Nutr.* 2016;40:405-411.
346. Fiorindi C, Dragoni G, Alpignano G, et al. Nutritional adequacy in surgical IBD patients. *Clin Nutr ESPEN.* 2021;41:198-207.
347. Brown S, Wall CL, Frampton C, et al. Dietary nutrient intake and blood micronutrient status of children with Crohn's disease compared with their shared-home environment, healthy siblings. *Nutrients.* 2022;14:3425.
348. Cox SR, Clarke H, O'Keefe M, et al. Nutrient, fibre, and FODMAP intakes and food-related quality of life in patients with inflammatory bowel disease, and their relationship with gastrointestinal symptoms of differing etiologies. *J Crohns Colitis.* 2021;15:2041-2053.
349. Filippi J, Al-Jaouni R, Wiroth JB, et al. Nutritional deficiencies in patients with Crohn's disease in remission. *Inflamm Bowel Dis.* 2006;12:185-191.
350. Głąbska D, Guzek D, Lech G. Analysis of the nutrients and food products intake of Polish males with ulcerative colitis in remission. *Nutrients.* 2019;11:2333.
351. Day AS, Davis R, Costello SP, et al. The adequacy of habitual dietary fiber intake in individuals with inflammatory bowel disease: a systematic review. *J Acad Nutr Diet.* 2021;121:688-708.e3.
352. Hartman C, Marderfeld L, Davidson K, et al. Food intake adequacy in children and adolescents with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2016;63:437-444.
353. Csontos ÁA, Molnár A, Piri Z, et al. The effect of anti-TNF α induction therapy on the nutritional status and dietary intake in inflammatory bowel disease. *J Gastrointest Liver Dis.* 2016;25:49-56.
354. Karachaliou A, Yannakoulia M, Bletsas M, et al. Assessment of dietary adequacy and quality in a sample of patients with Crohn's disease. *Nutrients.* 2022;14.
355. Chan SS, Luben R, Olsen A, et al. Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease. *Aliment Pharmacol Ther.* 2014;39:834-842.
356. Ananthakrishnan AN, Khalili H, Song M, et al. Genetic polymorphisms in fatty acid metabolism modify the association between dietary n3: n6 intake and risk of ulcerative colitis: a prospective cohort study. *Inflamm Bowel Dis.* 2017;23:1898-1904.
357. John S, Luben R, Shrestha SS, et al. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. *Eur J Gastroenterol Hepatol.* 2010;22:602-606.
358. Tjønneland A, Overvad K, Bergmann MM, et al. IBD in EPIC Study Investigators. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. *Gut.* 2009;58:1606-1611.
359. de Silva PS, Olsen A, Christensen J, et al. An association between dietary arachidonic acid, measured in adipose tissue, and ulcerative colitis. *Gastroenterology.* 2010;139:1912-1917.
360. de Silva PS, Luben R, Shrestha SS, et al. Dietary arachidonic and oleic acid intake in ulcerative colitis etiology: a prospective cohort study using 7-day food diaries. *Eur J Gastroenterol Hepatol.* 2014;26:11-18.

361. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. *Gut*. 2014;63:776-784.
362. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. *Gastroenterology*. 2013;145:970-977.
363. Andersen V, Chan S, Luben R, et al. Fibre intake and the development of inflammatory bowel disease: A European prospective multi-centre cohort study (EPIC-IBD). *J Crohns Colitis*. 2018;12:129-136.
364. Deng M, Dan L, Ye S, et al. Higher dietary fibre intake is associated with lower risk of inflammatory bowel disease: prospective cohort study. *Aliment Pharmacol Ther*. 2023;58:516-525.
365. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. *Annu Rev Pharmacol Toxicol*. 2011;51:311-336.
366. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. *Gastroenterology*. 2012;142:482-489.
367. Opstelten JL, Chan SSM, Hart AR, et al. Prediagnostic serum vitamin d levels and the risk of Crohn's disease and ulcerative colitis in European populations: a nested case-control study. *Inflamm Bowel Dis*. 2018;24:633-640.
368. Carreras-Torres R, Ibanez-Sanz G, Obon-Santacana M, et al. Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study. *Sci Rep*. 2020;10:19273.
369. Hart AR, Luben R, Olsen A, et al. Diet in the aetiology of ulcerative colitis: a European prospective cohort study. *Digestion*. 2008;77:57-64.
370. Jantchou P, Clavel-Chapelon F, Racine A, et al. High residential sun exposure is associated with a low risk of incident Crohn's disease in the prospective E3N cohort. *Inflamm Bowel Dis*. 2014;20:75-81.
371. Ananthakrishnan AN, Khalili H, Song M, et al. Zinc intake and risk of Crohn's disease and ulcerative colitis: a prospective cohort study. *Int J Epidemiol*. 2015;44:1995-2005.
372. Vasseur P, Dugelay E, Benamouzig R, et al. Dietary zinc intake and inflammatory bowel disease in the French nutrient-santé cohort. *Am J Gastroenterol*. 2020;115:1293-1297.
373. Khalili H, de Silva PS, Ananthakrishnan AN, et al. Dietary iron and heme iron consumption, genetic susceptibility, and risk of Crohn's disease and ulcerative colitis. *Inflamm Bowel Dis*. 2017;23:1088-1095.
374. Lu Y, Zamora-Ros R, Chan S, et al. Dietary polyphenols in the aetiology of Crohn's disease and ulcerative colitis-a multicenter European Prospective Cohort Study (EPIC). *Inflamm Bowel Dis*. 2017;23:2072-2082.
375. Talebi S, Zeraatlab-Motlagh S, Rahimlou M, et al. The association between total protein, animal protein, and animal protein sources with risk of inflammatory bowel diseases: a systematic review and meta-analysis of cohort studies. *Adv Nutr*. 2023;14:752-761.
376. Milajerdi A, Ebrahimi-Daryani N, Dieleman LA, et al. Association of dietary fiber, fruit, and vegetable consumption with risk of inflammatory bowel disease: a systematic review and meta-analysis. *Adv Nutr*. 2021;12:735-743.
377. Narula N, Wong ECL, Dehghan M, et al. Does a high-inflammatory diet increase the risk of inflammatory bowel disease? results from the prospective urban rural epidemiology (PURE) study: a prospective cohort study. *Gastroenterology*. 2021;161:1333-1335 e1.
378. Ng SC, Tang W, Leong RW, et al. Asia-Pacific Crohn's and Colitis Epidemiology Study ACCESS Group. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. *Gut*. 2015;64:1063-1071.
379. Ananthakrishnan AN, Khalili H, Song M, et al. High school diet and risk of Crohn's Disease and ulcerative colitis. *Inflamm Bowel Dis*. 2015;21:2311-2319.
380. Rubin KH, Rasmussen NF, Petersen I, et al. Intake of dietary fibre, red and processed meat and risk of late-onset chronic inflammatory diseases: A prospective Danish study on the "diet, cancer and health" cohort. *Int J Med Sci*. 2020;17:2487-2495.
381. Bergmann MM, Hernandez V, Bernigau W, et al. No association of alcohol use and the risk of ulcerative colitis or Crohn's disease: data from a European Prospective cohort study (EPIC). *Eur J Clin Nutr*. 2017;71:566-568.
382. Fu T, Chen H, Chen X, et al. Sugar-sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants. *Aliment Pharmacol Ther*. 2022;56:1018-1029.
383. Khalili H, Hakansson N, Chan SS, et al. No association between consumption of sweetened beverages and risk of later-onset crohn's disease or ulcerative colitis. *Clin Gastroenterol Hepatol*. 2019;17:123-129.
384. Lopes EW, Chan SSM, Song M, et al. EPIC-IBD investigators. Life-style factors for the prevention of inflammatory bowel disease. *Gut*. 2023;72:1093-1100.
385. Sun Y, Yuan S, Chen X, et al. The contribution of genetic risk and lifestyle factors in the development of adult-onset inflammatory bowel disease: a prospective cohort study. *Am J Gastroenterol*. 2023;118:511-522.
386. Meyer A, Dong C, Chan SSM, et al. Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis. *Aliment Pharmacol Ther*. 2024;59:558-568.
387. Fu T, Ye S, Sun Y, et al. Greater adherence to cardioprotective diet can reduce inflammatory bowel disease risk: a longitudinal cohort study. *Nutrients*. 2022;14:4058.
388. Khalili H, Hakansson N, Casey K, et al. Diet quality and risk of older-onset Crohn's disease and ulcerative colitis. *J Crohns Colitis*. 2023;17:746-753.
389. Khalili H, Hakansson N, Chan SS, et al. Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies. *Gut*. 2020;69:1637-1644.
390. Racine A, Carbonnel F, Chan SS, et al. Dietary patterns and risk of inflammatory bowel disease in europe: results from the EPIC study. *Inflamm Bowel Dis*. 2016;22:345-354.
391. Peters V, Bolte L, Schutttert EM, et al. Western and carnivorous dietary patterns are associated with greater likelihood of IBD development in a large prospective population-based cohort. *J Crohns Colitis*. 2022;16:931-939.
392. Guo A, Ludvigsson J, Brantsæter AL, et al. Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts. *Gut*. 2024;73:590-600.
393. Khorshidi M, Djafarian K, Aghayei E, Shab-Bidar S. A posteriori dietary patterns and risk of inflammatory bowel disease: a meta-analysis of observational studies. *Int J Vitam Nutr Res*. 2020;90:376-384.
394. Li T, Qiu Y, Yang HS, et al. Systematic review and meta-analysis: Association of a pre-illness Western dietary pattern with the risk of developing inflammatory bowel disease. *J Dig Dis*. 2020;21:362-371.
395. Guevara M, Salamanca-Fernandez E, Miquelèiz E, et al. Inflammatory potential of the diet and incidence of crohn's disease and ulcerative colitis in the EPIC-Spain cohort. *Nutrients*. 2021;13:2201.
396. Lo CH, Lochhead P, Khalili H, et al. Dietary inflammatory potential and risk of crohn's disease and ulcerative colitis. *Gastroenterology*. 2020;159:873-883.e1.

397. Monteiro CA, Cannon G, Moubarac JC, et al. The UN decade of nutrition, the NOVA food classification and the trouble with ultra-processing. *Public Health Nutr.* 2018;21:5-17.
398. Narula N, Chang NH, Mohammad D, et al. Food processing and risk of inflammatory bowel disease: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2023;21:2483-2495.e1.
399. Binns C, Lee M, Low WY. The long-term public health benefits of breastfeeding. *Asia Pac J Public Health.* 2016;28:7-14.
400. Agrawal M, Sabino J, Frias-Gomes C, et al. Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses. *EClinicalMedicine.* 2021;36:100884.
401. Barclay AR, Russell RK, Wilson ML, et al. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. *J Pediatr.* 2009;155:421-426.
402. Xu L, Lochhead P, Ko Y, et al. Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis. *Aliment Pharmacol Ther.* 2017;46:780-789.
403. Thompson NP, Montgomery SM, Wadsworth ME, et al. Early determinants of inflammatory bowel disease: use of two national longitudinal birth cohorts. *Eur J Gastroenterol Hepatol.* 2000;12:25-30.
404. Agrawal M, Stordal K, Vinkel Hansen A, et al. Breastfeeding duration is not associated with offspring inflammatory bowel disease risk in three population-based birth cohorts. *Clin Gastroenterol Hepatol.* 2024;22:2459-2467.e16.
405. Burgess CJ, Schnier C, Wood R, et al. Prematurity, delivery method, and infant feeding type are not associated with paediatric-onset inflammatory bowel disease risk: a scottish retrospective birth cohort study. *J Crohns Colitis.* 2022;16:1235-1242.